299. 嚢胞性線維症 Disease details / Clinical trials / Drug dev / DR info

/m2 dose
   University of Washington
      2010   Phase 1   NCT01093521   United States;
033841
   Erasmus University Medical Centre
      2012   -   EUCTR2012-002503-17-NL   Netherlands;
1,5 (Butylimino)-1,5-dideoxy-D-glucitol
   Actelion Pharmaceuticals Ltd
      2007   -   EUCTR2006-002049-35-ES   Spain;
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid
   Bayer HealthCare AG
      2007   -   EUCTR2007-002912-24-DE   Germany;
100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC
   Vertex Pharmaceuticals Incorporated
      -   Phase 3   EUCTR2018-000185-11-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-000833-37-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
100-mg ELX / 50-mg TEZ / 75 -mg IVA FDC
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-003455-11-GB   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-DE   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-BE   Australia;Belgium;Germany;United Kingdom;
100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC
   VERTEX PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2019-000833-37-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-000833-37-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000833-37-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-002835-76-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001735-31-GB   Australia;Belgium;Germany;United Kingdom;
      2019   Phase 3   EUCTR2019-000833-37-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-ES   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001735-31-BE   Australia;Belgium;Germany;United Kingdom;
      -   Phase 3   EUCTR2019-000833-37-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-002835-76-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-002835-76-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
100-mg VX-445 /50-mg TEZ/75-mg
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-004652-38-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004652-38-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004652-38-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
100-mg VX-445/50-mg TEZ/75-mg IVA FDC
   VERTEX PHARMACEUTICALS INCORPORATED
      2018   Phase 3   EUCTR2018-000183-28-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2018-000183-28-SE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000183-28-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
100g ELX / 50mg TEZ / 75mg IVA
   Vertex Pharmaceuticals Incorporated
      2021   Phase 3   EUCTR2020-002251-38-DE   Germany;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002239-31-DE   Australia;Canada;Germany;United Kingdom;United States;
129Xe Small and Large Human Lung Coil
   Thunder Bay Regional Research Institute
      2019   Early Phase 1   NCT02748798   Canada;
13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)
   University of Miami
      2022   -   NCT05223881   United States;
150-mg IVACAFTOR
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-003554-86-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
2,3-dihydroxybutanedioic acid
   University of LIverpool
      2019   Phase 1;Phase 2   EUCTR2017-001259-29-GB   United Kingdom;
2-aminoethanethiol
   University of LIverpool
      2019   Phase 1;Phase 2   EUCTR2017-001259-29-GB   United Kingdom;
2622U90 Duramycin
   AOP Orphan Pharmaceuticals AG
      2008   -   EUCTR2006-006693-24-CZ   Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
      2007   Phase 2;Phase 3   EUCTR2006-006693-24-DE   Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
      -   Phase 2   EUCTR2006-006693-24-PL   Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
291844
   PTC Therapeutics, Inc
      2010   Phase 3   EUCTR2010-019692-30-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-GB   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-SE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-NL   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-ES   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-DE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
3He Human Lung Coil
   Thunder Bay Regional Research Institute
      2019   Early Phase 1   NCT02748798   Canada;
4D-710
   4D Molecular Therapeutics
      2022   Phase 1/Phase 2   NCT05248230   United States;
5-methyltetrahydrofolate and vitamin B12
   Universita di Verona
      2004   -   NCT00730509   Italy;
5000 IU of cholecalciferol
   St. Michael's Hospital, Toronto
      2008   -   NCT00685971   Canada;
552-02
   Parion Sciences
      2006   Phase 1/Phase 2   NCT00274313   United States;
75-mg IVACAFTOR
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-005320-38-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-PT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)
   University Hospital, Strasbourg, France
      2020   Phase 4   NCT04381429   France;
AAC Hexal
   Aarhus University Hospital
      2016   Phase 2   EUCTR2016-000354-35-DK   Denmark;
ABBV-119
   AbbVie
      2021   Phase 2   NCT04853368   Australia;Belgium;Czechia;Germany;Hungary;Netherlands;New Zealand;Slovakia;
   AbbVie Deutschland GmbH & Co. KG
      2021   Phase 2   EUCTR2020-005805-25-NL   Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
      2021   Phase 2   EUCTR2020-005805-25-HU   Hungary;
      2021   Phase 2   EUCTR2020-005805-25-BE   Belgium;Hungary;Netherlands;
ABBV-2222
   AbbVie
      2019   Phase 2   NCT03969888   Belgium;Canada;Czechia;France;Hungary;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
   AbbVie Deutschland
      2019   Phase 2   EUCTR2019-000750-63-NL   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-HU   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-GB   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-FR   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-BE   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2021   Phase 2   EUCTR2020-005805-25-NL   Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
      2021   Phase 2   EUCTR2020-005805-25-HU   Hungary;
      2021   Phase 2   EUCTR2020-005805-25-BE   Belgium;Hungary;Netherlands;
      2020   Phase 2   EUCTR2019-000750-63-PL   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
ABBV-3067
   AbbVie
      2019   Phase 2   NCT03969888   Belgium;Canada;Czechia;France;Hungary;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
   AbbVie Deutschland
      2019   Phase 2   EUCTR2019-000750-63-NL   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-HU   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-GB   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-FR   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-BE   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2021   Phase 2   EUCTR2020-005805-25-NL   Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
      2021   Phase 2   EUCTR2020-005805-25-HU   Hungary;
      2021   Phase 2   EUCTR2020-005805-25-BE   Belgium;Hungary;Netherlands;
      2020   Phase 2   EUCTR2019-000750-63-PL   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
ACC
   Aarhus University Hospital
      2014   Phase 2   EUCTR2013-005481-19-DK   Denmark;
ACC600Tabs
   Rigshospitalet
      2010   Phase 4   EUCTR2007-001401-15-DK   Denmark;
ACETYLCYSTEINE SODIUM
   Aarhus University Hospital
      2016   Phase 2   EUCTR2016-000354-35-DK   Denmark;
ACIDE TRANEXAMIQUE MYLAN 0,5 g/ 5 mL, solution injectable
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 3   EUCTR2020-005931-58-FR   France;
AER002
   Aerovance Inc
      2005   Phase 1;Phase 2   EUCTR2005-000313-35-GB   United Kingdom;
AIR DNase
   Protalix
      2015   Phase 1   NCT02605590   Israel;
AIR DNase™
   Protalix
      2016   Phase 2   NCT02722122   Israel;
ALTU-135
   ALTUS PHARMACEUTICALS INC
      2007   -   EUCTR2007-000178-21-IT   Italy;
      2007   -   EUCTR2007-000171-41-IT   Italy;
   Altus Pharmaceuticals Inc
      2007   Phase 3   EUCTR2007-000171-41-SK   Italy;Slovakia;
      -   Phase 3   EUCTR2007-000171-41-PL   Italy;Poland;Slovakia;
   Altus Pharmaceuticals Inc.
      2007   Phase 3   EUCTR2007-000178-21-SK   Italy;Slovakia;
      -   Phase 3   EUCTR2007-000178-21-PL   Italy;Poland;Slovakia;
ALTUS-135
   ALTUS PHARMACEUTICALS INC
      2007   -   EUCTR2007-000171-41-IT   Italy;
ALX-009
   Alaxia SAS
      2015   Phase 1   NCT02598999   France;
AMIKACIN SULFATE
   INSMED INCORPORATED
      2012   -   EUCTR2011-000443-24-IT   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2011-000441-20-IT   Austria;Bulgaria;Canada;Denmark;Greece;Hungary;Ireland;Italy;Netherlands;Spain;United Kingdom;
   Insmed Incorporated
      2013   -   EUCTR2011-000443-24-NL   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-000443-24-PL   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-000443-24-BE   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-000441-20-BE   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-000443-24-SE   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-000443-24-DK   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-000441-20-NL   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-000441-20-IE   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-000441-20-DK   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-000441-20-BG   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-000443-24-SK   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2011-000443-24-GB   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2011-000443-24-FR   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000443-24-IE   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2011-000443-24-HU   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2011-000443-24-GR   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000443-24-DE   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2011-000443-24-BG   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2011-000443-24-AT   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2011-000441-20-SK   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-HU   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-GR   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
      2011   -   EUCTR2011-000441-20-GB   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-DE   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-AT   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
   Transave, Inc.
      -   Phase 2   EUCTR2006-006980-22-PL   Belgium;Hungary;Poland;Slovakia;
AMILASA
   ANTHERA Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2016-002851-92-ES   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
AMYLASE
   ANTHERA Pharmaceuticals, Inc.
      2017   Phase 3   EUCTR2017-000571-85-LT   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2017   Phase 3   EUCTR2017-000571-85-HU   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2017   Phase 3   EUCTR2017-000571-85-GB   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000571-85-ES   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2016   Phase 4   EUCTR2016-002851-92-CZ   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
      2016   Phase 3   EUCTR2016-002851-92-HU   Canada;Hungary;Israel;Spain;United States;
      -   Phase 3   EUCTR2017-000571-85-PL   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-002851-92-PL   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
AP-PA02
   Armata Pharmaceuticals, Inc.
      2020   Phase 1/Phase 2   NCT04596319   United States;
ARD-3150
   Aradigm Corporation
      2015   Phase 3   EUCTR2013-005366-19-PL   Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005366-19-FR   Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005348-28-PL   Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005366-19-RO   Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005366-19-IT   Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005366-19-HU   Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005366-19-GB   Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005366-19-ES   Australia;Canada;France;Germany;Hungary;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-RO   Australia;Canada;Georgia;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-LV   Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-IT   Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-IE   Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-HU   Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-GB   Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-ES   Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
ARIKACE™
   Insmed Incorporated
      2007   Phase 1/Phase 2   NCT00777296   Belgium;Bulgaria;Hungary;Macedonia, The Former Yugoslav Republic of;North Macedonia;Poland;Serbia;Slovakia;Ukraine;
ARO-ENaC
   Arrowhead Pharmaceuticals
      2020   Phase 1/Phase 2   NCT04375514   Australia;New Zealand;
AZD1236
   AstraZeneca
      2009   Phase 2   NCT00812045   Canada;Netherlands;Poland;Spain;
   AstraZeneca AB
      2008   -   EUCTR2008-004699-34-NL   Netherlands;Spain;
      2008   -   EUCTR2008-004699-34-ES   Netherlands;Spain;
AZD5634
   AstraZeneca
      2017   Phase 1   NCT02950805   United States;
AZD5634 for infusion
   AstraZeneca
      2016   Phase 1   NCT02679729   United States;
AZD5634 for inhalation
   AstraZeneca
      2016   Phase 1   NCT02679729   United States;
AZD7986
   Insmed Incorporated
      2021   Phase 3   EUCTR2020-003688-25-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-IE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003688-25-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003688-25-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-002533-32-BE   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-SE   Australia;Belgium;Bulgaria;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-PL   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-NL   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-GB   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-ES   Australia;Belgium;Bulgaria;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-DK   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-DE   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-BG   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
AZD9668
   AstraZeneca
      2008   Phase 2   NCT00757848   Denmark;Germany;Poland;Russian Federation;Sweden;United Kingdom;
   AstraZeneca AB
      2009   -   EUCTR2008-001530-27-GB   Denmark;Germany;Sweden;United Kingdom;
      2009   -   EUCTR2008-001530-27-DK   Denmark;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2008-001530-27-SE   Denmark;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2008-001530-27-DE   Denmark;Germany;Sweden;United Kingdom;
AZITHROMYCIN DIHYDRATE
   ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
      -   Phase 3   EUCTR2014-003023-22-FR   France;
AZLI
   Gilead Sciences, Inc.
      2012   Phase 3   EUCTR2011-001362-18-ES   France;Germany;Italy;Poland;Spain;United States;
   Gilead Sciences
      2017   Phase 3   NCT03219164   Austria;Belgium;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2012   Phase 3   NCT01641822   United States;
      2011   Phase 3   NCT01404234   France;Germany;Italy;Poland;Spain;United States;
      2011   Phase 3   NCT01314716   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2011   Phase 3   NCT01313624   Australia;Canada;United States;
      2010   Phase 3   NCT01059565   Canada;United States;
   Gilead Sciences Inc
      2010   -   EUCTR2007-004277-26-AT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2007-004277-26-GB   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-FR   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-ES   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-BE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-PT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-NL   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-IT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-IE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-DK   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-DE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Gilead Sciences, Inc.
      2018   Phase 3   EUCTR2016-002749-42-NL   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-002749-42-GR   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-IT   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-GB   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-FR   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-ES   Austria;Belgium;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-DK   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-DE   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-BE   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-AT   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-001255-36-BE   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001362-18-DE   France;Germany;Italy;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-NL   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-IE   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-DE   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-AT   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2011   Phase 2   EUCTR2011-001255-36-ES   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      -   Phase 3   EUCTR2016-002749-42-IE   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2011-001362-18-FR   France;Germany;Italy;Poland;Spain;United States;
      -   Phase 2   EUCTR2011-001255-36-FR   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      -   -   EUCTR2011-001362-18-Outside-EU/EEA   United States;
      -   -   EUCTR2011-001255-36-Outside-EU/EEA   United States;
AZLI 75 mg three times a day (TID)
   Gilead Sciences
      2005   Phase 3   NCT00112359   Australia;Canada;New Zealand;United States;
AZLI 75 mg three times daily (TID)
   Gilead Sciences
      2008   Phase 3   NCT00712166   Australia;Canada;United States;
AZLI 75 mg two times a day (BID)/ three times a day (TID)
   Gilead Sciences
      2005   Phase 3   NCT00128492   Australia;Canada;New Zealand;United States;
AZLI 75 mg two times a day (BID)/three times a day (TID)
   Gilead Sciences
      2005   Phase 3   NCT00104520   United States;
AZTREONAM LYSINE
   Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
      2014   Phase 4   EUCTR2013-004295-35-AT   Austria;
Acebilustat
   Celtaxsys Inc.
      2016   Phase 2   EUCTR2015-002677-38-IT   Belgium;France;Germany;Italy;Netherlands;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002677-38-GB   Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002677-38-DE   Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002677-38-BE   Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
Acetylcysteine
   University Hospital, Ghent
      2010   Phase 4   NCT00996424   Belgium;
   West China Hospital, Sichuan University
      2020   Phase 4   ChiCTR2000031817   China;
Active Treatment Group Hypertonic Saline
   University of Washington, the Collaborative Health Studies Coordinating Center
      2015   Phase 2/Phase 3   NCT02950883   Australia;Belgium;Canada;Denmark;France;Italy;Netherlands;Spain;United States;
Actrapid 100 IU/ml, Solution for injection in a vial
   St George's, University of London
      2008   -   EUCTR2007-004956-35-GB   United Kingdom;
Actrapid Penfill 100UI/ml
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2006   -   EUCTR2006-001254-27-FR   France;
Acute Antioxidant
   Augusta University
      2015   -   NCT02690064   United States;
Ad26.COV2-S.02
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
Adempas
   Bayer AG
      2015   Phase 2   EUCTR2013-004595-35-BE   Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-004595-35-GB   Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-004595-35-DE   Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2013-004595-35-NL   Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States;
Adeno-associated virus-CFTR vector
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1999   Phase 1   NCT00004533   -
Adrenalina
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-004068-24-IT   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
Advagraf prolonged-release hard capsules
   Hopital Erasme - Chest service
      2009   -   EUCTR2009-014050-15-BE   Belgium;
AeroVanc
   Savara Inc.
      2011   Phase 1   NCT01537666   Australia;
Aeroquin
   Mpex Pharmaceuticals, Inc.
      2011   Phase 3   EUCTR2010-019634-26-GB   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
      2011   -   EUCTR2010-019634-26-IE   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
      2011   -   EUCTR2010-019634-26-DE   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
      -   Phase 3   EUCTR2010-019634-26-FR   France;Germany;Ireland;United Kingdom;
Aerosolized, human, plasma-derived Alpha-1 Antitrypsin
   Kamada, Ltd.
      2007   Phase 2   NCT00499837   Israel;
Aerosoltherapy
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2018   -   NCT03655249   Belgium;
Air
   Assistance Publique - Hôpitaux de Paris
      2012   -   NCT01586728   France;
Airway clearance technique
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2012   -   NCT02201082   Belgium;
Albuterol
   National Center for Research Resources (NCRR)
      2000   -   NCT00005110   United States;
   University of Arizona
      2009   -   NCT01880723   United States;
Albuterol inhaler.
   University of Florida
      2007   -   NCT01851642   United States;
Alendronate
   Istituto Auxologico Italiano
      2002   Phase 3   NCT01812551   Holy See (Vatican City State);Italy;
   McMaster University
      2003   Phase 4   NCT00157690   Canada;
Alendronate sodium
   University of North Carolina
      1998   -   NCT00004489   United States;
Alginate oligosaccharide
   AlgiPharma AS
      2015   Phase 2   NCT02453789   Germany;
      2014   Phase 2   NCT02157922   Denmark;Germany;Norway;Sweden;United Kingdom;
Allo-hMSCs
   Joshua M Hare
      2020   Phase 1   NCT03058068   United States;
Alpha-1 HC
   Grifols Therapeutics Inc.
      2012   Phase 2   NCT01684410   United States;
Alpha1-Proteinase Inhibitor (Human)
   Grifols Therapeutics Inc.
      2003   Phase 2   NCT00486837   -
Amikacin
   Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine
      2015   -   ChiCTR-IPC-15005915   -
   Qilu Hospital of Shandong University
      2014   Phase 4   NCT02081963   China;
   The Leeds Teaching Hospitals NHS Trust
      2015   -   NCT02489955   United Kingdom;
Amikacin Sulfate
   Insmed Incorporated
      2011   -   EUCTR2011-000442-38-ES   Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2011   -   EUCTR2011-000442-38-BG   Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      -   Phase 3   EUCTR2011-000442-38-PL   Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
Amikacin nebulization
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2012   -   NCT02201082   Belgium;
Amikacin sulfate
   Transave, Inc.
      2007   -   EUCTR2006-006980-22-BE   Belgium;Hungary;
Amikacina liposomal (Arikace?)
   Insmed Incorporated
      2011   Phase 3   EUCTR2011-000441-20-ES   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
Amikacine nebulization
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2015   -   NCT02535130   Belgium;
Amikin, amiklin, amicacin, BB-K8, Biklin, Fabianol, Kaminax, Mikavir, Novamin, Pierami
   Transave, Inc
      2005   -   EUCTR2005-004389-17-HU   Hungary;
Amikin®, amiklin, amicacin, BB-K8, Biklin®, Fabianol®, Kaminax, Mikavir, Novamin®, Pierami
   Transave, Inc.
      2005   -   EUCTR2005-004899-21-BE   Belgium;
Amiloride
   FDA Office of Orphan Products Development
      1996   -   NCT00004705   -
Amiloride HCl
   University of North Carolina
      2001   Phase 2   NCT00274391   United States;
Amiloride Solution for Inhalation
   Children's Hospital Boston
      2006   Phase 1   NCT00547053   United States;
Amitriptylin-CT
   PSKS
      -   Phase 2   EUCTR2008-002673-13-DE   Germany;
Amitriptylin-ct Tabletten
   Paediatrisches Sekretariat fuer Klinische Studien
      2006   Phase 2   EUCTR2006-002259-33-DE   Germany;
Amitriptyline
   PSKS
      -   Phase 2   EUCTR2008-002673-13-DE   Germany;
   University Children’s Hospital Tuebingen
      2009   Phase 2   NCT01309178   Germany;
   University Hospital Tuebingen
      2006   Phase 2   NCT00515229   Germany;
Amoxicillin and Clavulanic acid
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
Amphotericin B
   AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
      2010   -   EUCTR2010-019194-15-IT   Italy;
Amylase
   Altus Pharmaceuticals Inc
      2007   Phase 3   EUCTR2007-000171-41-SK   Italy;Slovakia;
      -   Phase 3   EUCTR2007-000171-41-PL   Italy;Poland;Slovakia;
   Altus Pharmaceuticals Inc.
      2007   Phase 3   EUCTR2007-000178-21-SK   Italy;Slovakia;
      -   Phase 3   EUCTR2007-000178-21-PL   Italy;Poland;Slovakia;
Anakinra
   Heidelberg University
      2021   Phase 2   NCT03925194   Germany;
Andecaliximab
   Gilead Sciences
      2016   Phase 2   NCT02759562   Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
Anti-pseudomonas IgY gargle
   Immunsystem AB
      2003   Phase 1/Phase 2   NCT00633191   Sweden;
Anti-reflux pharmacotherapy
   Bayside Health
      2001   -   NCT00164021   Australia;
Antibiotic
   Aradigm Corporation
      2010   -   NCT01090908   -
Antioxidant Cocktail
   Augusta University
      2011   Phase 2   NCT01772758   United States;
Antistaminici H1 - H2
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-004068-24-IT   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
AquADEK
   University of Colorado, Denver
      2007   Phase 1/Phase 2   NCT01018303   United States;
AquADEKs-2
   University of Colorado, Denver
      2013   Phase 2   NCT01859390   United States;
Arginine
   Children's Hospital of Philadelphia
      2013   -   NCT01852448   United States;
Aridol or Osmohale
   Pharmaxis Pharmaceuticals Limited
      -   Phase 3   EUCTR2007-001412-23-DE   Germany;Ireland;United Kingdom;
Arikayce™
   Insmed Incorporated
      2009   Phase 2   NCT03905642   Belgium;Hungary;Macedonia, The Former Yugoslav Republic of;North Macedonia;Poland;Serbia;Slovakia;Ukraine;
      2008   Phase 1/Phase 2   NCT00558844   United States;
Ataluren
   PTC THERAPEUTICS, INC.
      2010   -   EUCTR2010-019692-30-IT   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
   PTC Therapeutics
      2015   Phase 3   NCT02456103   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 3   NCT02107859   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2010   Phase 3   NCT01140451   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2009   Phase 3   NCT00803205   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2007   Phase 2   NCT00458341   Belgium;France;Israel;
      2005   Phase 2   NCT00237380   Israel;
   PTC Therapeutics, Inc
      2011   Phase 3   EUCTR2010-019692-30-GB   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019692-30-ES   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-019692-30-DE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-019692-30-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019692-30-SE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2010-019692-30-NL   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2010-019692-30-BE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-003924-52-GB   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-BE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2009   -   EUCTR2008-003924-52-SE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-DE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
   PTC Therapeutics, Inc.
      2016   Phase 3   EUCTR2014-005355-83-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005355-83-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005355-83-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005355-83-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005355-83-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005355-83-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005355-83-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005355-83-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005449-35-FR   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2015   Phase 3   EUCTR2013-004581-34-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004581-34-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004581-34-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004581-34-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005449-35-SE   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-005449-35-IT   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-005449-35-ES   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-005449-35-DE   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-005449-35-BE   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-004581-34-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004581-34-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004581-34-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004581-34-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   University of Alabama at Birmingham
      2017   Phase 4   NCT03256968   United States;
Ataluren (PTC124®)
   PTC Therapeutics
      2014   Phase 3   NCT02139306   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Atorvastatin
   NHS Lothian
      2010   Phase 4   EUCTR2010-022042-24-GB   United Kingdom;
      2010   Phase 4   EUCTR2010-022040-20-GB   United Kingdom;
   University of Edinburgh
      2010   Phase 4   NCT01299181   United Kingdom;
Atropina
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-004068-24-IT   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
Augmentin
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
Aurexis® (tefibazumab)
   Bristol-Myers Squibb
      2005   Phase 2   NCT00198289   United States;
Avian polyclonal IgY antibody against PA
   MUKOVISZIDOSE E.V.
      2012   Phase 3   EUCTR2011-000801-39-IT   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
   Mukoviszidose Institute gGmbH
      2014   Phase 3   EUCTR2011-000801-39-HU   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2014   Phase 3   EUCTR2011-000801-39-ES   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2014   Phase 3   EUCTR2011-000801-39-AT   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2013   Phase 3   EUCTR2011-000801-39-IE   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2012   Phase 3   EUCTR2011-000801-39-SE   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2012   Phase 3   EUCTR2011-000801-39-BE   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2011   Phase 3   EUCTR2011-000801-39-DE   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
Azithromycin
   Assistance Publique Hopitaux De Marseille
      2015   Phase 3   NCT02531984   -
   Bonnie Ramsey
      2014   Phase 3   NCT02054156   United States;
   Hospices Civils de Lyon
      2014   -   NCT02803944   France;
   Instituto de Investigacion Sanitaria La Fe
      2006   -   NCT01463371   Spain;
   Seattle Children's Hospital
      2016   Phase 4   NCT02677701   United States;
   St. Michael's Hospital, Toronto
      2006   Phase 2   NCT00298922   Canada;
   The University of Queensland
      2012   Phase 3   NCT01270074   Australia;New Zealand;
   University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)
      2012   Phase 4   NCT03045198   -
   University of Colorado, Denver
      2014   -   NCT02372383   United States;
Azithromycin 250 mg tablets
   CF Therapeutics Development Network Coordinating Center
      2007   Phase 4   NCT00431964   Canada;United States;
Azithromycin 500 mg film-coated tablet
   university medical center utrecht
      2018   Phase 4   EUCTR2016-001440-18-NL   Netherlands;
Aztreonam
   Gilead Sciences Inc
      2008   -   EUCTR2007-004277-26-IT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Liverpool Heart & Chest Hospital
      2016   Phase 4   EUCTR2016-002832-34-GB   United Kingdom;
   Liverpool Heart and Chest Hospital NHS Foundation Trust
      2017   Phase 4   NCT02894684   United Kingdom;
Aztreonam Lysine for Inhalation
   Gilead Sciences
      2003   -   NCT00499720   Puerto Rico;United States;
Aztreonam for Inhalation (AI)
   Gilead Sciences
      2003   Phase 2   NCT01055847   United States;
Aztreonam for Inhalation Solution
   Gilead Sciences, Inc.
      2012   Phase 2   EUCTR2011-001255-36-BE   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001362-18-DE   France;Germany;Italy;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-NL   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-IE   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-DE   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-AT   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2011   Phase 2   EUCTR2011-001255-36-ES   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      -   Phase 3   EUCTR2011-001362-18-FR   France;Germany;Italy;Poland;Spain;United States;
      -   Phase 2   EUCTR2011-001255-36-FR   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      -   -   EUCTR2011-001362-18-Outside-EU/EEA   United States;
      -   -   EUCTR2011-001255-36-Outside-EU/EEA   United States;
Aztreonam for Inhalation Solution (AZLI)
   Gilead Sciences
      2011   Phase 2   NCT01375049   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2008   Phase 3   NCT00757237   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Aztreonam lysine
   Gilead Sciences
      2009   -   NCT00989807   Canada;
   Gilead Sciences Inc
      2010   -   EUCTR2007-004277-26-AT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2007-004277-26-GB   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-FR   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-ES   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-BE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-PT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-NL   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-IE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-DK   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-DE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
Aztreonam lysine for inhalation
   Novartis Pharmaceuticals
      2010   -   NCT01460836   -
Aztreonam solución para inhalación
   Gilead Sciences, Inc.
      2012   Phase 3   EUCTR2011-001362-18-ES   France;Germany;Italy;Poland;Spain;United States;
Aztreonan lysine
   Gilead Sciences Inc
      2008   -   EUCTR2007-004277-26-IT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
BAY 85-8501
   Bayer HealthCare AG
      2013   Phase 2   EUCTR2012-004491-18-IT   Italy;United Kingdom;
      2013   Phase 2   EUCTR2012-004491-18-GB   Italy;Spain;United Kingdom;
      2013   -   EUCTR2012-004491-18-ES   Spain;United Kingdom;
BAY q 3939
   Bayer HealthCare AG
      2007   -   EUCTR2007-002912-24-DE   Germany;
BAY63-2521
   Bayer AG
      2015   Phase 2   EUCTR2013-004595-35-BE   Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-004595-35-GB   Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-004595-35-DE   Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
   Bayer HealthCare AG
      2015   Phase 2   EUCTR2013-004595-35-NL   Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States;
BAY85-8501
   Bayer
      2013   Phase 2   NCT01818544   France;Germany;Italy;Spain;United Kingdom;
BAYQ3939
   Bayer AG
      2014   Phase 3   EUCTR2013-004659-19-BG   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
   Bayer AG
      2014   Phase 3   EUCTR2013-004659-19-NL   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-LT   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-DE   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-CZ   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-AT   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
   Bayer Healthcare AG, D-51368 Leverkusen, Germany
      2014   Phase 3   EUCTR2013-004659-19-SK   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-PT   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-LV   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
BAYq3939
   BAYER HEALTHCARE AG
      2013   Phase 3   EUCTR2011-004208-39-IT   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
   Bayer HealthCare AG
      2014   Phase 3   EUCTR2011-004208-39-SK   Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
      2014   -   EUCTR2011-004208-39-LV   Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-004208-39-GB   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-004208-39-FR   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-004208-39-ES   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-004208-39-DE   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
      2013   -   EUCTR2011-004208-39-DK   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
      2009   Phase 2   EUCTR2009-009869-34-ES   Germany;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-009869-34-SE   Germany;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-009869-34-GB   Germany;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-009869-34-DE   Germany;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008314-40-SE   Denmark;Germany;Sweden;United Kingdom;
      2009   -   EUCTR2008-008314-40-DK   Denmark;Germany;Sweden;United Kingdom;
      2009   -   EUCTR2008-008314-40-DE   Denmark;Germany;Sweden;United Kingdom;
   Bayer Healthcare AG
      2009   -   EUCTR2008-008314-40-GB   Denmark;Germany;Sweden;United Kingdom;
BCG TICE Vaccine
   Johns Hopkins University
      2021   Phase 2   NCT04884308   United States;
BH4
   Augusta University
      2011   Phase 2   NCT01772758   United States;
BI 1265162
   Boehringer Ingelheim
      2019   Phase 2   NCT04059094   Belgium;Canada;France;Germany;Spain;Sweden;United Kingdom;United States;
BI 1265162 10 µg
   Boehringer Ingelheim
      2019   Phase 2   EUCTR2019-000261-21-SE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim France
      2019   Phase 2   EUCTR2019-000261-21-FR   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim Limited
      2019   Phase 2   EUCTR2019-000261-21-IE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000261-21-GB   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2019   Phase 2   EUCTR2019-000261-21-DE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim, S.A.
      2019   Phase 2   EUCTR2019-000261-21-ES   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm.V
      2019   Phase 2   EUCTR2019-000261-21-BE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1265162 100 µg
   Boehringer Ingelheim
      2019   Phase 2   EUCTR2019-000261-21-SE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim France
      2019   Phase 2   EUCTR2019-000261-21-FR   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim Limited
      2019   Phase 2   EUCTR2019-000261-21-IE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000261-21-GB   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2019   Phase 2   EUCTR2019-000261-21-DE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim, S.A.
      2019   Phase 2   EUCTR2019-000261-21-ES   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm.V
      2019   Phase 2   EUCTR2019-000261-21-BE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1265162 25 µg
   Boehringer Ingelheim
      2019   Phase 2   EUCTR2019-000261-21-SE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim France
      2019   Phase 2   EUCTR2019-000261-21-FR   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim Limited
      2019   Phase 2   EUCTR2019-000261-21-IE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000261-21-GB   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2019   Phase 2   EUCTR2019-000261-21-DE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim, S.A.
      2019   Phase 2   EUCTR2019-000261-21-ES   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm.V
      2019   Phase 2   EUCTR2019-000261-21-BE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1265162 50 µg
   Boehringer Ingelheim
      2019   Phase 2   EUCTR2019-000261-21-SE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim France
      2019   Phase 2   EUCTR2019-000261-21-FR   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim Limited
      2019   Phase 2   EUCTR2019-000261-21-IE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000261-21-GB   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2019   Phase 2   EUCTR2019-000261-21-DE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   Boehringer Ingelheim, S.A.
      2019   Phase 2   EUCTR2019-000261-21-ES   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
   SCS Boehringer Ingelheim Comm.V
      2019   Phase 2   EUCTR2019-000261-21-BE   Belgium;Canada;France;Germany;Ireland;Spain;Sweden;United Kingdom;United States;
BI 1323495
   Boehringer Ingelheim
      2021   Phase 1   NCT04656275   Germany;United Kingdom;
BI 443651
   Boehringer Ingelheim
      2017   Phase 1   NCT02976519   Germany;United Kingdom;
BIIL 283 BS (Amelubent)
   Boehringer Ingelheim
      2003   Phase 2   NCT00060801   United States;
BIIL 284 BS, high dose
   Boehringer Ingelheim
      2002   Phase 1   NCT02269189   -
BIIL 284 BS, high dose, adult patients
   Boehringer Ingelheim
      2001   Phase 1   NCT02265679   -
BIIL 284 BS, high dose, pediatric patients
   Boehringer Ingelheim
      2001   Phase 1   NCT02265679   -
BIIL 284 BS, low dose
   Boehringer Ingelheim
      2002   Phase 1   NCT02269189   -
BIIL 284 BS, low dose, adult patients
   Boehringer Ingelheim
      2001   Phase 1   NCT02265679   -
BIIL 284 BS, low dose, pediatric patients
   Boehringer Ingelheim
      2001   Phase 1   NCT02265679   -
BIIL 284 BS, medium dose, adult patients
   Boehringer Ingelheim
      2001   Phase 1   NCT02265679   -
BIIL 284 BS, medium dose, pediatric patients
   Boehringer Ingelheim
      2001   Phase 1   NCT02265679   -
BLF
   Alaxia SAS
      2015   Phase 1   NCT02598999   France;
BRAMICIL - 100 MG/ 2 ML SOLUZIONE INIETTABILE 10 FIALE DA 2 ML
   UNIVERSITY OF LIVERPOOL
      -   Phase 4   EUCTR2009-012575-10-IT   Italy;Sweden;United Kingdom;
BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML
   ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
      -   Phase 4   EUCTR2014-001401-41-IT   Italy;Netherlands;
BRAMITOB*NEBUL 28F 300MG/4ML
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2011   -   EUCTR2011-001821-26-IT   Italy;
BRAMITOB*NEBUL 56F 300MG/4ML
   AZIENDA OSPEDALIERA MEYER
      2011   -   EUCTR2011-006171-19-IT   Italy;
BX004-A
   BiomX, Inc.
      2021   Phase 1/Phase 2   NCT05010577   -
Bactrim
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
Balance
   Hacettepe University
      2019   -   NCT03902236   Turkey;
   University of Alabama at Birmingham
      2008   -   NCT01759342   United States;
Benralizumab
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-004068-24-IT   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
   AstraZeneca
      2021   Phase 3   NCT05006573   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
   AstraZeneca AB
      2021   Phase 3   EUCTR2020-004068-24-DK   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-004068-24-DE   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Viet Nam;
Beta-Adrenergic cocktail
   Richard Barry Moss
      2015   -   NCT02310789   United States;
Bethkis
   Mylan Inc.
      2015   -   NCT02449031   United States;
Biaxin ( clarithromycin)
   Wake Forest University
      2000   Phase 2   NCT00205634   United States;
Bio-25 probiotic
   Sheba Medical Center
      2010   -   NCT01201434   -
Bisphosphonate treatment
   Gilles Boire
      2001   Phase 4   NCT01882400   Canada;
Blood draw
   Emory University
      2015   -   NCT02589444   United States;
Blood draw.
   University of Florida
      2007   -   NCT01851642   United States;
Blood or Saliva Sample Collection
   Children's Hospital of Philadelphia
      2013   -   NCT01852448   United States;
Blood sample
   Hopital Foch
      2016   -   NCT02850692   France;
Blood sampling for determination of serum Zn
   University Hospital, Ghent
      2004   -   NCT00221559   Belgium;
Blood test
   Assistance Publique - Hôpitaux de Paris
      2018   -   NCT03492567   France;
Boost VHC
   Virginia Commonwealth University
      2022   -   NCT03931252   United States;
Boots High Strength Garlic Odour Controlled
   University of Nottingham
      2005   Phase 2   EUCTR2005-000311-98-GB   United Kingdom;
Bramitob
   Erasmus University Medical Centre
      2012   -   EUCTR2012-002503-17-NL   Netherlands;
   Haga Hospital
      2014   -   EUCTR2013-004488-30-NL   Netherlands;
Bramitob 300mg/4ml Nebuliser Solution
Bramitob® administered by PARI LC® PLUS nebulizer
   Chiesi Farmaceutici S.p.A.
      2010   Phase 1   NCT01116089   Czech Republic;Czechia;Moldova, Republic of;Russian Federation;Slovakia;
Bramitob® administered by PARI eFlow® rapid electronic nebulizer
   Chiesi Farmaceutici S.p.A.
      2010   Phase 1   NCT01116089   Czech Republic;Czechia;Moldova, Republic of;Russian Federation;Slovakia;
Brensocatib
   Fernandez C
      2021   Phase 3   JPRN-jRCT2031210048   Australia;Canada;Germany;Japan;New Zealand;Taiwan;United States;
   INSMED INCORPORATED
      2021   Phase 3   EUCTR2020-003688-25-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
   Insmed Incorporated
      2021   Phase 3   EUCTR2020-003688-25-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-IE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 2   NCT05090904   United States;
      2020   Phase 3   NCT04594369   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003688-25-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003688-25-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Broccoli sprouts
   University Hospitals Cleveland Medical Center
      2011   -   NCT01315665   United States;
Bronchial mucus collection
   University Hospital, Grenoble
      2021   -   NCT04687319   -
Bronchitol
   PHARMAXIS LTD
      2014   Phase 3   EUCTR2013-005357-79-SK   Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
   Pharmaxis Limited
      2016   Phase 3   EUCTR2013-005357-79-SE   Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;European Union;Greece;Hungary;Israel;Italy;Macedonia, the former Yugoslav Republic of;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2013-005357-79-GR   Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2013-005357-79-BG   Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005357-79-IT   Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005357-79-HU   Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005357-79-CZ   Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005357-79-BE   Argentina;Belgium;Bulgaria;Canada;Czech Republic;France;Greece;Hungary;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Pharmaxis Ltd.
      2014   -   EUCTR2012-002699-14-NL   Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;
      2014   -   EUCTR2012-002699-14-IT   Argentina;Belgium;Canada;Italy;Netherlands;United Kingdom;
      2013   Phase 2   EUCTR2012-002699-14-GB   Argentina;Belgium;Canada;France;Italy;Netherlands;United Kingdom;
      2013   -   EUCTR2012-002699-14-BE   Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
      -   Phase 2   EUCTR2012-002699-14-FR   Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Bronchoscopy with BAL
   National Center for Research Resources (NCRR)
      2001   -   NCT00023465   United States;
Bucelipase alfa
   Biovitrum AB
      2008   -   EUCTR2007-004063-21-NL   Netherlands;
Budesonide-formoterol single inhaler
   Hospital General de Requena
      2004   -   NCT00728715   Spain;
Burlulipase
   Nordmark Arzneimittel GmbH & Co. KG
      2013   Phase 1/Phase 2   NCT01710644   United States;
C01CA04 - Dopamina
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-004068-24-IT   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
CAYSTON aztreonam 75 mg powder and solvent for nebuliser solution
   GILEAD SCIENCES INC.
      2012   Phase 3   EUCTR2011-001362-18-IT   France;Germany;Italy;Spain;United States;
CB-280
   Calithera Biosciences, Inc
      2020   Phase 1   NCT04279769   Canada;United States;
CEFTAZIDIMA PENTAIDRATO
   UNIVERSITY OF LIVERPOOL
      -   Phase 4   EUCTR2009-012575-10-IT   Italy;Sweden;United Kingdom;
CEFTAZIDIME PENTAHYDRATE
   Ghent University
      2016   Phase 4   EUCTR2016-000398-19-BE   Belgium;
CF patients with a G551D mutation and treated with Ivacaftor
   Assistance Publique - Hôpitaux de Paris
      2014   -   NCT02194881   France;
CFTR Modulators
   Children's Hospital Medical Center, Cincinnati
      2022   -   NCT04580368   -
   Societe Francaise de la Mucoviscidose
      2020   -   NCT04301856   France;
   Universidad Europea de Madrid
      2020   -   NCT04415268   Spain;
CFTR potentiator
   Novartis Pharma AG
      2021   Phase 2   EUCTR2019-002840-26-DE   China;Germany;Spain;United Kingdom;
      2020   Phase 2   EUCTR2019-002840-26-GB   China;Germany;Spain;United Kingdom;
CHF 6333
   Chiesi Farmaceutici S.p.A.
      2019   Phase 1   NCT04010799   Germany;
CHF6333 (Part 1 - SAD)
   Chiesi Farmaceutici S.p.A.
      2016   Phase 1   NCT03056326   Belgium;
CHF6333 (Part 2 - MAD)
   Chiesi Farmaceutici S.p.A.
      2016   Phase 1   NCT03056326   Belgium;
CIPROFLOXACIN HYDROCHLORIDE
   AZIENDA OSPEDALIERA MEYER
      2011   -   EUCTR2011-006171-19-IT   Italy;
   Aradigm Corporation
      2010   Phase 2   EUCTR2009-014412-35-DE   Germany;United Kingdom;
      2010   -   EUCTR2009-014412-35-GB   Germany;United Kingdom;
CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE
   COP:TRIN Region Hovedstaden (Gentofte hospital)
      2017   Phase 4   EUCTR2015-003399-58-DK   Denmark;
   St. Vincent's University Hospital
      2016   Phase 4   EUCTR2016-001785-29-IE   Ireland;
CIPROFLOXACINA CLORIDRATO
   UNIVERSITY OF LIVERPOOL
      -   Phase 4   EUCTR2009-012575-10-IT   Italy;Sweden;United Kingdom;
CIPROXIN - 500 MG COMPRESSE RIVESTITE 14 COMPRESSE
   UNIVERSITY OF LIVERPOOL
      -   Phase 4   EUCTR2009-012575-10-IT   Italy;Sweden;United Kingdom;
CIPROXIN*6CPR RIV
   AZIENDA OSPEDALIERA MEYER
      2011   -   EUCTR2011-006171-19-IT   Italy;
CLORURO SODICO
   ADELAIDA LAMAS FERREIRO
      2009   -   EUCTR2008-001284-11-ES   Spain;
COLIMICINA - 1000000 U/4 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 4 ML
   AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER
      2016   Phase 3   EUCTR2015-003881-96-IT   Italy;
COLIMYCINE inhalation
   Poitiers University Hospital
      2011   Phase 1   NCT01537614   France;
COLIMYCINE injectable
   Poitiers University Hospital
      2011   Phase 1   NCT01537614   France;
COLISTIMETATO SODICO
   AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER
      2016   Phase 3   EUCTR2015-003881-96-IT   Italy;
COLISTIMETHATE SODIUM
   Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
      2014   Phase 4   EUCTR2013-004295-35-AT   Austria;
   St. Vincent's University Hospital
      2016   Phase 4   EUCTR2016-001785-29-IE   Ireland;
COLISTIMETHATE SODIUM (A COMPONENT)
   CUB - Hôpital Erasme
      2014   -   EUCTR2013-004987-80-BE   Belgium;
COLISTIN MESILATE SODIUM
   AZIENDA OSPEDALIERA MEYER
      2011   -   EUCTR2011-006171-19-IT   Italy;
COLISTINEB 2MUI
   CUB - Hôpital Erasme
      2014   -   EUCTR2013-004987-80-BE   Belgium;
COVID-19 Vaccine (ChAdOx1-S [recombinant])
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant])
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 Vaccine Moderna dispersion for injection
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 mRNA vaccine (nucleoside-modified)
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 mRNA vaccine Moderna (CX-024414)
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 vaccine (Ad26.COV2-S [recombinant])
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19)
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
CPX
   FDA Office of Orphan Products Development
      1997   Phase 1   NCT00004428   -
CR002 Liquid API
   CSL Behring
      2011   Phase 1   NCT01347190   Bulgaria;Hungary;Poland;United Kingdom;
CRC3357, ZK-355322, Leukoton
   Celtaxsys Inc.
      2016   Phase 2   EUCTR2015-002677-38-IT   Belgium;France;Germany;Italy;Netherlands;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002677-38-GB   Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002677-38-DE   Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002677-38-BE   Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
CREON
   AbbVie
      2021   Phase 4   NCT05069597   United States;
      2020   Phase 4   NCT04315311   United States;
      2012   -   NCT01652157   United States;
CREON 10000 Capsules
   EURAND SPA
      2010   -   EUCTR2009-012842-21-IT   Bulgaria;Germany;Hungary;Italy;United Kingdom;
CREON IR
   Abbott Laboratories GmbH
      2015   -   EUCTR2014-004519-35-HU   Czech Republic;Hungary;Spain;United Kingdom;
      2015   -   EUCTR2014-004519-35-GB   Czech Republic;Hungary;Spain;United Kingdom;
      2015   -   EUCTR2014-004519-35-CZ   Czech Republic;Hungary;Spain;United Kingdom;
CREON N 25000
   Abbott Laboratories GmbH
      2013   -   EUCTR2013-002819-10-HU   Hungary;Russian Federation;Spain;
CSL787
   CSL Behring
      2020   Phase 1   NCT04643587   United Kingdom;
CTX-4430
   Celtaxsys Inc.
      2016   Phase 2   EUCTR2015-002677-38-IT   Belgium;France;Germany;Italy;Netherlands;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002677-38-GB   Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002677-38-DE   Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002677-38-BE   Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
   Celtaxsys, Inc.
      2015   Phase 2   NCT02443688   Belgium;Canada;France;Germany;Italy;United Kingdom;United States;
      2013   Phase 1   NCT01944735   United Kingdom;
CYC202
   CHRU de Brest
      2015   Phase 2   EUCTR2015-002911-13-FR   France;
CYCLO[L-ALANYL-L-SERYL-L-ISOLEUCYL-L-PROLYL-L-PROLYL-L-GLUTAMINYL-L-LYSYL-L-TYROSYL-D-PROLYL-L-PROLYL-(2S)-2-AMINODECANOYL-L-ALPHA-GLUTAMYL-L-THREONYL]
   Santhera Pharmaceuticals (Switzerland) Ltd
      2018   Phase 1;Phase 2   EUCTR2018-002550-71-DE   Germany;
Calcium carbonate
   University of North Carolina
      1998   -   NCT00004489   United States;
Calfactant
   University of Pittsburgh
      2008   -   NCT00628134   United States;
Cavosonstat
   Nivalis Therapeutics, Inc.
      2016   Phase 2   NCT02724527   United States;
      2016   Phase 1   NCT02934139   United States;
      2015   Phase 2   NCT02589236   United States;
Cayston
   Gilead Sciences, Inc.
      2012   Phase 3   EUCTR2011-001362-18-ES   France;Germany;Italy;Poland;Spain;United States;
   Gilead Sciences Inc
      2010   -   EUCTR2007-004277-26-AT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2007-004277-26-GB   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-DE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      -   -   EUCTR2007-004277-26-Outside-EU/EEA   United States;
   Gilead Sciences, Inc.
      2018   Phase 3   EUCTR2016-002749-42-NL   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-002749-42-GR   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-IT   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-GB   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-FR   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-ES   Austria;Belgium;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-DK   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-DE   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-BE   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002749-42-AT   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-001255-36-BE   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001362-18-DE   France;Germany;Italy;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-NL   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-IE   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-DE   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2012   -   EUCTR2011-001255-36-AT   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      2011   Phase 2   EUCTR2011-001255-36-ES   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      -   Phase 3   EUCTR2016-002749-42-IE   Austria;Belgium;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2011-001362-18-FR   France;Germany;Italy;Poland;Spain;United States;
      -   Phase 2   EUCTR2011-001255-36-FR   Austria;Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Spain;United States;
      -   -   EUCTR2015-000398-11-Outside-EU/EEA   United States;
      -   -   EUCTR2015-000397-36-Outside-EU/EEA   Canada;
      -   -   EUCTR2015-000396-26-Outside-EU/EEA   United States;
      -   -   EUCTR2015-000395-97-Outside-EU/EEA   Australia;Canada;United States;
      -   -   EUCTR2011-001362-18-Outside-EU/EEA   United States;
      -   -   EUCTR2011-001255-36-Outside-EU/EEA   United States;
      -   -   EUCTR2009-011740-19-Outside-EU/EEA   Canada;United States;
   Liverpool Heart & Chest Hospital
      2016   Phase 4   EUCTR2016-002832-34-GB   United Kingdom;
   Mylan Inc.
      2015   -   NCT02449031   United States;
Cayston 75 mg Pulver und Lösungsmittel zur Herstellung einer Lösung für einen Vernebler
   Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
      2014   Phase 4   EUCTR2013-004295-35-AT   Austria;
Cayston Aztreonam 75 mg powder and solvent for nebuliser solution
   GILEAD SCIENCES INC.
      2012   -   EUCTR2011-001255-36-IT   Austria;Germany;Ireland;Italy;Netherlands;Spain;United States;
Ceftaroline
   Children's Hospital Medical Center, Cincinnati
      2017   Phase 4   NCT03771313   United States;
Ceftazidim Fresenius Kabi 2000 mg poeder voor oplossing voor injectie of infusie
   Ghent University
      2016   Phase 4   EUCTR2016-000398-19-BE   Belgium;
Ceftazidime
   Association Nationale pour le Traitement à Domicile de l'Insuffisance Respiratoire
      2001   Phase 4   NCT00333385   France;
   Imperial College London
      2010   Phase 4   NCT01044719   United Kingdom;
   Imperial College, London
      2009   -   EUCTR2009-014042-28-GB   United Kingdom;
   UNIVERSITY OF LIVERPOOL
      -   Phase 4   EUCTR2009-012575-10-IT   Italy;Sweden;United Kingdom;
   University College Cork
      2015   -   NCT02526004   Ireland;
   University Ghent
      2016   -   NCT02840136   Belgium;
   University Hospitals Bristol NHS Foundation Trust
      2016   Phase 4   EUCTR2009-012575-10-SE   Sweden;United Kingdom;
      2009   Phase 4   EUCTR2009-012575-10-GB   Sweden;United Kingdom;
Ceftazidime and tobramycin
   University of North Carolina, Chapel Hill
      2004   Phase 1   NCT00823238   United States;
Ceftazidime/avibactam
   University of Southern California
      2015   Phase 4   NCT02504827   United States;
Ceftolozane/Tazobactam
   Joseph L. Kuti, PharmD
      2015   Phase 4   NCT02421120   United States;
Cefuroxim
   Västra Götalandsregionen
      2021   Phase 4   EUCTR2019-003501-10-DK   Denmark;Norway;Sweden;
      2020   Phase 4   EUCTR2019-003501-10-SE   Denmark;Norway;Sweden;
Cephalexin
   University of British Columbia
      2020   Phase 3   NCT04553419   Canada;
Cftr Modulators
   Indiana University
      2019   -   NCT04206436   United States;
Chlorhexidine Gluconate
   University of North Carolina, Chapel Hill
      2018   Phase 2   NCT03489629   United States;
Chlorhexidine gluconate oral rinse
   University of North Carolina, Chapel Hill
      2011   Phase 2   NCT01349192   United States;
Chlorhexidine solution wipes
   University of North Carolina, Chapel Hill
      2011   Phase 2   NCT01349192   United States;
Chloride
   Milton S. Hershey Medical Center
      2018   -   NCT03367494   United States;
Cholecalciferol
   Children's Hospital of Philadelphia
      2008   Phase 3   NCT00762918   United States;
   Emory University
      2011   Phase 3   NCT01426256   United States;
   Shanghai Pulmonary Hospital, Shanghai, China
      2015   Phase 4   NCT02507843   China;
   University of North Carolina
      1998   -   NCT00004489   United States;
Cholecalciferol (Vitamin D3)
   University of Pittsburgh
      2010   -   NCT01222273   United States;
Cholecalciferol (vitaminD3)
   Heba Omara
      2018   Phase 2/Phase 3   NCT04411901   Egypt;
Cholecalciferol Pill
   Hospital Infantil de Mexico Federico Gomez
      2022   Phase 4   NCT05276960   Mexico;
Choline Chloride
   University Hospital Tuebingen
      2014   -   NCT03312140   -
Choline supplementation
   University of British Columbia
      2007   -   NCT00686361   Canada;
Chronic Antioxidant
   Augusta University
      2015   -   NCT02690064   United States;
Cipro (Ciprofloxacin, BAYQ3939)
   Bayer
      2016   -   NCT02555059   Japan;
Cipro Inhale
   Bayer HealthCare AG
      2009   Phase 2   EUCTR2009-009869-34-ES   Germany;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-009869-34-SE   Germany;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-009869-34-GB   Germany;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-009869-34-DE   Germany;Spain;Sweden;United Kingdom;
Ciprofloxacin
   AZIENDA OSPEDALIERA MEYER
      2008   -   EUCTR2008-006502-42-IT   Italy;
   Bayer
      2016   -   NCT02661438   United States;
   Bayer HealthCare AG
      2009   Phase 2   EUCTR2009-009869-34-ES   Germany;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-009869-34-SE   Germany;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-009869-34-GB   Germany;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2009-009869-34-DE   Germany;Spain;Sweden;United Kingdom;
   UNIVERSITY OF LIVERPOOL
      -   Phase 4   EUCTR2009-012575-10-IT   Italy;Sweden;United Kingdom;
   University Hospitals Bristol NHS Foundation Trust
      2016   Phase 4   EUCTR2009-012575-10-SE   Sweden;United Kingdom;
      2009   Phase 4   EUCTR2009-012575-10-GB   Sweden;United Kingdom;
   Vertex Pharmaceuticals Incorporated
      2014   Phase 1   NCT02015507   -
      2013   Phase 1   NCT01768663   United States;
Ciprofloxacin (BAYQ3939) dry powder for inhalation
   Bayer
      2014   Phase 3   NCT02106832   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Czechia;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Ciprofloxacin (Cipro Inhale, BAYQ3939)
   Bayer
      2008   Phase 2   NCT00645788   Australia;Canada;Denmark;Germany;Israel;Norway;Sweden;United Kingdom;United States;
Ciprofloxacin (Cipro, BAYQ3939)
   Bayer
      2009   Phase 2   NCT00930982   Australia;Germany;Spain;Sweden;United Kingdom;United States;
      2009   Phase 1   NCT00910351   United States;
Ciprofloxacin (ciproxin)
   Belfast City Hospital Trust
      2005   Phase 4   EUCTR2005-003837-42-GB   United Kingdom;
Ciprofloxacin DPI
   BAYER HEALTHCARE AG
      2013   Phase 3   EUCTR2011-004208-39-IT   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
   Bayer AG
      2014   Phase 3   EUCTR2013-004659-19-BG   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
   Bayer AG
      2014   Phase 3   EUCTR2013-004659-19-NL   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-LT   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-DE   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-CZ   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-AT   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
   Bayer HealthCare AG
      2014   Phase 3   EUCTR2011-004208-39-SK   Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
      2014   -   EUCTR2011-004208-39-LV   Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-004208-39-GB   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-004208-39-FR   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-004208-39-ES   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-004208-39-DE   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
      2013   -   EUCTR2011-004208-39-DK   Argentina;Australia;Brazil;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Serbia;Slovakia;Spain;United Kingdom;United States;
   Bayer Healthcare AG, D-51368 Leverkusen, Germany
      2014   Phase 3   EUCTR2013-004659-19-SK   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-PT   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;China;Czech Republic;Germany;Hong Kong;Hungary;Korea, Republic of;Latvia;Lithuania;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
      2014   Phase 3   EUCTR2013-004659-19-LV   Argentina;Australia;Austria;Brazil;Bulgaria;China;Czech Republic;Germany;Hong Kong;Korea, Republic of;Latvia;Lithuania;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Taiwan;Thailand;Turkey;United States;
Ciprofloxacin DPI (BAYQ3939)
   Bayer
      2013   Phase 3   NCT01764841   Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom;United States;
Ciprofloxacin Inhale
   Bayer HealthCare AG
      2009   -   EUCTR2008-008314-40-SE   Denmark;Germany;Sweden;United Kingdom;
      2009   -   EUCTR2008-008314-40-DK   Denmark;Germany;Sweden;United Kingdom;
      2009   -   EUCTR2008-008314-40-DE   Denmark;Germany;Sweden;United Kingdom;
   Bayer Healthcare AG
      2009   -   EUCTR2008-008314-40-GB   Denmark;Germany;Sweden;United Kingdom;
Ciprofloxacin dispersion for inhalation
   Aradigm Corporation
      2014   Phase 3   NCT02104245   Australia;Canada;Former Serbia and Montenegro;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;New Zealand;Peru;Poland;Romania;Spain;United Kingdom;United States;
      2014   Phase 3   NCT01515007   Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;New Zealand;Poland;Romania;South Africa;Spain;Taiwan;United Kingdom;United States;
Ciprofloxacin for Inhalation
   Aradigm Corporation
      2010   Phase 2   NCT00889967   Canada;Germany;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-014412-35-DE   Germany;United Kingdom;
      2010   -   EUCTR2009-014412-35-GB   Germany;United Kingdom;
Ciproxin
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
Ciproxin Suspension
   Southampton University Hospital Trust
      2008   -   EUCTR2008-001769-27-GB   United Kingdom;
Clarithromycin
   Chinese University of Hong Kong
      2020   -   NCT04658277   Hong Kong;
Claritromycin 500mg film coated tablets
   university medical center utrecht
      2018   Phase 4   EUCTR2016-001440-18-NL   Netherlands;
Cobamamide
   AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
      2010   -   EUCTR2010-020516-11-IT   Italy;
Colistimethat-Natrium
   University of Jena
      2009   -   EUCTR2008-007877-19-DE   Germany;
Colistimethate
   Novartis Pharmaceuticals
      2013   Phase 4   NCT01844778   Germany;Ireland;Spain;Switzerland;United Kingdom;
Colistimethate 75 mg inhaled two times daily
   Dartmouth-Hitchcock Medical Center
      2014   -   NCT02113397   United States;
Colistimethate Sodium
   Zambon SpA
      2017   Phase 3   NCT03093974   Australia;Belgium;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Colistimethate sodium
   Forest Laboratories UK Ltd
      2005   -   EUCTR2004-003675-36-DK   Belgium;Denmark;
      2005   -   EUCTR2004-003675-36-BE   Belgium;Denmark;
      2005   -   EUCTR2004-003675-36-AT   Austria;Belgium;Denmark;
   Profile Pharma Ltd
      2010   -   EUCTR2008-005045-34-IE   Ireland;United Kingdom;
      2008   Phase 3   EUCTR2008-005045-34-GB   Ireland;Russian Federation;Ukraine;United Kingdom;
   University of Colorado, Denver
      2013   -   NCT02288429   United States;
   Zambon SpA
      2018   Phase 3   NCT03460704   Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
Colistimethate sodium (BAN, USAN), Colistimethatum natricum, Colistin sodium methanesulfonate
   Forest Laboratories UK Ltd.
      2011   -   EUCTR2011-000192-13-PL   Germany;Poland;Ukraine;United Kingdom;
      2011   -   EUCTR2011-000192-13-GB   Germany;Poland;United Kingdom;
      2011   -   EUCTR2011-000192-13-DE   Germany;Poland;Ukraine;United Kingdom;
Colistimethate sodium (promixin)
   Aarhus University Hospital, Department of Respiratory Medicine
      2015   Phase 2   EUCTR2015-003662-87-DK   Denmark;
Colistin
   AZIENDA OSPEDALIERA MEYER
      2008   -   EUCTR2008-006502-42-IT   Italy;
   National Jewish Health
      2016   Phase 4   NCT02918409   United States;
   St. Vincent's University Hospital
      2016   Phase 4   EUCTR2016-001785-29-IE   Ireland;
   University Hospital Tuebingen
      2014   Phase 3   NCT03341741   -
   University of Jena
      2009   Phase 2   NCT01035853   Germany;
Colistin CF
   University of Jena
      2009   -   EUCTR2008-007877-19-DE   Germany;
Colistin Forest - Trockenstechampullen mit Lösungsmittel
   Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
      2014   Phase 4   EUCTR2013-004295-35-AT   Austria;
Colobreathe
   Forest Laboratories UK Ltd
      2005   -   EUCTR2004-003675-36-DK   Belgium;Denmark;
      2005   -   EUCTR2004-003675-36-BE   Belgium;Denmark;
      2005   -   EUCTR2004-003675-36-AT   Austria;Belgium;Denmark;
   Forest Laboratories UK Ltd.
      2011   -   EUCTR2011-000192-13-PL   Germany;Poland;Ukraine;United Kingdom;
      2011   -   EUCTR2011-000192-13-GB   Germany;Poland;United Kingdom;
      2011   -   EUCTR2011-000192-13-DE   Germany;Poland;Ukraine;United Kingdom;
Colomycin
   Forest Laboratories UK Ltd
      2005   -   EUCTR2004-003675-36-DK   Belgium;Denmark;
      2005   -   EUCTR2004-003675-36-BE   Belgium;Denmark;
      2005   -   EUCTR2004-003675-36-AT   Austria;Belgium;Denmark;
   The Leeds Teaching Hospitals NHS Trust
      2015   -   NCT02489955   United Kingdom;
Comirnaty concentrate for dispersion for injection
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
Compound 1a
   PTC Therapeutics, Inc
      2010   Phase 3   EUCTR2010-019692-30-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-GB   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-SE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-NL   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-ES   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-DE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Continuous Glucose Monitoring
   Liverpool Heart and Chest Hospital NHS Foundation Trust
      2013   -   NCT01975259   United Kingdom;
Continuous Glucose Monitoring System (CGMS)
   University Hospital, Strasbourg, France
      2008   -   NCT00476281   France;
Continuous glucose monitor (CGM)
   Jagdeesh Ullal
      2021   Phase 4   NCT04533646   United States;
Continuous infusion Cefepime
   The Alfred
      2012   Phase 4   NCT01667094   Australia;
Continuous infusion Ceftazidime
   The Alfred
      2012   Phase 4   NCT01667094   Australia;
Continuous infusion Meropenem
   The Alfred
      2012   Phase 4   NCT01667094   Australia;
Continuous infusion Piperacillin tazobactam
   The Alfred
      2012   Phase 4   NCT01667094   Australia;
Continuous infusion Ticarcillin-clavulanate
   The Alfred
      2012   Phase 4   NCT01667094   Australia;
Control
   University Hospital Southampton NHS Foundation Trust.
      2011   Phase 2   NCT02295566   United Kingdom;
Control Group Isotonic Saline
   University of Washington, the Collaborative Health Studies Coordinating Center
      2015   Phase 2/Phase 3   NCT02950883   Australia;Belgium;Canada;Denmark;France;Italy;Netherlands;Spain;United States;
Control multivitamin
   University of Colorado, Denver
      2013   Phase 2   NCT01859390   United States;
Creon 10.000, hårde enterokapsler
   Terese Katzenstein
      2020   Phase 4   EUCTR2019-004940-31-DK   Denmark;
Creon 10000
   Solvay Pharmaceuticals GmbH
      2008   -   EUCTR2007-004004-12-BG   Bulgaria;
Creon 25.000, hårde enterokapsler
   Terese Katzenstein
      2020   Phase 4   EUCTR2019-004940-31-DK   Denmark;
Creon 25000
   Abbott Laboratories GmbH
      2013   -   EUCTR2013-002819-10-HU   Hungary;Russian Federation;Spain;
   Solvay Pharmaceuticals GmbH
      2008   -   EUCTR2007-004004-12-BG   Bulgaria;
Creon 40.000, hårde enterokapsler
   Terese Katzenstein
      2020   Phase 4   EUCTR2019-004940-31-DK   Denmark;
Creon IR
   Abbott
      2015   Phase 2   NCT02415959   Czech Republic;Hungary;Poland;Spain;
Creon N
   Abbott
      2014   Phase 3   NCT02137382   Hungary;Russian Federation;Spain;
Creon®
   Abbott
      2014   Phase 3   NCT02137382   Hungary;Russian Federation;Spain;
Creon® (DR/GR)
   Abbott
      2015   Phase 2   NCT02415959   Czech Republic;Hungary;Poland;Spain;
Creon® 25,000
   Abbott Laboratories GmbH
      2015   -   EUCTR2014-004519-35-HU   Czech Republic;Hungary;Spain;United Kingdom;
      2015   -   EUCTR2014-004519-35-GB   Czech Republic;Hungary;Spain;United Kingdom;
      2015   -   EUCTR2014-004519-35-CZ   Czech Republic;Hungary;Spain;United Kingdom;
Crestor
   University of Liverpool
      2014   Phase 2   EUCTR2014-002387-32-GB   United Kingdom;
Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm
   University Medical Centre Utrecht
      2014   Phase 2   EUCTR2014-000817-30-NL   Netherlands;
Cystagon
   University of LIverpool
      2019   Phase 1;Phase 2   EUCTR2017-001259-29-GB   United Kingdom;
Cystagon (cysteamine bitartrate) immediate-release capsules
   University of Aberdeen
      2014   Phase 1;Phase 2   EUCTR2014-000284-40-GB   United Kingdom;
Cysteamine
   NovaBiotics Ltd.
      2016   Phase 2   NCT03000348   Italy;United Kingdom;United States;
   University of Aberdeen
      2014   Phase 1/Phase 2   NCT02212431   United Kingdom;
Cysteamine bitartrate
   NovaBiotics, Ltd
      2017   Phase 2   EUCTR2015-004986-99-IT   Italy;Netherlands;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004986-99-GB   Italy;Netherlands;United Kingdom;United States;
   University of LIverpool
      2019   Phase 1;Phase 2   EUCTR2017-001259-29-GB   United Kingdom;
Cysteamine bitartrate (Cystagon)
   European Institute for Cystic Fibrosis Research (IERFC)
      2013   -   EUCTR2013-001258-82-IT   Italy;
Cystic Fibrosis Ready to Use Supplemental Food
   Washington University School of Medicine
      2018   Phase 1/Phase 2   NCT03462056   United States;
D-a-tocopheryl PEG 1000 succinate
   ORPHAN
      2007   -   EUCTR2007-001007-38-FR   France;
D6-25-hydroxyvitamin D3
   University of Washington
      2017   Phase 1   NCT03104855   United States;
DCI 1020
   Digestive Care, Inc.
      2009   -   NCT00663975   United States;
DEPELESTAT
   DEBIOPHARM S.A.
      2005   -   EUCTR2004-002341-12-IT   Belgium;Germany;Italy;United Kingdom;
DORIPENEM HYDRATE
   Johnson & Johnson Pharmaceutical Research & Development L.L.C
      -   -   EUCTR2015-001225-16-Outside-EU/EEA   United States;
DP Mannitol
   Pharmaxis Ltd
      2004   Phase 2   EUCTR2004-001888-21-GB   United Kingdom;
DTPA
   University of Pittsburgh
      2007   -   NCT00541190   United States;
DX-890
   DEBIOPHARM S.A.
      2005   -   EUCTR2004-002341-12-IT   Belgium;Germany;Italy;United Kingdom;
De-activated smart device
   Vertex Pharmaceuticals Incorporated
      2016   Phase 4   NCT02823470   Canada;United States;
Decolonization
   State University of New York - Upstate Medical University
      2011   -   NCT01229553   United States;
Denosumab
   University of Texas Southwestern Medical Center
      2022   Phase 4   NCT03921060   United States;
Denufosol Tetrasodium (INS37217) Inhalation Solution
   Merck Sharp & Dohme Corp.
      2008   Phase 3   NCT00625612   Australia;Canada;New Zealand;United States;
Denufosol tetrasodium (INS37217)
   Merck Sharp & Dohme Corp.
      2005   Phase 2   NCT00130182   United States;
      2005   Phase 2   NCT00103714   United States;
      2003   Phase 2   NCT00056147   United States;
Denufosol tetrasodium (INS37217) Inhalation Solution
   Merck Sharp & Dohme Corp.
      2007   Phase 2   NCT00425165   United States;
      2006   Phase 3   NCT00357279   Canada;United States;
      2001   Phase 1/Phase 2   NCT00034515   United States;
Denufosol tetrasodium Inhalation Solution
   Merck Sharp & Dohme Corp.
      2010   Phase 2   NCT01181622   United States;
      2009   Phase 3   NCT00846781   Australia;Canada;New Zealand;United States;
Depelestat
   Debiopharm SA
      2005   Phase 2   EUCTR2004-002341-12-GB   Belgium;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-002341-12-DE   Belgium;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-002341-12-BE   Belgium;Germany;Italy;United Kingdom;
Detoxifying agents for antineoplastic treatment
   AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
      2010   -   EUCTR2010-020516-11-IT   Italy;
Deuterated Ivacaftor
   Vertex Pharmaceuticals Incorporated
      2017   Phase 2   EUCTR2017-000797-11-BE   Australia;Belgium;Netherlands;United States;
      2017   Phase 2   EUCTR2016-003585-11-GB   Ireland;Israel;United Kingdom;United States;
Dexamethasone
   ISTITUTO GIANNINA GASLINI
      2008   -   EUCTR2007-001782-15-IT   Italy;
Dexamethasone sodium phosphate 250 mg/10 ml solution
   AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
      2011   -   EUCTR2011-000130-11-IT   Italy;
Diet
   Hospital de Clinicas de Porto Alegre
      2016   -   NCT03205904   Brazil;
Digitoxin
   National Jewish Health
      2010   Phase 2   NCT00782288   United States;
Docosahexaenoic acid
   Hospices Civils de Lyon
      2010   Phase 2   NCT02690857   -
Docosahexaenoic acid (DHA)
   University of Massachusetts, Worcester
      2003   -   NCT00530244   United States;
Docosahexaenoic acid administration: 50 mg/kg/day during 12 months
   Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
      2011   -   NCT01783613   Spain;
Docosahexanoic Acid Supplement
   Vanderbilt University
      2013   Phase 2   NCT00924547   United States;
Dornase alfa
   David Nichols, MD
      2020   -   NCT04378153   United States;
   Genentech, Inc.
      2008   Phase 4   NCT00680316   United States;
      2007   Phase 4   NCT00434278   United States;
   University of Jena
      -   Phase 3   EUCTR2007-001548-36-DE   Germany;
Dornase alfa (Pulmozyme)
   University of Jena
      2007   Phase 3   NCT00534079   Germany;
Dornase alfa [Pulmozyme®]
   Genentech, Inc.
      2012   Phase 4   NCT01712334   United States;
Dornase alpha
   Pharmaxis
      2005   Phase 2   NCT00117208   United Kingdom;
   University of Oklahoma
      2006   -   NCT00671723   United States;
Doxycyclin
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
Doxycycline
   Johns Hopkins University
      2012   Phase 2   NCT01594827   United States;
   University of Alabama at Birmingham
      2008   -   NCT01112059   United States;
   University of Southern California
      2008   Phase 4   NCT01323101   United States;
Dry powder tobramycin
   University Medical Center Groningen
      2013   -   EUCTR2012-004437-16-NL   Netherlands;
      -   Phase 2   EUCTR2016-005014-21-NL   Netherlands;
Dual Energy X-ray Absorptiometry (DEXA)
   University of Texas Southwestern Medical Center
      2006   -   NCT00287443   United States;
      2006   -   NCT00287430   -
Dulaglutide 0.75Mg/0.5Ml Inj Pen
   University of Pennsylvania
      2021   Phase 2   NCT04731272   United States;
Duramycin, 2622U90
   AOP Orphan Pharmaceuticals AG
      2006   Phase 2;Phase 3   EUCTR2005-005594-29-SK   Czech Republic;Hungary;Slovakia;
      2006   -   EUCTR2005-005594-29-HU   Czech Republic;Hungary;
      2006   -   EUCTR2005-005594-29-CZ   Czech Republic;Hungary;
      2006   -   EUCTR2005-004344-30-HU   Hungary;
      2005   -   EUCTR2005-004344-30-AT   Austria;Hungary;
ECGC
   Hadassah Medical Organization
      2011   -   NCT00889434   Israel;
EGCG + Tocotrienol
   Hadassah Medical Organization
      2011   -   NCT00889434   Israel;
ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC
   Vertex Pharmaceuticals Incorporated
      -   Phase 3   EUCTR2018-004652-38-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
ELX (VX-445)/TEZ (VX-661)/IVA (VX-770)
   VERTEX PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2020-003170-44-IT   Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2020-003170-44-CZ   Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
      -   Phase 3   EUCTR2020-003170-44-NL   Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
      -   Phase 3   EUCTR2020-003170-44-FR   Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
      -   Phase 3   EUCTR2020-003170-44-BE   Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
ELX / 40mg TEZ / 60mg IVA
   Vertex Pharmaceuticals Incorporated
      2021   Phase 3   EUCTR2020-002251-38-DE   Germany;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002239-31-DE   Australia;Canada;Germany;United Kingdom;United States;
ELX /50 mg TEZ /75 mg IVA FDC
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2018-000185-11-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-SE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
ELX-02
   Eloxx Pharmaceuticals Inc
      2019   Phase 2   EUCTR2018-000966-12-DE   Australia;Germany;Israel;
   Eloxx Pharmaceuticals, Inc.
      2019   Phase 2   NCT04135495   Canada;United States;
      2019   Phase 2   NCT04126473   Australia;Germany;Israel;
ELX/25 mg TEZ/37.5 mg IVA
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-005320-38-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-PT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
ELX/25 mg TEZ/37.5 mg IVA fixed dose combination
   Vertex Pharmaceuticals Incorporated
      2021   Phase 3   EUCTR2020-001404-42-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2021   Phase 3   EUCTR2020-001404-42-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2020-001404-42-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2020-001404-42-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2020-001404-42-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
ELX/50 mg TEZ /75 mg IVA FDC
   VERTEX PHARMACEUTICALS INCORPORATED
      2018   Phase 3   EUCTR2018-000185-11-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2019   Phase 3   EUCTR2018-000185-11-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
ELX/50 mg TEZ/75 mg IVA fixed dose combination
   Vertex Pharmaceuticals Incorporated
      2021   Phase 3   EUCTR2021-001628-16-ES   Australia;Belgium;Canada;Spain;
      2021   Phase 3   EUCTR2020-004885-21-ES   Belgium;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-004885-21-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-001404-42-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2021   Phase 3   EUCTR2020-001404-42-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2020-001404-42-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2021-001628-16-BE   Australia;Belgium;Canada;Spain;
      -   Phase 3   EUCTR2020-004885-21-NL   Belgium;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-004885-21-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-001404-42-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2020-001404-42-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
ELX/50mg TEZ /75mg IVA
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-005320-38-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-PT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
ELX/TEZ/IVA
   VERTEX PHARMACEUTICALS INCORPORATED
      2021   Phase 3   EUCTR2021-000694-85-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   NCT05274269   -
      2022   Phase 3   NCT05153317   United States;
      2022   Phase 3   NCT05111145   Australia;Spain;
      2022   Phase 3   EUCTR2021-000712-31-SE   Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000712-31-PT   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000712-31-DE   Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000694-85-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   NCT05076149   Australia;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
      2021   Phase 3   NCT05033080   Czechia;Germany;United Kingdom;United States;
      2021   Phase 3   NCT04969224   Australia;Belgium;Canada;Spain;
      2021   Phase 3   NCT04599465   Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
      2021   Phase 3   NCT04545515   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2021   Phase 3   EUCTR2021-000694-85-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NO   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-GR   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002251-38-DE   Germany;United Kingdom;United States;
      2021   -   NCT04702360   -
      2020   Phase 3   NCT04537793   Australia;Canada;Germany;United Kingdom;United States;
      2020   Phase 3   NCT04362761   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   NCT04353817   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   NCT04183790   Australia;Canada;Ireland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003455-11-GB   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-DE   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-BE   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-000833-37-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   -   NCT04058210   -
      2019   Phase 3   NCT04105972   Australia;Belgium;Germany;United Kingdom;
      2019   Phase 3   NCT04058366   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   NCT04058353   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   NCT04043806   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000185-11-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000712-31-IE   Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000712-31-CZ   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002239-31-DE   Australia;Canada;Germany;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-SE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
EMEA/H/C/000125
   European Institute for Cystic Fibrosis Research (IERFC)
      2013   -   EUCTR2013-001258-82-IT   Italy;
EPI-hNE4 DX-890
   Debiopharm SA
      2005   Phase 2   EUCTR2004-002341-12-GB   Belgium;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-002341-12-DE   Belgium;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-002341-12-BE   Belgium;Germany;Italy;United Kingdom;
ETD001 multiple once daily doses
   Enterprise Therapeutics Ltd
      2021   Phase 1   NCT04926701   United Kingdom;
ETD001 multiple twice daily doses
   Enterprise Therapeutics Ltd
      2021   Phase 1   NCT04926701   United Kingdom;
ETD001 single dose
   Enterprise Therapeutics Ltd
      2021   Phase 1   NCT04926701   United Kingdom;
EU Orphan Designation Number EU/3/02/120
   AOP Orphan Pharmaceuticals AG
      2006   -   EUCTR2005-004344-30-HU   Hungary;
      2005   -   EUCTR2005-004344-30-AT   Austria;Hungary;
EUR-1008
   Aptalis Pharma US Inc.
      2013   -   EUCTR2009-012842-21-HU   Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2012   Phase 3   EUCTR2009-012842-21-BE   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2011   -   EUCTR2009-012842-21-DE   Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2011   -   EUCTR2009-012842-21-BG   Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
      2010   Phase 3   EUCTR2009-012842-21-GB   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
EUR-1008 (APT-1008)
   Forest Laboratories
      2010   Phase 4   NCT01131507   United States;
      2010   Phase 4   NCT01100606   United States;
      2006   Phase 3   NCT00981214   United States;
      2006   Phase 3   NCT00297167   United States;
EUR-1008 25,000 Units
   Aptalis Pharma
      2012   Phase 3   NCT01641393   Belgium;Bulgaria;France;Germany;Italy;Poland;United Kingdom;
EZ-2053
   Neovii Biotech
      2005   Phase 3   NCT00105183   Australia;Austria;Canada;United States;
Elasomeran
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
Elexacaftor
   VERTEX PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2020-003170-44-IT   Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
      2019   Phase 3   EUCTR2019-000833-37-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-005320-38-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      2021   Phase 3   EUCTR2021-001628-16-ES   Australia;Belgium;Canada;Spain;
      2021   Phase 3   EUCTR2020-004885-21-ES   Belgium;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-004885-21-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-002251-38-DE   Germany;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001404-42-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2021   Phase 3   EUCTR2020-001404-42-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2020-003170-44-CZ   Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
      2020   Phase 3   EUCTR2020-001404-42-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-001827-11-IE   Australia;Canada;Ireland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000833-37-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000833-37-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-002835-76-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-ES   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001695-38-GB   Australia;Canada;Ireland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000185-11-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-005320-38-PT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-001628-16-BE   Australia;Belgium;Canada;Spain;
      -   Phase 3   EUCTR2020-004885-21-NL   Belgium;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-004885-21-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-003170-44-NL   Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
      -   Phase 3   EUCTR2020-003170-44-FR   Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
      -   Phase 3   EUCTR2020-003170-44-BE   Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
      -   Phase 3   EUCTR2020-002239-31-DE   Australia;Canada;Germany;United Kingdom;United States;
      -   Phase 3   EUCTR2020-001404-42-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2020-001404-42-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2019-001827-11-GB   Australia;Canada;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2019-000833-37-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-002835-76-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-002835-76-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-001695-38-IE   Australia;Canada;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-SE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Elexacaftor-tezacaftor-ivacaftor exposure
   Jennifer Taylor-Cousar
      2019   -   NCT04056702   United States;
Elexacaftor/tezacaftor/ivacaftor
   VERTEX PHARMACEUTICALS INCORPORATED
      2021   Phase 3   EUCTR2021-000694-85-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-000712-31-SE   Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000712-31-PT   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000712-31-DE   Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000694-85-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NO   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-GR   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000712-31-IE   Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000712-31-CZ   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
Engineerd Protein Inhibitor of human Neutrophil Elastase
   Debiopharm SA
      2005   Phase 2   EUCTR2004-002341-12-GB   Belgium;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-002341-12-DE   Belgium;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-002341-12-BE   Belgium;Germany;Italy;United Kingdom;
Engineered Protein Inhibitor of human Neutrophil Elastase
   Debiopharm SA
      2005   Phase 2   EUCTR2004-002341-12-GB   Belgium;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-002341-12-DE   Belgium;Germany;Italy;United Kingdom;
      2005   -   EUCTR2004-002341-12-BE   Belgium;Germany;Italy;United Kingdom;
Ensure High Protein
   Virginia Commonwealth University
      2022   -   NCT03931252   United States;
Ensure plus
   Texas A&M University
      2011   -   NCT01494909   United States;
Ergocalciferol (vitamin D2)
   Atlanta VA Medical Center
      2006   -   NCT00450073   United States;
Esomeprazole
   Biovitrum AB
      2008   -   EUCTR2007-004063-21-NL   Netherlands;
   Columbia University
      2008   Phase 2   NCT01983774   United States;
Essential amino acid intake + Leucine vs total AA supplement
   Texas A&M University
      2008   -   NCT01172301   United States;
Estradiol
   Emory University
      2019   Phase 4   NCT03724955   United States;
Ethambutol
   University of Colorado, Denver
      2014   -   NCT02372383   United States;
Exercise
   University of Kansas Medical Center
      2022   Phase 2   NCT05239611   United States;
Exhaled Nitric Oxide
   The Hospital for Sick Children
      2010   -   NCT01155115   Canada;
F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)
   University Hospital, Strasbourg, France
      2020   Phase 4   NCT04381429   France;
FDG-PET
   National Center for Research Resources (NCRR)
      2001   -   NCT00023465   United States;
FDL169
   Flatley Discovery Lab LLC
      2018   Phase 1/Phase 2   NCT03756922   United Kingdom;
      2018   Phase 1   NCT03527095   United Kingdom;
      2017   Phase 1   NCT03424252   United Kingdom;
      2017   Phase 1   NCT03093714   Australia;Czechia;Germany;United Kingdom;
      2016   Phase 1/Phase 2   NCT02767297   United Kingdom;
      2015   Phase 1   NCT02680418   United Kingdom;
      2015   Phase 1   NCT02359357   United Kingdom;
FDL176
   Flatley Discovery Lab LLC
      2018   Phase 1/Phase 2   NCT03756922   United Kingdom;
      2017   Phase 1   NCT03173573   Australia;
FDL176 & FDL169 coadministration
   Flatley Discovery Lab LLC
      2018   Phase 1   NCT03516331   United Kingdom;
FLUCLOXACILLIN SODIUM
   St. Vincent's University Hospital
      2016   Phase 4   EUCTR2016-001785-29-IE   Ireland;
FORLAX 4 g, poudre pour solution buvable en sachet
   CHU de Bordeaux
      2020   Phase 2   EUCTR2019-004958-29-FR   France;
FTI, AZLI
   Gilead Sciences
      2008   Phase 2   NCT00794586   United States;
Fasenra
   AstraZeneca AB
      2021   Phase 3   EUCTR2020-004068-24-DK   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-004068-24-DE   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Viet Nam;
Fenretinide
   Elias Matouk
      2014   Phase 1   NCT02141958   Canada;
Ferinject
   University of Oxford / Clinical Trials and Research Governance
      2018   Phase 4   EUCTR2018-002366-39-GB   United Kingdom;
Ferric carboxymaltose
   University of Oxford
      2019   Phase 4   NCT03632525   United Kingdom;
   University of Oxford / Clinical Trials and Research Governance
      2018   Phase 4   EUCTR2018-002366-39-GB   United Kingdom;
Ferrous sulfate
   Dartmouth-Hitchcock Medical Center
      2011   -   NCT01755455   United States;
Finely ground flaxseed powder
   University of Pennsylvania
      2012   Phase 1   NCT02014181   United States;
Fish oil
   Nestlé
      2016   -   NCT02646995   Switzerland;
Flucloxacillin 250mg/5ml Sugar-Free Powder for Oral Solution
   Alder Hey Children's NHS Foundation Trust
      2016   Phase 4   EUCTR2016-002578-11-GB   United Kingdom;
Flucloxicillin
   St. Vincent's University Hospital
      2016   Phase 4   EUCTR2016-001785-29-IE   Ireland;
Flumist®
   McGill University Health Center
      2013   -   NCT01885169   Canada;
Fluticasone
   Royal Brompton & Harefield NHS Foundation Trust
      2001   -   NCT00220259   United Kingdom;
Fortum
   St. Vincent's University Hospital
      2016   Phase 4   EUCTR2016-001785-29-IE   Ireland;
Frequently Sampled Oral Glucose Tolerance Test and CGM
   University Hospitals Cleveland Medical Center
      2019   -   NCT03961516   United States;
Fucidin Tablets
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
Fusidin
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
G1117337
   Galapagos NV
      2018   Phase 2   EUCTR2018-000098-61-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-002181-42-DE   Germany;
G914167
   Galapagos NV
      2018   Phase 2   EUCTR2018-000098-61-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
G957389
   Galapagos NV
      2018   Phase 2   EUCTR2018-000098-61-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004477-40-NL   Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004477-40-GB   Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004477-40-ES   Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004477-40-BE   Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002837-31-CZ   Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   EUCTR2016-002837-31-IE   Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   EUCTR2016-002837-31-GB   Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   EUCTR2016-002837-31-DE   Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   EUCTR2016-002837-31-BE   Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
GIP
   University of Pennsylvania
      2013   -   NCT01851694   United States;
GLP-1
   University of Pennsylvania
      2013   -   NCT01851694   United States;
GLPG1837
   Galapagos NV
      2016   Phase 2   EUCTR2015-003292-30-NL   Belgium;Netherlands;
      2016   Phase 2   EUCTR2015-003292-30-BE   Belgium;Netherlands;
      2016   Phase 2   EUCTR2015-003291-77-IE   Australia;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   EUCTR2015-003291-77-GB   Australia;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   EUCTR2015-003291-77-DE   Australia;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   EUCTR2015-003291-77-CZ   Australia;Czech Republic;Germany;Ireland;United Kingdom;
GLPG1837 dose 1
   Galapagos NV
      2016   Phase 2   NCT02707562   Australia;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   NCT02690519   Belgium;Netherlands;
GLPG1837 dose 2
   Galapagos NV
      2016   Phase 2   NCT02707562   Australia;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   NCT02690519   Belgium;Netherlands;
GLPG1837 dose 3
   Galapagos NV
      2016   Phase 2   NCT02707562   Australia;Czech Republic;Germany;Ireland;United Kingdom;
GLPG2222
   Galapagos NV
      2018   Phase 2   EUCTR2018-000098-61-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
      2018   Phase 1   NCT03540524   Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
      2017   Phase 2   NCT03119649   Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004477-40-NL   Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004477-40-GB   Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004477-40-ES   Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004477-40-BE   Belgium;Netherlands;Serbia;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002837-31-CZ   Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   EUCTR2016-002837-31-IE   Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   EUCTR2016-002837-31-GB   Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   EUCTR2016-002837-31-DE   Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
      2016   Phase 2   EUCTR2016-002837-31-BE   Australia;Belgium;Czech Republic;Germany;Ireland;United Kingdom;
GLPG2222 150 mg q.d.
   Galapagos NV
      2017   Phase 2   NCT03045523   Australia;Belgium;Czechia;Germany;Ireland;United Kingdom;
GLPG2222 300 mg q.d.
   Galapagos NV
      2017   Phase 2   NCT03045523   Australia;Belgium;Czechia;Germany;Ireland;United Kingdom;
GLPG2451 dose regimen A
   Galapagos NV
      2018   Phase 1   NCT03540524   Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
GLPG2451 dose regimen B
   Galapagos NV
      2018   Phase 1   NCT03540524   Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
GLPG2737
   Galapagos NV
      2018   Phase 2   EUCTR2018-000098-61-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
      2018   Phase 1   NCT03540524   Belgium;Bulgaria;Germany;Greece;Netherlands;Serbia;Sweden;United Kingdom;
      2017   Phase 2   NCT03474042   Germany;
      2017   Phase 2   EUCTR2017-002181-42-DE   Germany;
GLPG2737 single dose
   Galapagos NV
      2017   Phase 1   NCT03450720   Belgium;
GLPG3067
   Galapagos NV
      2018   Phase 2   EUCTR2018-000098-61-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Netherlands;New Zealand;Serbia;United Kingdom;United States;
GLPG3067 single dose
   Galapagos NV
      2018   Phase 1   NCT03589313   Belgium;
GLUTATHIONE SODIUM
   Aarhus University Hospital
      2014   Phase 2   EUCTR2013-005481-19-DK   Denmark;
GLYPRESSINE 1 mg/5 mL, poudre et solvant pour solution injectable (I.V.)
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 3   EUCTR2020-005931-58-FR   France;
GS-5737
   Gilead Sciences
      2013   Phase 1   NCT01840735   United States;
      2012   Phase 1   NCT01793649   United States;
GS-5745
   Gilead Sciences, Inc.
      2016   Phase 2   EUCTR2015-002192-23-ES   Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002192-23-DE   Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002192-23-BE   Australia;Belgium;Canada;France;Germany;Ireland;Spain;United Kingdom;United States;
GS-9411
   Gilead Sciences
      2009   Phase 1   NCT01025713   Australia;
      2009   Phase 1   NCT00999531   Australia;
      2009   Phase 1   NCT00951522   Australia;
      2008   Phase 1   NCT00800579   Australia;
GSH (Glutathione)
   Mukoviszidose Institut gGmbH i. G.
      2006   -   EUCTR2005-003870-88-DE   Germany;
Galicaftor
   AbbVie
      2021   Phase 2   NCT04853368   Australia;Belgium;Czechia;Germany;Hungary;Netherlands;New Zealand;Slovakia;
   AbbVie Deutschland
      2019   Phase 2   EUCTR2019-000750-63-NL   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-HU   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-GB   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-FR   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000750-63-BE   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 2   EUCTR2019-000750-63-PL   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
Gallium nitrate
   Chris Goss
      2021   Phase 1   NCT04294043   United States;
   University of Washington
      2016   Phase 2   NCT02354859   United States;
Genistein (Unconjugated Isoflavones 100)
   Children's Hospital of Philadelphia
      2003   Phase 1/Phase 2   NCT00590538   United States;
Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm
   University Medical Centre Utrecht
      2014   Phase 2   EUCTR2014-000817-30-NL   Netherlands;
Gentamicin
   Assistance Publique - Hôpitaux de Paris
      2003   Phase 2   NCT00376428   France;
Gernebcin
   University of Jena
      2008   -   EUCTR2008-000164-17-DE   Germany;
Ghrelin
   Papworth Hospital
      2010   -   NCT00763477   United Kingdom;
Giving DHA-rich supplement
   University Hospital, Ghent
      2007   Phase 2   NCT00221546   Belgium;
Glargine
   Federico II University
      2006   Phase 4   NCT00483769   Italy;
Glargine insulin
   University of Minnesota - Clinical and Translational Science Institute
      2003   Phase 3   NCT00222521   United States;
Glucose
   Children's Hospital of Philadelphia
      2013   -   NCT01852448   United States;
   Christoph Saner
      2015   -   NCT02569229   Switzerland;
   Emory University
      2014   -   NCT02202876   United States;
   Hospices Civils de Lyon
      2009   -   NCT02723968   -
   Imperial College London
      2009   -   NCT01091025   United Kingdom;
   Katie Larson Ode
      2019   -   NCT03650712   United States;
   Liverpool Heart and Chest Hospital NHS Foundation Trust
      2011   -   NCT03644199   United Kingdom;
   Mayo Clinic
      2021   -   NCT04579939   United States;
   National Center for Research Resources (NCRR)
      2001   -   NCT00014768   United States;
   Royal Brompton & Harefield NHS Foundation Trust
      2013   -   NCT01883037   United Kingdom;
   Yale University
      2015   Early Phase 1   NCT02398383   United States;
Glutamine
   Emory University
      2010   Phase 2   NCT01051999   United States;
Glutathione
   AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI
      2009   -   EUCTR2008-005080-33-IT   Italy;
Glycine
   Instituto Nacional de Enfermedades Respiratorias
      2012   Phase 2   NCT01417481   Mexico;
Glycine Buffer
   University Hospitals Cleveland Medical Center
      2018   Phase 1/Phase 2   NCT03617718   United States;
GlycosBio Nutritional Supplement
   GlycosBio, Inc.
      2018   -   NCT04966897   United States;
Gold
   The Alfred
      2016   -   NCT02717650   Australia;
Growth Hormone Stimulation Test
   University of Texas Southwestern Medical Center
      2006   -   NCT00287443   United States;
Growth hormone
   University of Utah
      2001   Phase 2   NCT00016445   United States;
H02 - Corticosteroidi Sistemici
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-004068-24-IT   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
HEPARIN SODIUM
   Vectura Limited
      2008   -   EUCTR2007-006276-11-IE   Ireland;Italy;
      2008   -   EUCTR2007-006276-11-GB   Ireland;Italy;United Kingdom;
      -   Phase 2   EUCTR2007-006276-11-PL   Ireland;Italy;Poland;United Kingdom;
HFNT during exercise
   The Leeds Teaching Hospitals NHS Trust
      2019   -   NCT03965832   United Kingdom;
HGPIV diagnosis test
   Hospices Civils de Lyon
      2009   -   NCT02723968   -
HMSCs
   Marilyn Glassberg
      2016   Phase 1   NCT02625246   United States;
HOMAR-IR diagnosis test
   Hospices Civils de Lyon
      2009   -   NCT02723968   -
HP 129Xe
   Thunder Bay Regional Research Institute
      2019   Early Phase 1   NCT02748798   Canada;
HP 3He
   Thunder Bay Regional Research Institute
      2019   Early Phase 1   NCT02748798   Canada;
Heparin 25mg inhalation powder, hard capsule
   VECTURA LIMITED
      2010   -   EUCTR2007-006276-11-IT   Ireland;Italy;
   Vectura Limited
      2008   -   EUCTR2007-006276-11-IE   Ireland;Italy;
      2008   -   EUCTR2007-006276-11-GB   Ireland;Italy;United Kingdom;
      -   Phase 2   EUCTR2007-006276-11-PL   Ireland;Italy;Poland;United Kingdom;
Heracillin
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
High dose of budesonide
   Hospital General de Requena
      2004   -   NCT00728715   Spain;
High flow nasal oxygen cannula
   St. Michael's Hospital, Toronto
      2014   -   NCT02262871   Canada;
High-Dose Vitamin D3
   Emory University
      2015   -   NCT02589444   United States;
History and physical exam.
   University of Florida
      2007   -   NCT01851642   United States;
Home Oral Glucose Tolerance Test kit
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2015   -   NCT02703155   United Kingdom;
Human recombinant growth hormone
   National Center for Research Resources (NCRR)
      2000   Phase 3   NCT00005112   United States;
Hyaluronan
   Ospedale Civile Ca' Foncello
      2009   -   NCT01658449   Italy;
Hydrocortisone
   Birmingham Children's Hospital NHS Foundation Trust
      2012   -   EUCTR2011-005790-23-GB   United Kingdom;
Hydroxychloroquine
   Vanderbilt University
      2006   Phase 1   NCT00311883   United States;
Hyperglycemic Clamp with concurrent GIP infusion
   Liverpool Heart and Chest Hospital NHS Foundation Trust
      2013   -   NCT01975259   United Kingdom;
Hyperglycemic clamp with concurrent GLP-1 infusion
   Liverpool Heart and Chest Hospital NHS Foundation Trust
      2013   -   NCT01975259   United Kingdom;
Hyperpolarized Helium-3
   University of Massachusetts, Worcester
      2008   -   NCT00846573   United States;
Hyperpolarized Helium-3 MRI of the chest
   University of Virginia
      2011   -   NCT02163681   United States;
Hyperpolarized Xe129
   Mario Castro, MD, MPH
      2020   Phase 1   NCT04624490   United States;
Hyperpolarized Xenon
   Children's Hospital Medical Center, Cincinnati
      2016   -   NCT02848560   United States;
Hyperpolarized Xenon 129
   Children's Hospital Medical Center, Cincinnati
      2020   Phase 4   NCT04467957   -
Hyperpolarized Xenon gas
   Children's Hospital Medical Center, Cincinnati
      2018   -   NCT03593434   United States;
   University of North Carolina, Chapel Hill
      2018   Early Phase 1   NCT03482960   United States;
Hyperpolarized xenon-129
   The University of Nottingham
      -   Phase 2   EUCTR2019-003052-36-GB   United Kingdom;
Hypertonic Saline
   Parion Sciences
      2015   Phase 2   NCT02343445   United States;
   The Hospital for Sick Children
      2011   Phase 2   NCT02276898   Canada;
      2006   Phase 2   NCT00721071   Canada;
      2006   Phase 1   NCT00753987   Canada;
   Tim Corcoran
      2017   Phase 1   NCT02947126   United States;
   University of North Carolina, Chapel Hill
      2009   -   NCT01031706   United States;
   University of Oklahoma
      2006   -   NCT00671723   United States;
Hypertonic Saline (HS)
   CF Therapeutics Development Network Coordinating Center
      2009   -   NCT00709280   Canada;United States;
   University of Washington, the Collaborative Health Studies Coordinating Center
      2015   -   NCT02378467   Canada;United States;
Hypertonic Saline (HS), 4mL
   Heidelberg University
      2012   Phase 2   NCT01619657   Germany;
Hypertonic bicarbonate
   Joseph Pilewski
      2014   Phase 1   NCT03391414   United States;
Hypertonic saline
   Adelaida Lamas Ferreiro
      2009   Phase 4   NCT01377792   Spain;
   Erasmus MC
      2018   Phase 3   EUCTR2015-004143-39-IT   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
      2017   Phase 3   EUCTR2015-004143-39-DK   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
      2016   Phase 3   EUCTR2015-004143-39-NL   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
      2016   Phase 3   EUCTR2015-004143-39-BE   Australia;Belgium;Denmark;Netherlands;Spain;United States;
      -   Phase 3   EUCTR2015-004143-39-FR   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
   Joseph Zabner
      2011   Phase 1/Phase 2   NCT01355796   United States;
   Royal Prince Alfred Hospital, Sydney, Australia
      2000   Phase 3   NCT00271310   -
   The Hospital for Sick Children
      2008   -   NCT00700050   Canada;
Hypertonic saline ()
   University of Pittsburgh
      2010   Phase 1   NCT01223183   United States;
Hypertonic saline () and isotonic saline ()
   The Hospital for Sick Children
      2008   Phase 3   NCT00635141   Canada;
Hypertonic saline -
   The Alfred
      2007   Phase 3   NCT00484263   Australia;
Hypertonic saline solution
   University Hospital Ghent
      2007   -   EUCTR2007-002707-40-BE   Belgium;
ICS+LABA
   Shanghai Pulmonary Hospital, Shanghai, China
      2011   Phase 4   NCT02782312   China;
IDPM
   Pharmaxis Pharmaceuticals Limited
      2009   Phase 3   EUCTR2008-002740-42-FR   Belgium;France;Germany;Netherlands;
      2009   -   EUCTR2008-002740-42-NL   Belgium;France;Germany;Netherlands;
      2009   -   EUCTR2008-002740-42-BE   Belgium;France;Germany;Netherlands;
      2008   -   EUCTR2008-002740-42-DE   Belgium;France;Germany;Netherlands;
      2007   -   EUCTR2007-001412-23-IE   Ireland;United Kingdom;
      -   Phase 3   EUCTR2007-001412-23-DE   Germany;Ireland;United Kingdom;
IDPM: Inhaled Dry Powder Mannitol
   Pharmaxis Ltd
      2009   -   EUCTR2008-008228-34-GB   United Kingdom;
   Pharmaxis Pharmaceuticals Limited
      2009   -   EUCTR2007-001412-23-GB   Ireland;United Kingdom;
   Pharmaxis UK Limited
      2007   Phase 3   EUCTR2006-004078-28-GB   United Kingdom;
IGE025
   Novartis Pharma Services AG
      2008   -   EUCTR2007-006648-23-DE   Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
INCRELEX*SC 1FL 4ML 10MG/ML
   AZIENDA OSPEDALIERA DI PARMA
      2011   -   EUCTR2011-002719-27-IT   Italy;
INDUSIL*OS GTT FL 30MG+FL 15ML
   AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
      2010   -   EUCTR2010-020516-11-IT   Italy;
INOmax 400ppm mol/mol inhalation gas
   Southampton University Hopsitals NHS Trust
      2011   -   EUCTR2010-023529-39-GB   United Kingdom;
INS1007
   INSMED INCORPORATED
      2021   Phase 3   EUCTR2020-003688-25-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-IT   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
   Insmed Incorporated
      2021   Phase 3   EUCTR2020-003688-25-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-IE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003688-25-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003688-25-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003688-25-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-002533-32-BE   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-SE   Australia;Belgium;Bulgaria;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-PL   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-NL   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-GB   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-ES   Australia;Belgium;Bulgaria;Canada;Denmark;France;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-DK   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-DE   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-002533-32-BG   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
INS1007 10 mg oral tablet
   Insmed Incorporated
      2017   Phase 2   NCT03218917   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
INS1007 25 mg oral tablet
   Insmed Incorporated
      2017   Phase 2   NCT03218917   Australia;Belgium;Bulgaria;Denmark;Germany;Italy;Korea, Republic of;Netherlands;New Zealand;Poland;Singapore;Spain;Sweden;United Kingdom;United States;
IONIS-ENaCRx
   Ionis Pharmaceuticals, Inc.
      2018   Phase 1   NCT03647228   Germany;United Kingdom;
IV amikacin
   Seattle Children's Hospital
      2004   -   NCT00153634   United States;
IV ceftazidime
   Seattle Children's Hospital
      2004   -   NCT00153634   United States;
IV glucose tolerance test
   University of Texas Southwestern Medical Center
      2006   -   NCT00287443   United States;
IV meropenem
   Seattle Children's Hospital
      2004   -   NCT00153634   United States;
IV piperacillin-tazobactam
   Seattle Children's Hospital
      2004   -   NCT00153634   United States;
IV ticarcillin-clavulanate
   Seattle Children's Hospital
      2004   -   NCT00153634   United States;
IV tobramycin
   Seattle Children's Hospital
      2004   -   NCT00153634   United States;
IV vancomycin hydrochloride
   Savara Inc.
      2011   Phase 1   NCT01537666   Australia;
IVA
   Vertex Pharmaceuticals Incorporated
      2019   Phase 2   NCT03911713   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-PT   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-NL   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-GB   Germany;Netherlands;Portugal;United Kingdom;United States;
      2018   Phase 3   NCT03691779   Australia;Ireland;United Kingdom;United States;
      2018   Phase 3   NCT03601637   Canada;United States;
      2018   Phase 3   NCT03537651   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   NCT03525574   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   NCT03447262   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 2   NCT03625466   Germany;
      2016   Phase 2   NCT02971839   United States;
      2016   Phase 2   NCT02951182   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;United Kingdom;United States;
      2016   Phase 1   NCT03486236   United Kingdom;
IVACAFTOR 59,
   Vertex Pharmaceuticals Incorporated
      2021   Phase 3   EUCTR2020-002251-38-DE   Germany;United Kingdom;United States;
Ibuprofen
   FDA Office of Orphan Products Development
      1996   -   NCT00004440   -
   Ramsey, Bonnie, MD
      2004   -   NCT00219895   United States;
   University Hospitals Cleveland Medical Center
      2007   -   NCT00531882   United States;
Icenticaftor
   Novartis Pharma AG
      2021   Phase 2   EUCTR2019-002840-26-DE   China;Germany;Spain;United Kingdom;
      2020   Phase 2   EUCTR2019-002840-26-GB   China;Germany;Spain;United Kingdom;
IgY
   Mukoviszidose Institut gGmbH
      2011   Phase 3   NCT01455675   Austria;Belgium;Germany;Hungary;Ireland;Italy;Poland;Spain;Sweden;
Impact
   Alcresta Therapeutics, Inc.
      2016   -   NCT02750501   United States;
Impact-Nutridrink
   University Hospital, Motol
      2013   Phase 4   NCT02048592   Czech Republic;
Indirect Calorimetry
   University of Texas Southwestern Medical Center
      2006   -   NCT00287443   United States;
Indium
   University of Pittsburgh
      2007   -   NCT00541190   United States;
Indium-DTPA
   Tim Corcoran
      2017   Phase 1   NCT02947126   United States;
Influenza vaccination
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 4   NCT01499914   France;
Inhaled AR-501
   Aridis Pharmaceuticals, Inc.
      2018   Phase 1/Phase 2   NCT03669614   United States;
Inhaled Mannitol
   Pharmaxis
      2013   Phase 2   NCT01883531   United Kingdom;
Inhaled Reduced Glutathione
   Serafino A. Marsico
      2010   Phase 3   NCT01450267   Italy;
Inhaled SNSP113
   Synspira, Inc.
      2017   Phase 1   NCT03309358   United Kingdom;
Inhaled Sodium Pyruvate
   University of Minnesota - Clinical and Translational Science Institute
      2006   Phase 1   NCT00332215   United States;
Inhaled Vancomycin
   Johns Hopkins University
      2012   Phase 2   NCT01594827   United States;
Inhaled dry powder mannitol
   Pharmaxis Pharmaceuticals Limited
      2007   -   EUCTR2007-001412-23-IE   Ireland;United Kingdom;
      -   Phase 3   EUCTR2007-001412-23-DE   Germany;Ireland;United Kingdom;
Inhaled hypertonic saline ()
   Tim Corcoran
      2013   Phase 1   NCT01887197   United States;
   University of Pittsburgh
      2014   Phase 1   NCT02141191   United States;
Inhaled hypertonic saline (HS)
   CF Therapeutics Development Network Coordinating Center
      2007   -   NCT00546663   Canada;United States;
Inhaled mannitol
   Pharmaxis
      2014   Phase 3   NCT02134353   Argentina;Australia;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Israel;Italy;Mexico;New Zealand;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2008   Phase 3   NCT00630812   Argentina;Belgium;Canada;France;Germany;Netherlands;United States;
      2004   Phase 2   NCT00455130   Australia;New Zealand;
Inhaled tobramycin
   Seattle Children's Hospital
      2016   Phase 4   NCT02677701   United States;
   University of North Carolina, Chapel Hill
      2004   Phase 1   NCT00823238   United States;
Initiation of CFTR Modulator
   Children's Hospital Medical Center, Cincinnati
      2020   Phase 4   NCT04467957   -
      2020   Phase 4   NCT04259970   Canada;United States;
Insulin
   Fondazione per la ricerca sulla Fibrosi Cistica
      2005   Phase 3   NCT00687466   Italy;
   Jagdeesh Ullal
      2021   Phase 4   NCT04533646   United States;
   National Center for Research Resources (NCRR)
      2001   -   NCT00014768   United States;
Insulin Asparte
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2001   Phase 3   NCT00072904   Canada;United States;
Insulin Pump
   University of Texas Southwestern Medical Center
      2006   -   NCT00287456   United States;
Insulin detemir [rDNA origin] injection
   Nationwide Children's Hospital
      2008   Phase 2/Phase 3   NCT00639626   United States;
Insulin glargine
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2005-002135-27-IT   Italy;
Insuline humaine recombinante
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2006   -   EUCTR2006-001254-27-FR   France;
Interferon gamma-1b
   InterMune
      2002   Phase 1/Phase 2   NCT00043342   United States;
      2001   Phase 1/Phase 2   NCT00043316   United States;
Intermittent, short infusion Cefepime
   The Alfred
      2012   Phase 4   NCT01667094   Australia;
Intermittent, short infusion Ceftazidime
   The Alfred
      2012   Phase 4   NCT01667094   Australia;
Intermittent, short infusion Meropenem
   The Alfred
      2012   Phase 4   NCT01667094   Australia;
Intermittent, short infusion Piperacillin tazobactam
   The Alfred
      2012   Phase 4   NCT01667094   Australia;
Intermittent, short infusion Ticarcillin-clavulanate
   The Alfred
      2012   Phase 4   NCT01667094   Australia;
Inulin
   Emory University
      2020   Phase 4   NCT04118010   United States;
Isotonic Saline
   Tim Corcoran
      2017   Phase 1   NCT02947126   United States;
Isotonic Saline (IS)
   CF Therapeutics Development Network Coordinating Center
      2009   -   NCT00709280   Canada;United States;
   University of Washington, the Collaborative Health Studies Coordinating Center
      2015   -   NCT02378467   Canada;United States;
Isotonic Saline (IS), 4mL
   Heidelberg University
      2012   Phase 2   NCT01619657   Germany;
Isotonic saline
   Erasmus MC
      2018   Phase 3   EUCTR2015-004143-39-IT   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
      2017   Phase 3   EUCTR2015-004143-39-DK   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
      2016   Phase 3   EUCTR2015-004143-39-NL   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
      2016   Phase 3   EUCTR2015-004143-39-BE   Australia;Belgium;Denmark;Netherlands;Spain;United States;
      -   Phase 3   EUCTR2015-004143-39-FR   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
   University of Jena
      2007   Phase 3   NCT00534079   Germany;
   University of Pittsburgh
      2010   Phase 1   NCT01223183   United States;
      2008   -   NCT00628134   United States;
Itraconazole
   Novartis Pharmaceuticals
      2008   Phase 4   NCT00787917   Belgium;Germany;Italy;Netherlands;United Kingdom;
   Ottawa Hospital Research Institute
      2007   Phase 4   NCT00528190   Canada;
   Vertex Pharmaceuticals Incorporated
      2013   Phase 1   NCT01768663   United States;
Itraconazole/voriconazole
   Rennes University Hospital
      2014   Phase 2   NCT01576315   France;United Kingdom;
Ivacaftor
   Children's Hospital of Philadelphia
      2019   -   NCT03783286   United States;
   Eloxx Pharmaceuticals Inc
      2019   Phase 2   EUCTR2018-000966-12-DE   Australia;Germany;Israel;
   Eloxx Pharmaceuticals, Inc.
      2019   Phase 2   NCT04135495   Canada;United States;
   Medical University of South Carolina
      2016   Phase 3   NCT02934698   -
   Richard Barry Moss
      2015   -   NCT02310789   United States;
   The Alfred
      2014   Phase 4   NCT01937325   Australia;
   University of California, San Francisco
      2013   -   NCT01784419   United States;
   VERTEX PHARMACEUTICALS INCORPORATED
      2018   Phase 3   EUCTR2018-000183-28-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2019   Phase 2   EUCTR2018-003970-28-NL   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-GB   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-NL   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-BE   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-SE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2017   Phase 3   NCT03277196   Australia;Canada;Germany;Ireland;United Kingdom;United States;
      2017   Phase 3   NCT03068312   Israel;
      2016   Phase 3   NCT02742519   Australia;Canada;United Kingdom;
      2016   Phase 3   NCT02725567   Australia;Canada;Ireland;United Kingdom;United States;
      2016   Phase 2   NCT02951195   United States;
      2016   Phase 1   NCT03029455   United Kingdom;
      2015   Phase 3   NCT02390219   United States;
      2015   -   NCT02445053   Italy;Netherlands;United Kingdom;
      2014   Phase 2   NCT02070744   United States;
      2014   Phase 1   NCT02015507   -
      2013   Phase 3   NCT01946412   Canada;United Kingdom;United States;
      2013   Phase 3   NCT01897233   Canada;United States;
      2013   Phase 3   NCT01707290   Belgium;France;Ireland;United Kingdom;United States;
      2013   Phase 3   NCT01705145   Canada;United Kingdom;United States;
      2013   Phase 1   NCT01910415   Netherlands;
      2013   Phase 1   NCT01899105   United States;
      2013   Phase 1   NCT01768663   United States;
      2012   Phase 3   NCT01614470   Belgium;France;United States;
      2012   Phase 3   NCT01614457   Ireland;United Kingdom;United States;
      2012   Phase 2   NCT01685801   United States;
      2012   Phase 2   NCT01531673   Canada;Germany;United Kingdom;United States;
      2011   Phase 2   NCT01262352   Canada;Ireland;United Kingdom;United States;
      2010   Phase 3   NCT01117012   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012997-11-GB   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2010   Phase 2   NCT01225211   Australia;Belgium;France;Germany;Ireland;New Zealand;United Kingdom;United States;
      2010   -   EUCTR2010-020546-96-GB   Canada;United Kingdom;United States;
      2010   -   EUCTR2009-012997-11-IE   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2010   -   EUCTR2009-012997-11-DE   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2010   -   EUCTR2009-012997-11-CZ   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2009   Phase 3   NCT00909727   Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
      2009   Phase 3   NCT00909532   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-007479-26-GB   Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-007416-15-GB   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2009   Phase 2   NCT00953706   United States;
      2009   -   EUCTR2008-007479-26-IE   Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
      2009   -   EUCTR2008-007479-26-DE   Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
      2009   -   EUCTR2008-007416-15-IE   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000183-28-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   -   EUCTR2008-007416-15-DE   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
   university medical center utrecht
      2018   Phase 4   EUCTR2016-001440-18-NL   Netherlands;
Ivacaftor (proposed INN)
   Vertex Pharmaceuticals Incorporated
      -   -   EUCTR2009-010261-23-Outside-EU/EEA   United States;
Ivacaftor 125mg tablet
   Vertex Pharmaceuticals Incorporated
      2014   Phase 3   EUCTR2013-000604-41-NL   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-000604-41-IT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   -   EUCTR2013-000604-41-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-ES   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-AT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-SE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-GB   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-CZ   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-NL   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-IT   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-IE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-DE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
Ivacaftor 150 mg or
   Vertex Pharmaceuticals Incorporated
      2007   Phase 2   NCT00457821   Canada;Germany;United States;
Ivacaftor 25 mg/
   Vertex Pharmaceuticals Incorporated
      2007   Phase 2   NCT00457821   Canada;Germany;United States;
Ivacaftor 75 mg/
   Vertex Pharmaceuticals Incorporated
      2007   Phase 2   NCT00457821   Canada;Germany;United States;
Ivacaftor Exposed
   Vertex Pharmaceuticals Incorporated
      2013   -   NCT01863238   United States;
Ivacaftor or elexacaftor/tezacaftor/ivacaftor
   Sonya Heltshe
      2020   -   NCT04509050   United States;
Ivacaftor+lumacaftor
   Assistance Publique - Hôpitaux de Paris
      2016   -   NCT03475381   France;
Ivacaftor/Ataluren
   University of Alabama at Birmingham
      2017   Phase 4   NCT03256799   United States;
Ivacaftor/Kalydeco
   University Medical Centre Utrecht
      2014   Phase 2   EUCTR2014-000817-30-NL   Netherlands;
Ivacaftor/Trikafta
   University of Alabama at Birmingham
      2018   Phase 4   NCT03624101   United States;
J01GB01
   University Medical Center Groningen
      2013   -   EUCTR2012-004437-16-NL   Netherlands;
      -   Phase 2   EUCTR2016-005014-21-NL   Netherlands;
JBT-101
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 2   EUCTR2017-003723-29-IT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
   Corbus Pharmaceuticals, Inc.
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-003723-29-PL   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-003723-29-NL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-SK   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-PT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-GR   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-ES   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-BG   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-BE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-002581-23-DE   Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-002581-23-GB   Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-002581-23-FR   Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
      2015   Phase 2   EUCTR2015-002581-23-BE   Belgium;France;Germany;Israel;Italy;Poland;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2017-003723-29-FR   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
JBT-101 (lenabasum)
   Corbus Pharmaceuticals Inc.
      2015   Phase 2   NCT02465450   Belgium;France;Germany;Italy;Poland;United Kingdom;United States;
KB001
   KaloBios Pharmaceuticals
      2008   Phase 1/Phase 2   NCT00638365   United States;
KB001-A
   KaloBios Pharmaceuticals
      2012   Phase 2   NCT01695343   Australia;Israel;New Zealand;United States;
KREON 25000
   Aptalis Pharma US Inc.
      2013   -   EUCTR2009-012842-21-HU   Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2012   Phase 3   EUCTR2009-012842-21-BE   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2011   -   EUCTR2009-012842-21-DE   Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2011   -   EUCTR2009-012842-21-BG   Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
      2010   Phase 3   EUCTR2009-012842-21-GB   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
   Axcan Pharma Inc.
      -   -   EUCTR2010-019267-11-DE   Germany;
KREON N 25000
   Abbott Laboratories GmbH
      2013   -   EUCTR2013-002819-10-ES   Hungary;Russian Federation;Spain;
KREON de Liberación Inmediata
   Abbott Laboratories GmbH
      2015   Phase 2   EUCTR2014-004519-35-ES   Czech Republic;Hungary;Spain;United Kingdom;
Kaftrio
   Haga Teaching Hospital
      2021   Phase 4   EUCTR2020-005224-12-NL   Netherlands;
   Royal College of Surgeons, Ireland
      2020   Phase 4   NCT04602468   Ireland;United Kingdom;
   VERTEX PHARMACEUTICALS INCORPORATED
      2021   Phase 3   EUCTR2021-000694-85-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-000712-31-PT   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000694-85-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004885-21-ES   Belgium;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-004885-21-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      2020   Phase 3   EUCTR2019-003455-11-BE   Australia;Belgium;Germany;United Kingdom;
      -   Phase 3   EUCTR2021-000712-31-IE   Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004885-21-NL   Belgium;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-004885-21-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
Kalydeco
   Eloxx Pharmaceuticals Inc
      2019   Phase 2   EUCTR2018-000966-12-DE   Australia;Germany;Israel;
   St. Vincent's University Hospital
      2016   Phase 4   EUCTR2016-001785-29-IE   Ireland;
   VERTEX PHARMACEUTICALS INCORPORATED
      2021   Phase 3   EUCTR2021-000694-85-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-000712-31-PT   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000694-85-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004885-21-ES   Belgium;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-004885-21-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-002251-38-DE   Germany;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-PL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004479-35-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2017   Phase 3   EUCTR2017-001379-21-GB   Canada;Germany;Ireland;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001997-16-IE   Canada;Germany;Ireland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001267-39-GB   Australia;Canada;France;United Kingdom;
      2016   Phase 3   EUCTR2014-004838-25-DE   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004838-25-AT   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004827-29-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004827-29-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004788-18-BE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-IT   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-IE   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-BE   Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-SE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-NL   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-IT   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-IE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-GB   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-ES   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-DK   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-DE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-NL   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-IT   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-GB   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-DE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004787-37-ES   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   Phase 3   EUCTR2014-004787-37-DE   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   Phase 3   EUCTR2014-004787-37-AT   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   -   EUCTR2014-004827-29-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   Phase 2   EUCTR2010-020413-90-GB   Australia;Belgium;Germany;Ireland;United Kingdom;United States;
      2014   -   EUCTR2010-020413-90-IE   Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-000386-20-GB   Canada;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000389-39-GB   Belgium;France;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000389-39-BE   Belgium;France;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000388-26-BE   Belgium;France;United States;
      2012   -   EUCTR2012-000387-19-GB   United Kingdom;United States;
      2011   -   EUCTR2010-020413-90-DE   Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
      2011   -   EUCTR2010-020413-90-BE   Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012997-11-GB   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2010   -   EUCTR2009-012997-11-CZ   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000712-31-IE   Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004885-21-NL   Belgium;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-004885-21-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-002239-31-DE   Australia;Canada;Germany;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002968-40-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002968-40-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-001379-21-IE   Canada;Germany;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-001379-21-DE   Canada;Germany;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001997-16-GB   Canada;Germany;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001997-16-DE   Canada;Germany;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001267-39-FR   Australia;Canada;France;United Kingdom;
      -   Phase 2   EUCTR2017-000673-37-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2017-000672-28-Outside-EU/EEA   United States;
Kalydeco 150 mg film-c
   Vertex Pharmaceuticals Incorporated
      -   Phase 3   EUCTR2018-000185-11-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Kalydeco 150 mg film-coated tablets
   VERTEX PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2019-000833-37-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-IT   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2021   Phase 3   EUCTR2021-001628-16-ES   Australia;Belgium;Canada;Spain;
      2020   Phase 3   EUCTR2019-003455-11-GB   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-DE   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-BE   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-001827-11-IE   Australia;Canada;Ireland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000833-37-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000833-37-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004652-38-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-002835-76-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001735-31-GB   Australia;Belgium;Germany;United Kingdom;
      2019   Phase 3   EUCTR2019-000833-37-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-ES   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004652-38-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004652-38-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001695-38-GB   Australia;Canada;Ireland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000185-11-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004134-29-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-NL   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-GB   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-DE   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-BE   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-PT   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-NL   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-GB   Germany;Netherlands;Portugal;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-GB   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-SE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-ES   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-IE   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-GB   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-ES   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-ES   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2018-000126-55-NL   Netherlands;
      2017   Phase 3   EUCTR2017-000540-18-DE   France;Germany;United States;
      2017   Phase 2   EUCTR2017-000797-11-NL   Australia;Belgium;Netherlands;United States;
      2017   Phase 2   EUCTR2017-000797-11-BE   Australia;Belgium;Netherlands;United States;
      2017   Phase 2   EUCTR2016-003585-11-GB   Ireland;Israel;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-NL   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-GB   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-ES   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-DE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-BE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-AT   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000454-36-DK   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-001628-16-BE   Australia;Belgium;Canada;Spain;
      -   Phase 3   EUCTR2019-001827-11-GB   Australia;Canada;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001735-31-BE   Australia;Belgium;Germany;United Kingdom;
      -   Phase 3   EUCTR2019-000833-37-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-002835-76-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-002835-76-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-001695-38-IE   Australia;Canada;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-SE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000183-28-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004133-82-DE   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004132-11-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000540-18-FR   France;Germany;United States;
Ketone Monoester
   University of Alabama at Birmingham
      2021   -   NCT04938726   -
Kineret
   Ruprecht-Karls-University Heidelberg, Medical Faculty
      -   Phase 2   EUCTR2016-004786-80-DE   Germany;
Klacid
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
Kreon 25 000
   Abbott Laboratories GmbH
      2015   Phase 2   EUCTR2014-004519-35-ES   Czech Republic;Hungary;Spain;United Kingdom;
      2015   -   EUCTR2014-004519-35-HU   Czech Republic;Hungary;Spain;United Kingdom;
      2015   -   EUCTR2014-004519-35-GB   Czech Republic;Hungary;Spain;United Kingdom;
      2015   -   EUCTR2014-004519-35-CZ   Czech Republic;Hungary;Spain;United Kingdom;
   Aptalis Pharma US Inc.
      2013   -   EUCTR2009-012842-21-HU   Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2012   Phase 3   EUCTR2009-012842-21-BE   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2011   -   EUCTR2009-012842-21-DE   Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2011   -   EUCTR2009-012842-21-BG   Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
      2010   Phase 3   EUCTR2009-012842-21-GB   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
Kreon 25,000 Units
   Aptalis Pharma
      2012   Phase 3   NCT01641393   Belgium;Bulgaria;France;Germany;Italy;Poland;United Kingdom;
Kreon 25000
   Abbott Laboratories GmbH
      2013   -   EUCTR2013-002819-10-ES   Hungary;Russian Federation;Spain;
Kreon® 25,000
   Abbott Laboratories GmbH
      2015   Phase 2   EUCTR2014-004519-35-ES   Czech Republic;Hungary;Spain;United Kingdom;
   Forest Laboratories
      2011   Phase 4   NCT01327703   Germany;Poland;
L-Glutamine
   University of Nottingham
      2008   Phase 4   EUCTR2007-006204-37-GB   United Kingdom;
L-Lysine N acetylcysteinate
   LABORATOIRES SMB S.A.
      2010   -   EUCTR2010-018454-13-IT   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine N-acetylcysteinate
   LABORATOIRES SMB S.A.
      2010   -   EUCTR2010-018454-13-IT   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine- N-acetylcysteinate
   Laboratoires SMB S.A.
      2010   Phase 3   EUCTR2010-018454-13-ES   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine-N-acetyl-L-cysteinate
   Laboratoires SMB S.A.
      -   Phase 3   EUCTR2010-018454-13-BE   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-Lysine-N-acetylcysteinate
   Laboratoires SMB S.A.
      2010   Phase 3   EUCTR2010-018454-13-FR   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-018454-13-DK   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-HU   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-GB   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-DE   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-CZ   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
L-alanine
   Emory University
      2010   Phase 2   NCT01051999   United States;
L-arginine
   The Hospital for Sick Children
      2006   Phase 2   NCT00405665   Canada;
LABA/LAMA
   Shanghai Pulmonary Hospital, Shanghai, China
      2020   Phase 4   NCT04509661   -
LANTUS*SC 5CAR3ML100UI/ML
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2005-002135-27-IT   Italy;
LAU-7b
   Laurent Pharmaceuticals Inc.
      2018   Phase 2   NCT03265288   Australia;Canada;United States;
LEVOFLOXACIN HEMIHYDRATE
   Medical University of Vienna
      2020   Phase 4   EUCTR2019-000955-16-AT   Austria;
LIPASA
   ANTHERA Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2016-002851-92-ES   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
LIPASE
   ANTHERA Pharmaceuticals, Inc.
      2017   Phase 3   EUCTR2017-000571-85-LT   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2017   Phase 3   EUCTR2017-000571-85-HU   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2017   Phase 3   EUCTR2017-000571-85-GB   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000571-85-ES   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2016   Phase 4   EUCTR2016-002851-92-CZ   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
      2016   Phase 3   EUCTR2016-002851-92-HU   Canada;Hungary;Israel;Spain;United States;
      2016   Phase 3   EUCTR2015-002739-17-CZ   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      2015   Phase 3   EUCTR2015-002739-17-HU   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      2015   Phase 3   EUCTR2015-002739-17-ES   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      -   Phase 3   EUCTR2017-000571-85-PL   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-002851-92-PL   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
LU 70274
   Nordmark Arzneimittel GmbH
      2006   -   EUCTR2006-005180-25-DE   Germany;
LUM
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   NCT03601637   Canada;United States;
      2018   Phase 2   NCT03625466   Germany;
LUM/IVA
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   NCT04235140   Canada;United States;
      2017   Phase 3   NCT03125395   Canada;United States;
      2017   Phase 2   NCT03061331   Netherlands;
      2016   Phase 4   NCT02875366   Australia;United Kingdom;
      2016   Phase 4   NCT02823470   Canada;United States;
      2016   Phase 3   NCT02797132   Canada;United States;
      2015   Phase 3   NCT02544451   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
LUM/IVA fixed-dose combination
   Vertex Pharmaceuticals Incorporated
      2018   Phase 2   EUCTR2017-003761-99-DE   Germany;
      2016   Phase 2   EUCTR2016-001585-29-NL   Netherlands;
Lactic acid producing organisms
   UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
      2009   -   EUCTR2009-015875-28-IT   Italy;
      2009   -   EUCTR2009-011289-27-IT   Italy;
Lactizole nebulization
   Medical Universtity of Lodz
      2019   -   NCT04058340   Poland;
Lactobacillus reuteri
   Azienda Policlinico Umberto I
      2009   Phase 4   NCT01737983   Italy;
Lactobacillus rhamnosus
   Cantonal Hospital of St. Gallen
      2013   -   NCT01837355   Switzerland;
Lactobacillus rhamnosus GG
   Federico II University
      2010   Phase 3   NCT01956916   Italy;
      2009   Phase 3   NCT01961661   Italy;
Lansoprazole
   Arkansas Children's Hospital Research Institute
      2006   Phase 1   NCT00458614   United States;
Lantus 100 units/ml solution for injection in a cartridge
   HagaZiekenhuis, pulmonary department
      2012   -   EUCTR2011-001916-69-NL   Netherlands;
Lantus® 100 Units/ml solution for injection in a vial. Lantus® 100 Units/ml solution for injection in a cartridge. Lantus® 100 Units/ml solution for injection in a pre-filled pen
   St George's, University of London
      2008   -   EUCTR2007-004956-35-GB   United Kingdom;
Lefamulin
   Nabriva Therapeutics AG
      2022   Phase 1   NCT05225805   -
Lenabasum
   CORBUS PHARMACEUTICALS, INC
      2018   Phase 2   EUCTR2017-003723-29-IT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
   Corbus Pharmaceuticals Inc.
      2017   Phase 2   NCT03451045   Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
   Corbus Pharmaceuticals, Inc.
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-003723-29-PL   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-SK   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-GR   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-ES   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-BG   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2017-003723-29-FR   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Leucine
   National Center for Research Resources (NCRR)
      2001   -   NCT00014768   United States;
Levemir 100 U/ml solution for injection in a cartridge, Levemir 100 U/ml solution for injection in a pre-filled pen
   St George's, University of London
      2008   -   EUCTR2007-004956-35-GB   United Kingdom;
Levemir FlexPen
   Liverpool Heart and Chest Hospital NHS Trust
      2013   -   EUCTR2012-002880-86-GB   United Kingdom;
Levemir Penfill
   Sheffield Children's NHS Trust
      2006   Phase 4   EUCTR2005-002997-31-GB   United Kingdom;
Levemir insulin
   University of Minnesota
      2015   Phase 2/Phase 3   NCT02496780   United States;
Levofloxacin
   Mpex Pharmaceuticals, Inc.
      2008   -   EUCTR2008-001728-30-NL   Germany;Netherlands;
      2008   -   EUCTR2008-001728-30-DE   Germany;Netherlands;
Levofloxacin Kabi
   Medical University of Vienna
      2020   Phase 4   EUCTR2019-000955-16-AT   Austria;
Levofloxacin hemihydrate
   Mpex Pharmaceuticals, Inc.
      2011   Phase 3   EUCTR2010-019634-26-GB   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
      2011   -   EUCTR2010-019634-26-IE   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
      2011   -   EUCTR2010-019634-26-DE   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
      -   Phase 3   EUCTR2010-019634-26-FR   France;Germany;Ireland;United Kingdom;
Linez
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
Linezolid
   University of Texas Southwestern Medical Center
      2010   Phase 2   NCT00625703   United States;
Linoleic acid supplementation
   Karolinska Institutet
      2021   -   NCT04531410   Italy;Norway;Poland;Sweden;
Lipase CLEC
   Altus Pharmaceuticals Inc
      2007   Phase 3   EUCTR2007-000171-41-SK   Italy;Slovakia;
      -   Phase 3   EUCTR2007-000171-41-PL   Italy;Poland;Slovakia;
   Altus Pharmaceuticals Inc.
      2007   Phase 3   EUCTR2007-000178-21-SK   Italy;Slovakia;
      -   Phase 3   EUCTR2007-000178-21-PL   Italy;Poland;Slovakia;
Lipase Lip2 from Yarrowia lipolytica
   AzurRx
      2020   Phase 2   EUCTR2018-003831-31-ES   Hungary;Poland;Spain;
   AzurRx SAS
      -   Phase 2   EUCTR2018-003831-31-PL   Hungary;Poland;Spain;Turkey;
Lipitor
   NHS Lothian
      2010   Phase 4   EUCTR2010-022042-24-GB   United Kingdom;
      2010   Phase 4   EUCTR2010-022040-20-GB   United Kingdom;
Liposomal Amikacin
   INSMED INCORPORATED
      2012   -   EUCTR2011-000443-24-IT   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Spain;Sweden;United Kingdom;
Liposomal Amikacin (Arikace TM)
   Insmed Incorporated
      2011   Phase 3   EUCTR2011-000443-24-ES   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
Liposomal Amikacin (Arikace™)
   INSMED INCORPORATED
      2011   -   EUCTR2011-000441-20-IT   Austria;Bulgaria;Canada;Denmark;Greece;Hungary;Ireland;Italy;Netherlands;Spain;United Kingdom;
   Insmed Incorporated
      2013   -   EUCTR2011-000443-24-NL   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-000443-24-PL   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-000443-24-BE   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2011-000441-20-BE   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-000443-24-SE   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-000443-24-DK   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2011-000441-20-NL   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-000441-20-IE   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-000441-20-DK   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-000441-20-BG   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
      2011   Phase 3   EUCTR2011-000443-24-SK   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2011-000443-24-GB   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2011-000443-24-FR   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000443-24-IE   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2011-000443-24-HU   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2011-000443-24-GR   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000443-24-DE   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2011-000443-24-BG   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2011-000443-24-AT   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2011-000442-38-ES   Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2011   -   EUCTR2011-000442-38-BG   Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
      2011   -   EUCTR2011-000441-20-SK   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-HU   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-GR   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
      2011   -   EUCTR2011-000441-20-GB   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-DE   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-AT   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      -   Phase 3   EUCTR2011-000442-38-PL   Australia;Bulgaria;France;Macedonia, the former Yugoslav Republic of;New Zealand;Poland;Serbia;Spain;Sweden;Ukraine;United States;
   Transave, Inc.
      2007   Phase 2   EUCTR2006-006980-22-SK   Belgium;Hungary;Poland;Slovakia;
      2007   -   EUCTR2006-006980-22-HU   Belgium;Hungary;
      2007   -   EUCTR2006-006980-22-BE   Belgium;Hungary;
      -   Phase 2   EUCTR2006-006980-22-PL   Belgium;Hungary;Poland;Slovakia;
Liposomal amikacin for inhalation
   Insmed Incorporated
      2012   Phase 3   NCT01316276   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
      2012   Phase 3   NCT01315691   -
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
   Insmed Incorporated
      2012   Phase 3   NCT01315678   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
Liposomal amphotericin B (Ambisome®)
   Poitiers University Hospital
      2014   Phase 2   NCT02273661   France;
Liprotamasa
   ANTHERA Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2016-002851-92-ES   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
Liprotamase
   ANTHERA Pharmaceuticals, Inc.
      2017   Phase 3   EUCTR2017-000571-85-LT   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2017   Phase 3   EUCTR2017-000571-85-HU   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2017   Phase 3   EUCTR2017-000571-85-GB   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000571-85-ES   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2016   Phase 4   EUCTR2016-002851-92-CZ   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
      2016   Phase 3   EUCTR2016-002851-92-HU   Canada;Hungary;Israel;Spain;United States;
      2016   Phase 3   EUCTR2015-002739-17-CZ   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      2015   Phase 3   EUCTR2015-002739-17-HU   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      2015   Phase 3   EUCTR2015-002739-17-ES   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      -   Phase 3   EUCTR2017-000571-85-PL   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-002851-92-PL   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
   Anthera Pharmaceuticals
      2017   Phase 3   NCT03051490   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
      2016   Phase 4   NCT02823964   Czech Republic;Czechia;Hungary;Israel;Poland;Spain;United States;
      2015   Phase 3   NCT02279498   Canada;Czech Republic;Czechia;Hungary;Israel;Poland;Spain;United States;
      2007   Phase 3   NCT00449904   United States;
      2007   Phase 3   NCT00449878   United States;
      2004   Phase 2   NCT00095732   United States;
Liprotamase Powder for Oral Solution
   Anthera Pharmaceuticals
      2016   Phase 3   NCT02734810   United States;
Loestrin (norethindrone acetate and ethinyl estradiol)
   University of Texas Southwestern Medical Center
      2014   Early Phase 1   NCT02036879   United States;
Lonodelestat
   Santhera Pharmaceuticals (Switzerland) Ltd
      2018   Phase 1;Phase 2   EUCTR2018-002550-71-DE   Germany;
Losartan
   University of Kansas Medical Center
      2022   Early Phase 1   NCT03435939   United States;
   University of Miami
      2017   Phase 2   NCT03206788   United States;
Lubiprostone
   University of Arkansas
      2008   -   NCT00706004   United States;
Lucinactant first
   University of North Carolina, Chapel Hill
      2008   Phase 2   NCT00934362   United States;
Lumacaftor
   Vertex Pharmaceuticals Incorporated
      2015   Phase 3   NCT02390219   United States;
      2013   Phase 3   NCT01897233   Canada;United States;
      2013   Phase 1   NCT01910415   Netherlands;
      2013   Phase 1   NCT01899105   United States;
      2013   Phase 1   NCT01768663   United States;
      2010   Phase 2   NCT01225211   Australia;Belgium;France;Germany;Ireland;New Zealand;United Kingdom;United States;
Lumacaftor / ivacaftor
   Vertex Pharmaceuticals Incorporated
      2018   Phase 2   EUCTR2017-003761-99-DE   Germany;
Lumacaftor Plus Ivacaftor Combination
   Vertex Pharmaceuticals Incorporated
      2013   Phase 3   NCT01931839   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   NCT01807949   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   NCT01807923   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
Lumacaftor plus Ivacaftor
   Hannover Medical School
      2016   -   NCT02807415   Germany;
Lumacaftor, Ivacaftor Drug Combination
   Carmel Medical Center
      2016   -   NCT04623879   -
Lumacaftor-Ivacaftor treatment
   University Hospital, Strasbourg, France
      2016   -   NCT03512119   France;
Lumacaftor-ivacaftor
   Massachusetts General Hospital
      2018   -   NCT02653027   -
      2016   -   NCT02858843   -
Lumacaftor/Ivacaftor
   Vertex Pharmaceuticals Incorporated
      2014   Phase 2   EUCTR2010-020413-90-GB   Australia;Belgium;Germany;Ireland;United Kingdom;United States;
      2014   -   EUCTR2010-020413-90-IE   Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
      2011   -   EUCTR2010-020413-90-DE   Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
      2011   -   EUCTR2010-020413-90-BE   Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
Lumacaftor/ivacaftor
   Vertex Pharmaceuticals Incorporated
      2016   Phase 4   EUCTR2016-000066-34-GB   Australia;United Kingdom;
      -   Phase 3   EUCTR2017-001309-34-Outside-EU/EEA   United States;
      -   Phase 3   EUCTR2017-001078-41-Outside-EU/EEA   Canada;United States;
Lumacaftor/ivacaftor 100mg/125mg tablets
   Vertex Pharmaceuticals Incorporated
      2016   Phase 3   EUCTR2015-001644-11-GB   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-FR   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-DK   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-DE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-BE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000543-16-SE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000543-16-GB   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000543-16-DK   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000543-16-DE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000543-16-BE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001644-11-SE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2015-000543-16-FR   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
Lumacaftor/ivacaftor 200mg/
   Vertex Pharmaceuticals Inc.
      2016   Phase 2   EUCTR2015-004841-13-IE   Czech Republic;France;Ireland;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2017   Phase 2   EUCTR2015-004841-13-CZ   Czech Republic;France;Ireland;United Kingdom;United States;
   Vertex Pharmaceuticals, Inc.
      2016   Phase 2   EUCTR2015-004841-13-GB   Czech Republic;France;Ireland;United Kingdom;United States;
Lumacaftor/ivacaftor 200mg/125mg tablets
   Vertex Pharmaceuticals Inc.
      -   Phase 2   EUCTR2015-004841-13-FR   Czech Republic;France;Ireland;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2016   Phase 3   EUCTR2015-001644-11-GB   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-FR   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-DK   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-DE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-BE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-000604-41-NL   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-000604-41-IT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   -   EUCTR2013-000604-41-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-ES   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-AT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-SE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-GB   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-CZ   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-NL   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-IT   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-IE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-DE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001644-11-SE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
Lumacaftor/ivacaftor 200mg/83mg tablet
   Vertex Pharmaceuticals Incorporated
      2014   Phase 3   EUCTR2013-000604-41-NL   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-000604-41-IT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   -   EUCTR2013-000604-41-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-ES   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-AT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-SE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-GB   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-CZ   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-NL   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-IT   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-IE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-DE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
Lung Clearance Index
   The Hospital for Sick Children
      2015   Phase 2   NCT02740868   Canada;
   University of North Carolina, Chapel Hill
      2015   Early Phase 1   NCT03497117   United States;
Lym-X-Sorb powder
   Avanti Polar Lipids, Inc.
      2007   Phase 2   NCT00406536   United States;
Lysomucil
   University Hospital Ghent
      2009   -   EUCTR2008-008317-20-BE   Belgium;
MAG-DHA
   SCF Pharma
      2015   Phase 2   NCT02518672   Canada;
MEDI-563
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-004068-24-IT   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
   AstraZeneca AB
      2021   Phase 3   EUCTR2020-004068-24-DK   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-004068-24-DE   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Japan;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Viet Nam;
MEROPENEM TRIHYDRATE
   Ghent University
      2016   Phase 4   EUCTR2016-000398-19-BE   Belgium;
MINOCYCLINE HYDROCHLORIDE
   AOU Meyer
      2013   Phase 3   EUCTR2013-000219-25-IT   Italy;
MOLI 1901
   AOP ORPHAN PHARMACEUTICALS
      2008   -   EUCTR2006-006693-24-IT   Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
MP-376
   Horizon Pharma USA, Inc.
      2008   Phase 2   NCT00677365   Germany;Netherlands;United States;
   Mpex Pharmaceuticals, Inc.
      2011   Phase 3   EUCTR2010-019634-26-GB   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
      2011   -   EUCTR2010-019634-26-IE   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
      2011   -   EUCTR2010-019634-26-DE   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
      2008   -   EUCTR2008-001728-30-NL   Germany;Netherlands;
      2008   -   EUCTR2008-001728-30-DE   Germany;Netherlands;
      -   Phase 3   EUCTR2010-019634-26-FR   France;Germany;Ireland;United Kingdom;
MP-376 (Levofloxacin Solution for Inhalation)
   Horizon Pharma USA, Inc.
      2011   Phase 3   NCT01270347   France;Germany;Ireland;Israel;United Kingdom;United States;
MP-376 (Levofloxacin solution for Inhalation)
   Horizon Pharma USA, Inc.
      2010   Phase 3   NCT01180634   Australia;Canada;Israel;New Zealand;United States;
      2009   Phase 1   NCT00840333   United States;
      2007   Phase 1   NCT00503490   United States;
MRI with PFP
   University of North Carolina, Chapel Hill
      2015   Early Phase 1   NCT03497117   United States;
MRT5005
   Translate Bio, Inc.
      2018   Phase 1/Phase 2   NCT03375047   United States;
MS1819
   AzurRx BioPharma, Inc.
      2020   Phase 2   NCT04375878   Poland;United States;
MS1819-SD
   AzurRx
      2020   Phase 2   EUCTR2018-003831-31-ES   Hungary;Poland;Spain;
      2019   Phase 2   EUCTR2018-003831-31-HU   Hungary;Poland;Spain;
   AzurRx BioPharma, Inc.
      2019   Phase 2   NCT03746483   Poland;United States;
   AzurRx SAS
      2019   Phase 2   NCT04302662   Hungary;Turkey;
      -   Phase 2   EUCTR2018-003831-31-PL   Hungary;Poland;Spain;Turkey;
MSI-1995
   Genaera Corporation
      2005   Phase 2   EUCTR2004-004334-13-IE   Ireland;
MTT
   Pharmaxis Pharmaceuticals Limited
      2009   Phase 3   EUCTR2008-002740-42-FR   Belgium;France;Germany;Netherlands;
      2009   -   EUCTR2008-002740-42-NL   Belgium;France;Germany;Netherlands;
      2009   -   EUCTR2008-002740-42-BE   Belgium;France;Germany;Netherlands;
      2008   -   EUCTR2008-002740-42-DE   Belgium;France;Germany;Netherlands;
Macroduct sweat stimulator
   Richard Barry Moss
      2015   -   NCT02310789   United States;
Magnetic Resonance Imaging
   The Hospital for Sick Children
      2015   Phase 2   NCT02740868   Canada;
Mannite
   University Children’s Hospital Tuebingen
      2009   Phase 2   NCT01309178   Germany;
Mannitol
   Pharmaxis
      2008   Phase 1   NCT00792714   Australia;United Kingdom;
      2007   Phase 3   NCT00446680   Australia;Ireland;United Kingdom;
      2005   Phase 2   NCT00251056   Argentina;Canada;
   Pharmaxis Ltd.
      2014   -   EUCTR2012-002699-14-NL   Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;
      2014   -   EUCTR2012-002699-14-IT   Argentina;Belgium;Canada;Italy;Netherlands;United Kingdom;
      2013   Phase 2   EUCTR2012-002699-14-GB   Argentina;Belgium;Canada;France;Italy;Netherlands;United Kingdom;
      2013   -   EUCTR2012-002699-14-BE   Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
      -   Phase 2   EUCTR2012-002699-14-FR   Argentina;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Mannitol + pulmozyme
   Pharmaxis
      2005   Phase 2   NCT00117208   United Kingdom;
Mannitol inhalation powder
   Tim Corcoran
      2013   Phase 1   NCT01887197   United States;
Manuka honey sinus rinse
   Swansea University
      2019   -   NCT04589897   United Kingdom;
Matched isoglycemic clamp
   Liverpool Heart and Chest Hospital NHS Foundation Trust
      2013   -   NCT01975259   United Kingdom;
Medical Grade Oxygen
   Hal C Charles
      2012   Phase 1   NCT01731015   United States;
Melphalan
   Federal State Budgetary Institution, Pulmonology Scientific Research Institute
      2018   Phase 2   NCT04278040   Russian Federation;
Menadiol sodium diphosphate
   Barts and the London NHS Trust
      2006   Phase 3   EUCTR2006-000945-20-GB   United Kingdom;
Meropenem
   Imperial College London
      2010   Phase 4   NCT01044719   United Kingdom;
   Imperial College, London
      2009   -   EUCTR2009-014042-28-GB   United Kingdom;
   Joseph Kuti
      2012   Phase 4   NCT01429259   United States;
   University Ghent
      2016   -   NCT02840136   Belgium;
Meropenem Fresenius Kabi 1 g poeder voor oplossing voor injectie of infusie
   Ghent University
      2016   Phase 4   EUCTR2016-000398-19-BE   Belgium;
Meropenem Infusion
   St. Michael's Hospital, Toronto
      2010   -   NCT01158937   Canada;
Mesenchymal Stem Cells
   Erica Roesch
      2016   Phase 1   NCT02866721   United States;
Metformin Hydrochloride
   University of Kansas Medical Center
      2022   Phase 2   NCT04530383   United States;
Metformine HCL 500 PCH
   Staf Longziekten
      2009   -   EUCTR2009-009875-37-NL   Netherlands;
Miglustat
   Actelion
      2008   Phase 2   NCT00742092   Belgium;
      2007   Phase 2   NCT00537602   Spain;
   Actelion Pharmaceuticals Ltd
      2008   -   EUCTR2008-002352-20-BE   Belgium;
      2007   -   EUCTR2006-002049-35-ES   Spain;
   Assistance Publique - Hôpitaux de Paris
      2015   Phase 2/Phase 3   NCT02325362   France;
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2009   Phase 2   NCT00945347   Belgium;
Minocycline
   University of North Carolina, Chapel Hill
      2018   Phase 2   NCT03489629   United States;
      2011   Phase 2   NCT01349192   United States;
Modified Oral Glucose Tolerance Test (50g 4-hours)
   Liverpool Heart and Chest Hospital NHS Foundation Trust
      2013   -   NCT01975259   United Kingdom;
Modified lipid formulation
   Nestlé
      2016   -   NCT02646995   Switzerland;
Molgramostim
   Savara Inc.
      2015   Phase 1   NCT02468908   United Kingdom;
Molgramostim nebulizer solution
   Savara Inc.
      2019   Phase 2   NCT03597347   United States;
Moli 1901 (2622U90, duramycin)
   AOP Orphan Pharmaceuticals AG
      2007   Phase 2;Phase 3   EUCTR2006-006693-24-FR   Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
Moli1901
   AOP Orphan Pharmaceuticals AG
      2007   Phase 2   NCT00671736   Austria;
      2006   Phase 2;Phase 3   EUCTR2005-005594-29-SK   Czech Republic;Hungary;Slovakia;
      2006   -   EUCTR2005-005594-29-HU   Czech Republic;Hungary;
      2006   -   EUCTR2005-005594-29-CZ   Czech Republic;Hungary;
Moli1901 (2622U90, duramycin)
   AOP Orphan Pharmaceuticals AG
      2008   Phase 2;Phase 3   EUCTR2006-006693-24-ES   Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
      2008   -   EUCTR2006-006693-24-CZ   Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
      2007   Phase 2;Phase 3   EUCTR2006-006693-24-DE   Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
      2007   -   EUCTR2006-006693-24-SE   Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
      2007   -   EUCTR2006-006693-24-HU   Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
      2007   -   EUCTR2006-006693-24-AT   Austria;Czech Republic;France;Germany;Hungary;Italy;Spain;Sweden;
      2006   -   EUCTR2005-004344-30-HU   Hungary;
      2005   -   EUCTR2005-004344-30-AT   Austria;Hungary;
      -   Phase 2   EUCTR2006-006693-24-PL   Austria;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Sweden;
Moxifloxacin hydrochloride
   Vertex Pharmaceuticals Incorporated
      2013   Phase 1   NCT01910415   Netherlands;
Mucoid exopolysaccharide P. aeruginosa immune globulin IV
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004747   -
Mucolysin
   Aarhus University Hospital
      2016   Phase 2   EUCTR2016-000354-35-DK   Denmark;
      2014   Phase 2   EUCTR2013-005481-19-DK   Denmark;
Mucomyst
   Aarhus University Hospital
      2014   Phase 2   EUCTR2013-005481-19-DK   Denmark;
Multienzymes (lipase, protease etc.)
   ALTUS PHARMACEUTICALS INC
      2007   -   EUCTR2007-000178-21-IT   Italy;
      2007   -   EUCTR2007-000171-41-IT   Italy;
   EURAND SPA
      2010   -   EUCTR2009-012842-21-IT   Bulgaria;Germany;Hungary;Italy;United Kingdom;
Mupirocin
   University of North Carolina, Chapel Hill
      2018   Phase 2   NCT03489629   United States;
      2011   Phase 2   NCT01349192   United States;
Mupirocin Intranasal Creme
   Johns Hopkins University
      2012   Phase 2   NCT01594827   United States;
N-(5-hydroxy-2,4- bis(trimethylsilyl)phenyl)-4-oxo- 1,4-dihydroquinoline-3-carboxamide
   Proteostasis Therapeutics, Inc.
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-DE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
   Proteostasis Therapeutics, Inc.
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-GB   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-BE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide
   Proteostasis Therapeutics, Inc.
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-GB   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-DE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-BE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
N-acetylcystein
   Rigshospitalet
      2010   Phase 4   EUCTR2007-001401-15-DK   Denmark;
N-acetylcysteine
   Qilu Hospital of Shandong University
      2014   -   NCT02088216   China;
   University Hospital Ghent
      2009   -   EUCTR2008-008317-20-BE   Belgium;
N-acetylcysteine (NAC)
   Stanford University
      2008   Phase 2   NCT00809094   United States;
N6022
   Nivalis Therapeutics, Inc.
      2014   Phase 1   NCT01746784   United States;
N91115
   Nivalis Therapeutics, Inc.
      2015   Phase 1   NCT02275936   United States;
      2014   Phase 1   NCT02227888   United States;
NAL
   LABORATOIRES SMB S.A.
      2010   -   EUCTR2010-018454-13-IT   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
   Laboratoires SMB S.A.
      2010   Phase 3   EUCTR2010-018454-13-FR   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-018454-13-ES   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-018454-13-DK   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-HU   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-GB   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-DE   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-CZ   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      -   Phase 3   EUCTR2010-018454-13-BE   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
NEB/01-07
   Laboratoire Erempharma
      2008   -   EUCTR2007-003868-22-FR   France;
NEBCINE
   CHRU de Lille
      -   Phase 2   EUCTR2014-003882-10-FR   France;
NO
   Southampton University Hopsitals NHS Trust
      2011   -   EUCTR2010-023529-39-GB   United Kingdom;
NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE
   IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
      2020   Phase 2;Phase 3   EUCTR2019-004511-31-IT   Czech Republic;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
NOXAFIL - 40 mg/ml oral suspension
   Bambino Gesù Children's Hospital
      -   Phase 2;Phase 3   EUCTR2019-004511-31-IE   Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
NOXAFIL - oral suspension 40 mg/ml
   Bambino Gesù Children's Hospital
      2022   Phase 2;Phase 3   EUCTR2019-004511-31-NL   Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
      2022   Phase 2;Phase 3   EUCTR2019-004511-31-DE   Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
      2021   Phase 2;Phase 3   EUCTR2019-004511-31-PT   Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
      2021   Phase 2;Phase 3   EUCTR2019-004511-31-GR   Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
      -   Phase 2;Phase 3   EUCTR2019-004511-31-FR   Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
   Bambino Gesù Children´s Hospital
      2022   Phase 2;Phase 3   EUCTR2019-004511-31-ES   Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
NR
   Virginia Commonwealth University
      2020   -   NCT04166396   United States;
NaCl
   University of North Carolina
      2001   Phase 2   NCT00274391   United States;
NaCl/Inhalation solution
   Vertex Pharmaceuticals Inc.
      2016   Phase 2   EUCTR2015-004841-13-IE   Czech Republic;France;Ireland;United Kingdom;United States;
   Vertex Pharmaceuticals, Inc.
      2016   Phase 2   EUCTR2015-004841-13-GB   Czech Republic;France;Ireland;United Kingdom;United States;
NaCl/inhalation solution
   Vertex Pharmaceuticals Inc.
      -   Phase 2   EUCTR2015-004841-13-FR   Czech Republic;France;Ireland;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2017   Phase 2   EUCTR2015-004841-13-CZ   Czech Republic;France;Ireland;United Kingdom;United States;
Nacystelyn
   LABORATOIRES SMB S.A.
      2010   -   EUCTR2010-018454-13-IT   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
Nacystelyn®
   Laboratoires SMB S.A.
      2010   Phase 3   EUCTR2010-018454-13-FR   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-018454-13-ES   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   Phase 3   EUCTR2010-018454-13-DK   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-HU   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-GB   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-DE   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2010   -   EUCTR2010-018454-13-CZ   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      -   Phase 3   EUCTR2010-018454-13-BE   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;
Nasal Aztreonam
   Virginia Commonwealth University
      2017   Phase 2   NCT02730793   United States;
Navocaftor
   AbbVie
      2021   Phase 2   NCT04853368   Australia;Belgium;Czechia;Germany;Hungary;Netherlands;New Zealand;Slovakia;
   AbbVie Deutschland GmbH & Co. KG
      2021   Phase 2   EUCTR2020-005805-25-NL   Australia;Belgium;Germany;Hungary;Netherlands;New Zealand;Slovakia;United Kingdom;
      2021   Phase 2   EUCTR2020-005805-25-HU   Hungary;
      2021   Phase 2   EUCTR2020-005805-25-BE   Belgium;Hungary;Netherlands;
Nebcin
   University Hospital, Lille
      2017   Phase 3   NCT03066453   France;
Nebcin (tobramycin)
   The Univeristy of Nottingham
      2010   Phase 4   EUCTR2010-023030-23-GB   United Kingdom;
Nebcinal
   EREMPHARMA SAS
      -   Phase 1   EUCTR2010-023533-34-FR   France;
   Erempharma SAS
      2009   -   EUCTR2009-013660-39-FR   France;
Nebcinal Tobi
   Erempharma
      2010   -   NCT01288170   France;
Nebulization of Amikacin during NIV (RR: 15 cycles/minute)
   University Hospital St Luc, Brussels
      2014   -   NCT02084043   Belgium;Switzerland;
Nebulization of Amikacin during NIV (RR: 25 cycles/minute)
   University Hospital St Luc, Brussels
      2014   -   NCT02084043   Belgium;Switzerland;
Nebulization tobramycin
   University Medical Center Groningen
      -   Phase 2   EUCTR2016-005014-21-NL   Netherlands;
Nexium 20
   Biovitrum AB
      2008   -   EUCTR2007-004063-21-NL   Netherlands;
Nitric Oxide
   Southampton University Hopsitals NHS Trust
      2011   -   EUCTR2010-023529-39-GB   United Kingdom;
   University Hospital Southampton NHS Foundation Trust.
      2011   Phase 2   NCT02295566   United Kingdom;
Nitric Oxide 160 ppm
   Novoteris, LLC
      2017   Phase 2   NCT02498535   Canada;United States;
Nitric Oxide for Inhalation
   Mallinckrodt
      2004   Phase 1/Phase 2   NCT00570349   United States;
Nitrogen
   Mallinckrodt
      2004   Phase 1/Phase 2   NCT00570349   United States;
Nocturnal oxygen , nocturnal bi-level positive pressure ventilation
   Bayside Health
      2003   Phase 1/Phase 2   NCT00157183   Australia;
Non invasive ventilation
   Karolinska University Hospital
      2016   -   NCT02684552   Sweden;
None
   AstraZeneca AB
      2009   -   EUCTR2008-001530-27-GB   Denmark;Germany;Sweden;United Kingdom;
      2009   -   EUCTR2008-001530-27-DK   Denmark;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2008-001530-27-SE   Denmark;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2008-001530-27-DE   Denmark;Germany;Sweden;United Kingdom;
   Proteostasis Therapeutics, Inc.
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-GB   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-DE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-BE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
   University of Nottingham
      2008   Phase 4   EUCTR2007-006204-37-GB   United Kingdom;
None assigned
   Aradigm Corporation
      2010   Phase 2   EUCTR2009-014412-35-DE   Germany;United Kingdom;
      2010   -   EUCTR2009-014412-35-GB   Germany;United Kingdom;
Noninvasive ventilation
   St. Michael's Hospital, Toronto
      2014   -   NCT02262871   Canada;
Normal Saline
   University of Washington
      2016   Phase 2   NCT02354859   United States;
Normal saline
   Nivalis Therapeutics, Inc.
      2014   Phase 1   NCT01746784   United States;
   Qilu Hospital of Shandong University
      2014   Phase 4   NCT02081963   China;
   Translate Bio, Inc.
      2018   Phase 1/Phase 2   NCT03375047   United States;
   University Hospital, Ghent
      2010   Phase 4   NCT00996424   Belgium;
Normal saline IV, salt tablets
   Bayside Health
      2004   Phase 2/Phase 3   NCT00163852   Australia;
Normal saline solution
   University Hospital Ghent
      2007   -   EUCTR2007-002707-40-BE   Belgium;
Normal saline:
   University of Oklahoma
      2006   -   NCT00671723   United States;
Norvir 100 mg film-coated tablets
   university medical center utrecht
      2018   Phase 4   EUCTR2016-001440-18-NL   Netherlands;
Novo Rapid
   Papworth Hospital NHS Foundation Trust
      2005   Phase 4   EUCTR2004-005019-28-GB   United Kingdom;
Novo Rapid Insulin (Novonordisk)
   Hadassah Medical Organization
      2010   -   NCT01149005   Israel;
NovoNorm
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2006   -   EUCTR2006-001254-27-FR   France;
NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen.
   St George's, University of London
      2008   -   EUCTR2007-004956-35-GB   United Kingdom;
NovoRapid Aspartate
   Papworth Hospital NHS Foundation Trust
      2005   Phase 4   EUCTR2004-005019-28-GB   United Kingdom;
Novolog insulin
   University of Minnesota
      2015   Phase 2/Phase 3   NCT02496780   United States;
Novorapid / humalog short acting insulin
   Hadassah Medical Organization
      2010   -   NCT01149005   Israel;
Noxafil
   MSD
      2012   -   EUCTR2012-003140-68-GB   United Kingdom;
Noxafil - oral suspension 40 mg/ml
   Bambino Gesù Children's Hospital
      -   Phase 2;Phase 3   EUCTR2019-004511-31-GB   Czech Republic;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
Noxafil 100 mg Tablets Gastro-Resistant
   Bambino Gesù Children's Hospital
      -   Phase 2;Phase 3   EUCTR2019-004511-31-IE   Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
Noxafil®
   Karolinska University Hospital, Stockholm CF center
      2018   Phase 2   EUCTR2018-002579-16-SE   Sweden;
Nutridrink-Impact
   University Hospital, Motol
      2013   Phase 4   NCT02048592   Czech Republic;
Nutropin AQ
   University of Massachusetts, Worcester
      2008   Phase 1   NCT00803179   United States;
   University of Texas Southwestern Medical Center
      2000   Phase 2/Phase 3   NCT00256555   -
Nutropin AQ [somatropin (DNA origin) injection]
   Genentech, Inc.
      2003   Phase 2   NCT00079742   United States;
OGT 918
   Actelion Pharmaceuticals Ltd
      2007   -   EUCTR2006-002049-35-ES   Spain;
OSCN-
   Alaxia SAS
      2015   Phase 1   NCT02598999   France;
Oleic acid supplementation
   Karolinska Institutet
      2021   -   NCT04531410   Italy;Norway;Poland;Sweden;
OligoG (60 mg/ml)
   AlgiPharma AS
      2011   Phase 2   EUCTR2010-023090-19-GB   Ireland;United Kingdom;
      2011   -   EUCTR2010-023090-19-IE   Ireland;United Kingdom;
OligoG CF-5/20
   AlgiPharma AS
      2011   Phase 1/Phase 2   NCT01465529   Ireland;United Kingdom;
      2009   Phase 1   NCT00970346   United Kingdom;
OligoG CF-5/20 -
   AlgiPharma AS
      2020   Phase 2   EUCTR2018-000378-30-GB   Austria;Germany;Ireland;Poland;United Kingdom;
      -   Phase 2   EUCTR2018-000378-30-IE   Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF-5/20, 17,5 mg, Hartkapsel mit Pulver zur Inhalation
   AlgiPharma AS
      2020   Phase 2   EUCTR2018-000378-30-DE   Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF/20 -
   AlgiPharma AS
      2020   Phase 2   EUCTR2018-000378-30-GB   Austria;Germany;Ireland;Poland;United Kingdom;
      -   Phase 2   EUCTR2018-000378-30-IE   Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF/20, 27,5 mg, Hartkapsel mit Pulver zur Inhalation
   AlgiPharma AS
      2020   Phase 2   EUCTR2018-000378-30-DE   Austria;Germany;Ireland;Poland;United Kingdom;
OligoG CF/20, 37,5 mg, Hartkapsel mit Pulver zur Inhalation
   AlgiPharma AS
      2020   Phase 2   EUCTR2018-000378-30-DE   Austria;Germany;Ireland;Poland;United Kingdom;
OligoG DPI
   AlgiPharma AS
      2019   Phase 2   NCT03822455   Australia;
OligoG Dry powder for inhalation
   AlgiPharma AS
      2020   Phase 2/Phase 3   NCT03698448   Germany;
OligoG-CF5/20, Alginate oligosaccharide (G-block) fragment
   AlgiPharma AS
      2011   Phase 2   EUCTR2010-023090-19-GB   Ireland;United Kingdom;
Oligomer of Sodium Alginate
   Algipharma AS
      2014   Phase 2   EUCTR2014-002125-35-DE   Germany;
      2014   Phase 2   EUCTR2014-000844-13-SE   Denmark;Germany;Sweden;
      2014   Phase 2   EUCTR2014-000844-13-DK   Denmark;Germany;Sweden;
Omadacycline Injection [Nuzyra]
   Paul Beringer
      2021   Phase 4   NCT04460586   United States;
Omadacycline Oral Tablet [Nuzyra]
   Paul Beringer
      2021   Phase 4   NCT04460586   United States;
Omalizumab
   NOVARTIS FARMA
      2009   -   EUCTR2007-006648-23-IT   Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
   Novartis Pharma Services AG
      2009   -   EUCTR2007-006648-23-GB   Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-006648-23-DE   Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-006648-23-BE   Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
   Novartis Pharmaceuticals
      2008   Phase 4   NCT00787917   Belgium;Germany;Italy;Netherlands;United Kingdom;
Omega 3 Premium
   Hôpital Universitaire Des Enfants Reine Fabiola (H.U.D.E.R.F.)
      2008   -   EUCTR2006-004155-38-BE   Belgium;
Omega-3 triglycerides
   Queen Fabiola Children's University Hospital
      2008   Phase 3   NCT00959010   Belgium;
Omeprazole 40mg Capsule
   Children's Hospital of Philadelphia
      2018   Phase 2   NCT03551691   United States;
Once-daily insulin detemir
   Sydney Children's Hospitals Network
      2010   Phase 3   NCT01100892   Australia;United States;
Oral Aztreonam
   Virginia Commonwealth University
      2017   Phase 2   NCT02730793   United States;
Oral Glucose Tolerance Test
   University of Texas Southwestern Medical Center
      2006   -   NCT00287456   United States;
Oral Glucose Tolerance test (75g 2-hour)
   Liverpool Heart and Chest Hospital NHS Foundation Trust
      2013   -   NCT01975259   United Kingdom;
Oral Glucose tolerance test
   University of Texas Southwestern Medical Center
      2006   -   NCT00287443   United States;
Oral Glutathione
   University of Minnesota
      2017   Phase 2   NCT03020719   United States;
Oral ciprofloxacin
   Seattle Children's Hospital
      2004   Phase 2   NCT00097773   United States;
Oral ciprofloxacin plus inhaled colistin
   Universitaire Ziekenhuizen Leuven
      2001   Phase 4   NCT01400750   Belgium;
Oral reduced l-glutathione
   Clark Bishop
      2011   -   NCT02029521   Italy;
Oral roflumilast
   The University of Hong Kong
      2018   Phase 2   NCT03428334   Hong Kong;
Orkambi
   Antwerp University Hospital
      2018   Phase 4   EUCTR2018-001573-24-BE   Belgium;
   Assistance Publique - Hôpitaux de Paris
      2019   -   NCT03894657   France;
   Children's Hospital of Philadelphia
      2019   -   NCT03795363   United States;
   Parion Sciences
      2016   Phase 2   NCT02709109   France;Ireland;United Kingdom;United States;
   University Hospital, Antwerp
      2018   Phase 4   NCT03956589   Belgium;
   Vertex Pharmaceuticals Inc.
      2016   Phase 2   EUCTR2015-004841-13-IE   Czech Republic;France;Ireland;United Kingdom;United States;
      -   Phase 2   EUCTR2015-004841-13-FR   Czech Republic;France;Ireland;United Kingdom;United States;
   Vertex Pharmaceuticals Incoporated
      2017   Phase 4   EUCTR2016-004996-33-ES   Australia;Canada;Spain;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2017   Phase 2   EUCTR2015-004841-13-CZ   Czech Republic;France;Ireland;United Kingdom;United States;
      2016   Phase 4   EUCTR2016-000066-34-GB   Australia;United Kingdom;
   Vertex Pharmaceuticals, Inc.
      2016   Phase 2   EUCTR2015-004841-13-GB   Czech Republic;France;Ireland;United Kingdom;United States;
Orkambi 100 mg/125 mg film-coated tablets
   Vertex Pharmaceuticals Incorporated
      2018   Phase 2   EUCTR2017-003761-99-DE   Germany;
Orkambi 200 mg/125 mg film-coated tablets
   Vertex Pharmaceuticals Incorporated
      2016   Phase 2   EUCTR2016-001585-29-NL   Netherlands;
Orkambi: contains lumacaftor and ivacaftor
Orkambi®
   ASSISTANC-PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
      -   Phase 4   EUCTR2018-002624-16-FR   France;
Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/
   University of Pennsylvania
      2014   Phase 1   NCT02144246   United States;
Oseltamivir
   Inserm
      2009   -   EUCTR2009-016662-90-FR   France;
Other non-sponsor pancreatic enzyme replacement therapy
   AbbVie
      2012   -   NCT01652157   United States;
Other respiratory system products
   DEBIOPHARM S.A.
      2005   -   EUCTR2004-002341-12-IT   Belgium;Germany;Italy;United Kingdom;
Oxygen
   Assistance Publique - Hôpitaux de Paris
      2012   -   NCT01586728   France;
   Karolinska University Hospital
      2016   -   NCT02684552   Sweden;
P-1037
   Parion Sciences
      2015   Phase 2   NCT02343445   United States;
PAAG15
   Synspira Therapeutics, Inc.
      2019   Phase 2   EUCTR2019-003178-25-HU   Hungary;
PANCREASE MT
   Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
      -   -   EUCTR2015-001219-11-Outside-EU/EEA   Canada;United States;
PANCREASLIPASE
   Aptalis Pharma US Inc.
      2012   Phase 3   EUCTR2009-012842-21-BE   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2010   Phase 3   EUCTR2009-012842-21-GB   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
PANCREATIN (PAncreas Powder)
   Abbott Laboratories GmbH
      2015   -   EUCTR2014-004519-35-GB   Czech Republic;Hungary;Spain;United Kingdom;
      2015   -   EUCTR2014-004519-35-CZ   Czech Republic;Hungary;Spain;United Kingdom;
PANCREATIN (Pancreas Powder)
   Abbott Laboratories GmbH
      2015   -   EUCTR2014-004519-35-HU   Czech Republic;Hungary;Spain;United Kingdom;
      2015   -   EUCTR2014-004519-35-GB   Czech Republic;Hungary;Spain;United Kingdom;
      2015   -   EUCTR2014-004519-35-CZ   Czech Republic;Hungary;Spain;United Kingdom;
PANCREATINA
   Abbott Laboratories GmbH
      2013   -   EUCTR2013-002819-10-ES   Hungary;Russian Federation;Spain;
PANCREATINA (Páncreas Polvo)
   Abbott Laboratories GmbH
      2015   Phase 2   EUCTR2014-004519-35-ES   Czech Republic;Hungary;Spain;United Kingdom;
PANCREAZE
   AbbVie
      2012   -   NCT01652157   United States;
PANCREAZE®
   ANTHERA Pharmaceuticals, Inc.
      2017   Phase 3   EUCTR2017-000571-85-LT   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2017   Phase 3   EUCTR2017-000571-85-HU   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2017   Phase 3   EUCTR2017-000571-85-GB   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000571-85-ES   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2016   Phase 3   EUCTR2015-002739-17-CZ   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      2015   Phase 3   EUCTR2015-002739-17-HU   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      2015   Phase 3   EUCTR2015-002739-17-ES   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      -   Phase 3   EUCTR2017-000571-85-PL   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
PANCRECARB® (pancrelipase)
   Digestive Care, Inc.
      2007   Phase 3   NCT00432861   United States;
PANZYTRAT 25000
   Axcan Pharma Inc.
      -   -   EUCTR2010-019267-11-DE   Germany;
PARI eFlow nebulizer system
   Savara Inc.
      2019   Phase 2   NCT03597347   United States;
PBI4050
   Liminal BioSciences Ltd.
      2017   Phase 2   NCT02955888   Canada;
PC945
   Pulmocide Ltd
      2019   Phase 2   NCT03870841   United Kingdom;
      2018   Phase 2   EUCTR2018-000243-87-GB   United Kingdom;
PERTZYE
   AbbVie
      2012   -   NCT01652157   United States;
PFP
   University of North Carolina, Chapel Hill
      2018   Early Phase 1   NCT03482960   United States;
      2015   Early Phase 1   NCT03489590   United States;
PFP and SF6 Human Lung Coil
   Thunder Bay Regional Research Institute
      2019   Early Phase 1   NCT02748798   Canada;
PFT
   Indiana University
      2018   -   NCT03579173   United States;
PGM169/GL67A
   Imperial College
      2012   Phase 2   EUCTR2011-004761-33-GB   United Kingdom;
      2008   -   EUCTR2007-004050-85-GB   United Kingdom;
   Imperial College London
      2012   Phase 2   NCT01621867   United Kingdom;
      2008   Phase 1/Phase 2   NCT00789867   United Kingdom;
PIPERACILLIN SODIUM
   Ghent University
      2016   Phase 4   EUCTR2016-000398-19-BE   Belgium;
PL 0010/0211
   Southampton University Hospital Trust
      2008   -   EUCTR2008-001769-27-GB   United Kingdom;
PO azithromycin
   Seattle Children's Hospital
      2004   -   NCT00153634   United States;
PO ciprofloxacin
   Seattle Children's Hospital
      2004   -   NCT00153634   United States;
POL6014
   Santhera Pharmaceuticals
      2018   Phase 1/Phase 2   NCT03748199   Germany;
   Santhera Pharmaceuticals (Switzerland) Ltd
      2018   Phase 1;Phase 2   EUCTR2018-002550-71-DE   Germany;
      2017   Phase 1;Phase 2   EUCTR2016-005110-22-DE   Germany;
POL7080
   Polyphor Ltd.
      2014   Phase 2   EUCTR2013-002202-31-DE   Germany;Spain;United Kingdom;
      2013   Phase 2   NCT02096315   Spain;United Kingdom;
      2013   Phase 2   EUCTR2013-002202-31-GB   Germany;Spain;United Kingdom;
      2013   -   EUCTR2013-002202-31-ES   Germany;Spain;United Kingdom;
PPI treatment
   University of Colorado, Denver
      2017   -   NCT02769637   United States;
PREFOLIC*30CPR GASTROR
   AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
      2010   -   EUCTR2010-020516-11-IT   Italy;
PROMIXIN*NEBUL 30MONOD 1MUI
   AZIENDA OSPEDALIERA MEYER
      2011   -   EUCTR2011-006171-19-IT   Italy;
PROTEASA
   ANTHERA Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2016-002851-92-ES   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
PROTEASE
   ANTHERA Pharmaceuticals, Inc.
      2017   Phase 3   EUCTR2017-000571-85-LT   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2017   Phase 3   EUCTR2017-000571-85-HU   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2017   Phase 3   EUCTR2017-000571-85-GB   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000571-85-ES   Hungary;Israel;Lithuania;Poland;Spain;United States;
      2016   Phase 4   EUCTR2016-002851-92-CZ   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
      2016   Phase 3   EUCTR2016-002851-92-HU   Canada;Hungary;Israel;Spain;United States;
      2016   Phase 3   EUCTR2015-002739-17-CZ   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      2015   Phase 3   EUCTR2015-002739-17-HU   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      2015   Phase 3   EUCTR2015-002739-17-ES   Canada;Czech Republic;Hungary;Israel;Spain;United States;
      -   Phase 3   EUCTR2017-000571-85-PL   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2016-002851-92-PL   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
PTC-0161480
   PTC Therapeutics, Inc
      2010   Phase 3   EUCTR2010-019692-30-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-GB   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-SE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-NL   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-ES   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-DE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC-124
   PTC Therapeutics, Inc
      2010   Phase 3   EUCTR2010-019692-30-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-GB   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-SE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-NL   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-ES   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-DE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC-C124
   PTC Therapeutics, Inc
      2010   Phase 3   EUCTR2010-019692-30-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-GB   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-SE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-NL   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-ES   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-DE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
PTC124
   PTC THERAPEUTICS, INC.
      2010   -   EUCTR2010-019692-30-IT   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-IT   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
   PTC Therapeutics
      2006   Phase 2   NCT00351078   Israel;
      2005   Phase 2   NCT00234663   United States;
   PTC Therapeutics, Inc
      2011   Phase 3   EUCTR2010-019692-30-GB   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-019692-30-ES   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-019692-30-DE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-019692-30-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019692-30-SE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2010-019692-30-NL   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2010-019692-30-BE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-003924-52-GB   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-BE   Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2009   -   EUCTR2008-003924-52-SE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-NL   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-ES   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-DE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
   PTC Therapeutics, Inc.
      2016   Phase 3   EUCTR2014-005355-83-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005355-83-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005355-83-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-005355-83-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005355-83-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005355-83-FR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005355-83-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005355-83-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005449-35-FR   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2015   Phase 3   EUCTR2013-004581-34-NL   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004581-34-GR   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004581-34-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-004581-34-BE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005449-35-SE   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-005449-35-IT   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-005449-35-ES   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-005449-35-DE   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-005449-35-BE   Belgium;France;Germany;Israel;Italy;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-004581-34-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004581-34-GB   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004581-34-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Germany;Greece;Israel;Italy;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004581-34-DE   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2007   -   EUCTR2007-000724-40-BE   Belgium;
PTI-428
   Proteostasis Therapeutics
      2017   Phase 1;Phase 2   EUCTR2016-001214-24-DK   Canada;Czech Republic;Denmark;France;Germany;Italy;United Kingdom;United States;
      2017   Phase 1;Phase 2   EUCTR2016-001214-24-DE   Canada;Czech Republic;Denmark;France;Germany;Italy;United Kingdom;United States;
   Proteostasis Therapeutics, Inc.
      2018   Phase 2   NCT03591094   United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-GB   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-DE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-BE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1/Phase 2   NCT03500263   United Kingdom;
      2017   Phase 1/Phase 2   NCT03251092   Australia;Belgium;Canada;Denmark;France;Germany;New Zealand;United Kingdom;United States;
      2017   Phase 1   NCT03258424   United Kingdom;
      2016   Phase 1/Phase 2   NCT02718495   Canada;Czechia;Denmark;France;Germany;United Kingdom;United States;
PTI-801
   Proteostasis Therapeutics, Inc.
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-GB   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-DE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-BE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1/Phase 2   NCT03500263   United Kingdom;
      2017   Phase 1/Phase 2   NCT03251092   Australia;Belgium;Canada;Denmark;France;Germany;New Zealand;United Kingdom;United States;
      2017   Phase 1   NCT03140527   Canada;Denmark;Germany;Portugal;Sweden;United States;
PTI-808
   Proteostasis Therapeutics, Inc.
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-GB   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-DE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-BE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1/Phase 2   NCT03500263   United Kingdom;
      2017   Phase 1/Phase 2   NCT03251092   Australia;Belgium;Canada;Denmark;France;Germany;New Zealand;United Kingdom;United States;
      2017   Phase 1   NCT03140527   Canada;Denmark;Germany;Portugal;Sweden;United States;
PUR118
   Pulmatrix Inc.
      2012   Phase 1   NCT01543191   United Kingdom;
Pancreas Powder
   Aptalis Pharma US Inc.
      2013   -   EUCTR2009-012842-21-HU   Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2012   Phase 3   EUCTR2009-012842-21-BE   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2011   -   EUCTR2009-012842-21-DE   Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2011   -   EUCTR2009-012842-21-BG   Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
      2010   Phase 3   EUCTR2009-012842-21-GB   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
   Axcan Pharma Inc.
      -   -   EUCTR2010-019267-11-DE   Germany;
Pancrease MT 10.5, or MT 21
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2008   Phase 3   NCT00662675   Canada;United States;
Pancreatin
   Abbott Products
      2012   Phase 3   NCT01747330   Russian Federation;
   McNeil Consumer and Specialty Pharmaceuticals
      -   Phase 2   EUCTR2005-001438-34-BE   Belgium;
Pancrelipase
   AbbVie
      2019   Phase 4   NCT03924947   Spain;United States;
   Digestive Care, Inc.
      2008   Phase 4   NCT00744250   United States;
   University of Colorado, Denver
      2014   -   NCT02372383   United States;
Pancrelipase Delayed Release
   Solvay Pharmaceuticals
      2009   Phase 3   NCT00775528   United States;
      2008   Phase 3   NCT00690820   United States;
      2007   Phase 3   NCT00510484   Hungary;Israel;South Africa;Spain;United States;
Pancrelipase Delayed Release Capsule
   Solvay Pharmaceuticals GmbH
      2008   -   EUCTR2007-004004-12-BG   Bulgaria;
Pancrelipase Microtablets
   McNeil Consumer and Specialty Pharmaceuticals
      -   Phase 2   EUCTR2005-001438-34-BE   Belgium;
Pancrelipase microtablets
   McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
      2005   Phase 2   NCT00217204   Belgium;Netherlands;
Pancrelipase with bicarbonate
   National Center for Research Resources (NCRR)
      1999   -   NCT00006063   -
Pancrelipase/Pancreas Powder
   Solvay Pharmaceuticals GmbH
      2008   -   EUCTR2007-004004-12-BG   Bulgaria;
Pankreatin
   Terese Katzenstein
      2020   Phase 4   EUCTR2019-004940-31-DK   Denmark;
Panzytrat® 25,000
   Forest Laboratories
      2011   Phase 4   NCT01327703   Germany;Poland;
Panzytrat® ok
   McNeil Consumer and Specialty Pharmaceuticals
      -   Phase 2   EUCTR2005-001438-34-BE   Belgium;
Perfluorinated gas/oxygen mixture
   Hal C Charles
      2009   Phase 1   NCT01710449   United States;
Perform three multiple breath nitrogen washout tests (N2-MBW-test)
   Universitair Ziekenhuis Brussel
      2017   -   NCT02950116   Belgium;
Physiologic serum nebulized nasally
   Virginie ESCABASSE
      2017   Phase 3   NCT02888730   France;
Physiological solution
   Serafino A. Marsico
      2010   Phase 3   NCT01450267   Italy;
Physiotherapy, exercise, percutaneous gastrostomy feeds
   Bayside Health
      2001   -   NCT00164021   Australia;
Pilocarpine
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2017   -   NCT03584841   Belgium;
Pilocarpine Iontophoresis
   Emory University
      2022   -   NCT04732195   United States;
Pilocarpine Nitrate
   Richard Barry Moss
      2015   -   NCT02310789   United States;
Pilocarpine microneedle patch
   Emory University
      2022   -   NCT04732195   United States;
Pioglitazone
   Paul Beringer
      2008   Phase 1   NCT00719381   United States;
   University Hospitals Cleveland Medical Center
      2007   -   NCT00531882   United States;
      2006   -   NCT00322868   United States;
Piperacillin sodium , tazobactam sodium
   COP:TRIN Region Hovedstaden (Gentofte hospital)
      2017   Phase 4   EUCTR2015-003399-58-DK   Denmark;
Piperacillin with Tazobactam (tazocin)
   Aarhus University Hospital, Department of Respiratory Medicine
      2015   Phase 2   EUCTR2015-003662-87-DK   Denmark;
Piperacillin-tazobactam combination product
   University Ghent
      2016   -   NCT02840136   Belgium;
   West Virginia University
      2012   Phase 4   NCT01694069   United States;
Piperacillin/Tazobactam
   COP:TRIN Region Hovedstaden (Gentofte hospital)
      2017   Phase 4   EUCTR2015-003399-58-DK   Denmark;
Piperacillin/Tazobactam Kabi - Fresenius Kabi Austria
   Medical University of Vienna
      2020   Phase 4   EUCTR2019-000955-16-AT   Austria;
Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie
   Ghent University
      2016   Phase 4   EUCTR2016-000398-19-BE   Belgium;
Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie
   Ghent University
      2016   Phase 4   EUCTR2016-000398-19-BE   Belgium;
Plerixafor mobilization of autologous CD117 stem cells
   University of Colorado, Denver
      2013   Phase 1   NCT01916577   United States;
Polyethylene Glycol 3350
   St. Louis University
      2019   Phase 4   NCT04210427   United States;
Porcine (pig) PERT
   Anthera Pharmaceuticals
      2015   Phase 3   NCT02279498   Canada;Czech Republic;Czechia;Hungary;Israel;Poland;Spain;United States;
Porcine PERT
   Anthera Pharmaceuticals
      2017   Phase 3   NCT03051490   Hungary;Israel;Lithuania;Poland;Spain;United Kingdom;United States;
   AzurRx BioPharma, Inc.
      2020   Phase 2   NCT04375878   Poland;United States;
      2019   Phase 2   NCT03746483   Poland;United States;
Posaconazole
   Bambino Gesù Children's Hospital
      2022   Phase 2;Phase 3   EUCTR2019-004511-31-DE   Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;
   Bayside Health
      2018   -   NCT03421366   Australia;
   MSD
      2012   -   EUCTR2012-003140-68-GB   United Kingdom;
Posaconazole 100 MG [Noxafil]
   Bambino Gesù Hospital and Research Institute
      2021   Phase 2/Phase 3   NCT04966234   Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Switzerland;United Kingdom;
Posaconazole 40 MG/ML
   Bambino Gesù Hospital and Research Institute
      2021   Phase 2/Phase 3   NCT04966234   Czechia;France;Germany;Greece;Ireland;Italy;Netherlands;Portugal;Spain;Switzerland;United Kingdom;
Positive expiratory pressure
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2015   -   NCT02535130   Belgium;
Prednisolone
   Birmingham Children's Hospital NHS Foundation Trust
      2012   -   EUCTR2011-005790-23-GB   United Kingdom;
Prednisone
   The Hospital for Sick Children
      2017   Phase 3   NCT03070522   Canada;
Prograft capsules
   Hopital Erasme - Chest service
      2009   -   EUCTR2009-014050-15-BE   Belgium;
Prolastin (drug)
   Université de Sherbrooke
      2004   Phase 2   NCT02010411   Canada;
Promixin
   ZAMBON SPA
      2020   Phase 3   EUCTR2016-004558-13-IT   Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
Promixin 1 million International Units (IU) Powder for Nebuliser Solution
   Profile Pharma Ltd
      2010   -   EUCTR2008-005045-34-IE   Ireland;United Kingdom;
      2008   Phase 3   EUCTR2008-005045-34-GB   Ireland;Russian Federation;Ukraine;United Kingdom;
Promixin, 1 million International Units (IU) Powder for Nebuliser Solution
   Zambon S.p.A.
      2020   Phase 3   EUCTR2016-004558-13-PT   Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
      2020   Phase 3   EUCTR2016-004558-13-GR   Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
      2020   Phase 3   EUCTR2016-004558-13-DE   Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
      2017   Phase 3   EUCTR2016-004558-13-PL   Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
      2017   Phase 3   EUCTR2016-004558-13-FR   Canada;France;Poland;United States;
Promixin,1 millón de Unidades Internacionales,polvo para solución para inhalación por nebulizador
   Novartis Farmaceutica, S.A.
      2013   -   EUCTR2012-001565-33-ES   Germany;Ireland;Spain;Switzerland;United Kingdom;
Promixin/Tadim
   ZAMBON SPA
      2017   Phase 3   EUCTR2015-002743-33-IT   Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
   Zambon S.p.A.
      2018   Phase 3   EUCTR2015-002743-33-NL   Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2015-002743-33-GR   Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
      2017   Phase 3   EUCTR2015-002743-33-PT   Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
      2017   Phase 3   EUCTR2015-002743-33-GB   Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
      2017   Phase 3   EUCTR2015-002743-33-ES   Belgium;Germany;Italy;Portugal;Spain;United Kingdom;
      2017   Phase 3   EUCTR2015-002743-33-DE   Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Protease
   Altus Pharmaceuticals Inc
      2007   Phase 3   EUCTR2007-000171-41-SK   Italy;Slovakia;
      -   Phase 3   EUCTR2007-000171-41-PL   Italy;Poland;Slovakia;
   Altus Pharmaceuticals Inc.
      2007   Phase 3   EUCTR2007-000178-21-SK   Italy;Slovakia;
      -   Phase 3   EUCTR2007-000178-21-PL   Italy;Poland;Slovakia;
PsAer IgY
   MUKOVISZIDOSE E.V.
      2012   Phase 3   EUCTR2011-000801-39-IT   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
   Mukoviszidose Institute gGmbH
      2014   Phase 3   EUCTR2011-000801-39-HU   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2014   Phase 3   EUCTR2011-000801-39-ES   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2014   Phase 3   EUCTR2011-000801-39-AT   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2013   Phase 3   EUCTR2011-000801-39-IE   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2012   Phase 3   EUCTR2011-000801-39-SE   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2012   Phase 3   EUCTR2011-000801-39-BE   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
      2011   Phase 3   EUCTR2011-000801-39-DE   Austria;Belgium;Germany;Hungary;Ireland;Italy;Spain;Sweden;
Pulmaquin®
   Aradigm Corporation
      2015   Phase 3   EUCTR2013-005366-19-PL   Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005366-19-FR   Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-005348-28-PL   Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005366-19-RO   Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005366-19-IT   Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005366-19-HU   Australia;Canada;France;Georgia;Germany;Hungary;Israel;Italy;New Zealand;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005366-19-GB   Australia;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005366-19-ES   Australia;Canada;France;Germany;Hungary;Italy;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-RO   Australia;Canada;Georgia;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-LV   Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;New Zealand;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-IT   Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-IE   Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-HU   Australia;Canada;France;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-GB   Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Poland;Romania;South Africa;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-005348-28-ES   Australia;Canada;Germany;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
Pulmonary Function Testing
   The Hospital for Sick Children
      2010   -   NCT01155115   Canada;
Pulmonary function testing.
   University of Florida
      2007   -   NCT01851642   United States;
Pulmozyme
   F. Hoffmann-La Roche AG
      -   Phase 4   EUCTR2015-003537-99-Outside-EU/EEA   United States;
   University Hospital, Tours
      2009   Phase 4   NCT00843817   France;
   University of Jena
      2005   Phase 3   NCT00265434   Germany;
      -   Phase 3   EUCTR2007-001548-36-DE   Germany;
Pulmozyme (Dornase alpha)
   ErasmusMC - Sophia Children's Hospital
      -   -   EUCTR2007-000935-25-NL   Netherlands;
Pulmozyme (dornase alfa)
   Pharmaxis Ltd
      2004   Phase 2   EUCTR2004-001888-21-GB   United Kingdom;
   University of Vermont
      2006   Phase 2   NCT00416182   United States;
Pulmozyme single use ampule
   Milton S. Hershey Medical Center
      2013   Phase 3   NCT01155752   United States;
Pulmozyme®
   AO GENERIUM
      2017   Phase 3   NCT04468100   Russian Federation;
QAU145
   Novartis Pharmaceuticals
      2007   Phase 2   NCT00506792   United States;
QBW251
   Novartis Pharma AG
      2021   Phase 2   EUCTR2019-002840-26-DE   China;Germany;Spain;United Kingdom;
      2020   Phase 2   EUCTR2019-002840-26-GB   China;Germany;Spain;United Kingdom;
   Novartis Pharma Services AG
      2015   -   EUCTR2011-005085-37-FR   Belgium;France;Germany;Ireland;United Kingdom;United States;
      2015   -   EUCTR2011-005085-37-BE   Belgium;France;Ireland;United Kingdom;United States;
      2014   Phase 1;Phase 2   EUCTR2011-005085-37-DE   Belgium;France;Germany;Ireland;United Kingdom;United States;
      2014   -   EUCTR2011-005085-37-IE   Belgium;France;Ireland;United Kingdom;United States;
      2012   Phase 1;Phase 2   EUCTR2011-005085-37-GB   Belgium;France;Germany;Ireland;Netherlands;Romania;United Kingdom;United States;
   Novartis Pharmaceuticals
      2012   Phase 1/Phase 2   NCT02190604   Belgium;France;Germany;Ireland;Netherlands;Romania;United Kingdom;United States;
QBW276
   Novartis Pharmaceuticals
      2017   Phase 1/Phase 2   NCT02566044   Germany;United Kingdom;United States;
QBW276 1500mcg
   Novartis Pharma AG
      2017   Phase 1;Phase 2   EUCTR2014-004915-35-DE   Germany;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2014-004915-35-GB   Germany;United Kingdom;United States;
QBW276 300mcg
   Novartis Pharma AG
      2017   Phase 1;Phase 2   EUCTR2014-004915-35-DE   Germany;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2014-004915-35-GB   Germany;United Kingdom;United States;
QBW276 Succinate
   Novartis Pharma AG
      2017   Phase 1;Phase 2   EUCTR2014-004915-35-DE   Germany;United Kingdom;United States;
      2015   Phase 1;Phase 2   EUCTR2014-004915-35-GB   Germany;United Kingdom;United States;
QR-010
   ProQR Therapeutics
      2015   Phase 1/Phase 2   NCT02532764   Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2015   Phase 1   NCT02564354   Belgium;France;United States;
Quercetin
   University of Alabama at Birmingham
      2010   Phase 2   NCT01348204   United States;
R03AC02
   University Medical Centre Utrecht
      2014   Phase 2   EUCTR2014-000057-37-NL   Netherlands;
R03CC02
   University Medical Centre Utrecht
      2014   Phase 2   EUCTR2014-000057-37-NL   Netherlands;
R05C B01
   Rigshospitalet
      2010   Phase 4   EUCTR2007-001401-15-DK   Denmark;
RELiZORB (immobilized lipase) cartridge
   Alcresta Therapeutics, Inc.
      2016   -   NCT02750501   United States;
RPL554
   Verona Pharma plc
      2017   Phase 2   NCT02919995   United Kingdom;
      2017   Phase 2   EUCTR2015-004263-36-DE   Germany;United Kingdom;
      2016   Phase 2   EUCTR2015-004263-36-GB   Germany;United Kingdom;
RPS 2505
   PTC Therapeutics, Inc
      2010   Phase 3   EUCTR2010-019692-30-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-GB   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003924-52-FR   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-SE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-NL   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-ES   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003924-52-DE   Belgium;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Radiolabelled OligoG CF-5/20 DPI
   Bio-Images Research Ltd
      2014   Phase 2   NCT01991028   United Kingdom;
Radiolabelled OligoG CF-5/20 Dry Powder for Inhalation (DPI)
   AlgiPharma AS
      2014   Phase 2   EUCTR2013-003774-27-GB   United Kingdom;
Radiolabelled OligoG CF-5/20 Solution
   Bio-Images Research Ltd
      2014   Phase 2   NCT01991028   United Kingdom;
Radiolabelled OligoG CF-5/20 Solution for Nebulisation
   AlgiPharma AS
      2014   Phase 2   EUCTR2013-003774-27-GB   United Kingdom;
Rapeglinide
   Papworth Hospital NHS Foundation Trust
      2005   Phase 4   EUCTR2004-005019-28-GB   United Kingdom;
Ravicti high dose
   National Jewish Health
      2018   Phase 1/Phase 2   NCT02323100   United States;
Ravicti low dose
   National Jewish Health
      2018   Phase 1/Phase 2   NCT02323100   United States;
Recombiant human Desoxyribonuclease ( rhDNase)
   University of Jena
      -   Phase 3   EUCTR2007-001548-36-DE   Germany;
Recombinant Human DNase (Pulmozyme)
   Nationwide Children's Hospital
      2005   Phase 2   NCT00179998   United States;
Recombinant human IGF-1
   Stony Brook University
      2008   Phase 1   NCT00566241   United States;
Recombinant humanized monoclonal antibody omalizumab to IgE
   Novartis Pharma Services AG
      2009   -   EUCTR2007-006648-23-NL   Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Recombinant truncated SPINT2 protease inhibitor
   Aerovance Inc
      2005   Phase 1;Phase 2   EUCTR2005-000313-35-GB   United Kingdom;
Red Blood Cell Zn
   Indiana University
      2019   -   NCT04302428   United States;
Reduced glutathione
   Mukoviszidose Institut gGmbH i. G.
      2006   -   EUCTR2005-003870-88-DE   Germany;
Reduced glutathione sodium salt
   Mukoviszidose Institut gGmbH
      2007   Phase 2   NCT00506688   Germany;
Repaglinide
   Arbelaez, Ana Maria
      2006   -   NCT00763412   United States;
   Mukoviszidose Institut gGmbH
      2001   Phase 3   NCT00662714   Austria;France;Germany;Italy;
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2001   Phase 3   NCT00072904   Canada;United States;
Repaglinide and Insulin
   Children's Hospital of Philadelphia
      2005   -   NCT00231192   United States;
Reparixin
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2010   -   EUCTR2009-013340-36-IT   Italy;
Resunab, ajulemic acid, anabasum
   Corbus Pharmaceuticals, Inc.
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2020-001762-11-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-003723-29-PL   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-003723-29-NL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-SK   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-PT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-GR   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-ES   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-BG   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-BE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-003723-29-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2020-001762-11-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2017-003723-29-FR   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Portugal;Romania;Russian Federation;Réunion;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
Resveratrol
   Virginia Commonwealth University
      2020   -   NCT04166396   United States;
RhBSSL
   Biovitrum AB
      2008   -   EUCTR2007-004063-21-NL   Netherlands;
   Swedish Orphan Biovitrum
      2008   Phase 2   NCT00743483   Netherlands;Poland;
RhDNAse
   Pharmaxis Ltd
      2004   Phase 2   EUCTR2004-001888-21-GB   United Kingdom;
   The Hospital for Sick Children
      2008   Phase 4   NCT00557089   Canada;
Rifampin
   AOU Meyer
      2013   Phase 3   EUCTR2013-000219-25-IT   Italy;
   Johns Hopkins University
      2020   Phase 4   NCT02547116   United States;
      2012   Phase 2   NCT01594827   United States;
   University of Colorado, Denver
      2014   -   NCT02372383   United States;
   University of North Carolina, Chapel Hill
      2011   Phase 2   NCT01349192   United States;
   Vertex Pharmaceuticals Incorporated
      2013   Phase 1   NCT01768663   United States;
      2009   Phase 1   NCT01018368   United States;
Rimactan
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
Riociguat (Adempas, BAY63-2521)
   Bayer
      2014   Phase 2   NCT02170025   Belgium;Canada;France;Germany;Greece;Italy;Netherlands;United Kingdom;United States;
Roflumilast
   Assiut University
      2019   Early Phase 1   NCT04090294   -
   Prince of Songkla University
      2015   Phase 3   NCT04122547   Thailand;
   University of Sao Paulo General Hospital
      2019   Phase 2   NCT03988816   Brazil;
Roflumilast Oral Tablet
   The University of Hong Kong
      2020   Phase 2   NCT04322929   Hong Kong;
Roscovitine
   University Hospital, Brest
      2016   Phase 2   NCT02649751   France;
Rosuvastatin calcium
   University of Liverpool
      2014   Phase 2   EUCTR2014-002387-32-GB   United Kingdom;
Roxithromycin
   First Affiliated Hospital of Guangxi Medical University
      2009   -   ChiCTR-TRC-13003979   China;
Répaglinide
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2006   -   EUCTR2006-001254-27-FR   France;
S-1226
   SolAeroMed Inc.
      2019   Phase 2   NCT03903913   Canada;
SB-656933 Tablets
   GlaxoSmithKline Research & Development Limited
      2010   -   EUCTR2010-018738-27-DE   Germany;
SB-656933-AAA
   GlaxoSmithKline Research & Development Limited
      2010   -   EUCTR2010-018738-27-DE   Germany;
SB656933
   GlaxoSmithKline
      2009   Phase 2   NCT00903201   Canada;France;Germany;Israel;United States;
      2008   Phase 1   NCT00605761   United States;
SE10599
   University of Nottingham
      2005   Phase 2   EUCTR2005-000311-98-GB   United Kingdom;
SIN ASIGNAR
   ANTHERA Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2016-002851-92-ES   Canada;Czech Republic;Hungary;Israel;Poland;Spain;United States;
SLIT Amikacin
   Transave, Inc
      2005   -   EUCTR2005-004389-17-HU   Hungary;
SLIT(TM) Amikacin
   Transave, Inc.
      2005   -   EUCTR2005-004899-21-BE   Belgium;
SNSP113
   Synspira Therapeutics, Inc.
      2019   Phase 2   EUCTR2019-003178-25-HU   Hungary;
SODIUM BICARBONATE BP
   Fundació Parc Taulí
      2017   Phase 2   EUCTR2016-004033-25-ES   Spain;
SODIUM CHLORIDE PH. EUR.
   Erasmus MC
      -   Phase 3   EUCTR2015-004143-39-FR   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
SODIUM CHLORIDE SOLUTION
   Erasmus MC
      2018   Phase 3   EUCTR2015-004143-39-IT   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
      2017   Phase 3   EUCTR2015-004143-39-DK   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
      2016   Phase 3   EUCTR2015-004143-39-NL   Australia;Belgium;Denmark;France;Italy;Netherlands;Spain;United States;
      2016   Phase 3   EUCTR2015-004143-39-BE   Australia;Belgium;Denmark;Netherlands;Spain;United States;
SPI-1005 Ebselen 200mg Capsule x1
   Sound Pharmaceuticals, Incorporated
      2017   Phase 2   NCT02819856   United States;
SPI-1005 Ebselen 200mg Capsule x2
   Sound Pharmaceuticals, Incorporated
      2017   Phase 2   NCT02819856   United States;
SPI-1005 Ebselen 200mg Capsule x3
   Sound Pharmaceuticals, Incorporated
      2017   Phase 2   NCT02819856   United States;
SPX-101
   SPYRYX BIOSCIENCES, INC.
      2017   Phase 2   EUCTR2016-005230-30-IT   Australia;Canada;France;Italy;Portugal;United Kingdom;
   Spyryx Biosciences, Inc.
      2017   Phase 2   NCT03229252   Canada;France;Italy;Portugal;United Kingdom;
      2017   Phase 2   EUCTR2016-005230-30-PT   Australia;Canada;France;Italy;Portugal;United Kingdom;
      2017   Phase 2   EUCTR2016-005230-30-GB   Australia;Canada;France;Italy;Portugal;United Kingdom;
      2017   Phase 1   NCT03056989   Canada;
STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE ( W / V)
   Erasmus MC
      2017   Phase 3   EUCTR2015-004143-39-ES   Australia;Denmark;Netherlands;Spain;United States;
SUB185183
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-003455-11-GB   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-DE   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-BE   Australia;Belgium;Germany;United Kingdom;
Salbutamol
   UMC Utrecht
      2015   Phase 2   EUCTR2015-001317-28-NL   Netherlands;
   University of British Columbia
      2018   -   NCT03522831   Canada;
Salbutamol-ratiopharm® N metered-dose aerosol inhaler
   ZAMBON SPA
      2020   Phase 3   EUCTR2016-004558-13-IT   Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
Salbutamol-ratiopharm® N metereddose aerosol inhaler
   ZAMBON SPA
      2020   Phase 3   EUCTR2016-004558-13-IT   Argentina;Canada;France;Germany;Greece;Italy;Poland;Portugal;United States;
Salbutamolo
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-004068-24-IT   Argentina;Australia;Canada;China;Denmark;Germany;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Spain;United Kingdom;United States;Vietnam;
Saline
   AlgiPharma AS
      2011   Phase 1/Phase 2   NCT01465529   Ireland;United Kingdom;
   Joseph Zabner
      2013   Phase 1/Phase 2   NCT00928135   United States;
   Lakshmi Durairaj
      2017   Phase 1   NCT03078088   United States;
   Parion Sciences
      2016   Phase 2   NCT02709109   France;Ireland;United Kingdom;United States;
Saline Solution
   Zambon SpA
      2018   Phase 3   NCT03460704   Argentina;Australia;Canada;France;Germany;Greece;Israel;Italy;New Zealand;Poland;Portugal;United States;
      2017   Phase 3   NCT03093974   Australia;Belgium;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Saline inhalation solution
   Medical Center Alkmaar
      2016   Phase 2/Phase 3   NCT02657473   Netherlands;
Salmeterol
   National Center for Research Resources (NCRR)
      2000   -   NCT00005110   United States;
Saxagliptin
   Ram Weiss
      2015   -   NCT02239458   Israel;
      2014   -   NCT02148978   Israel;
Serum Zn
   Indiana University
      2019   -   NCT04302428   United States;
Short-acting Insulin (Actrapid)
   Mukoviszidose Institut gGmbH
      2001   Phase 3   NCT00662714   Austria;France;Germany;Italy;
Sildenafil
   Children's Hospital Medical Center, Cincinnati
      2012   Phase 1/Phase 2   NCT01194232   United States;
   National Jewish Health
      2015   Phase 2   NCT01132482   United States;
      2015   Phase 1/Phase 2   NCT02626182   United States;
      2008   Phase 1/Phase 2   NCT00659529   United States;
Sildenafil (Acute-1 hour)
   Augusta University
      2014   Phase 2   NCT02057458   United States;
Sildenafil (Subchronic-4 weeks)
   Augusta University
      2014   Phase 2   NCT02057458   United States;
Sildenafil 40mg oral capsule
   National Jewish Health
      2019   Phase 2/Phase 3   NCT04039087   United States;
Simvastatin
   University Hospitals Cleveland Medical Center
      2007   -   NCT00531882   United States;
   University of British Columbia
      2010   Phase 1/Phase 2   NCT01092572   Canada;
Simvastatin treatment for 28 days
   Akron Children's Hospital
      2004   Phase 1   NCT00255242   United States;
Sitagliptin
   Emory University
      2010   Phase 3   NCT00967798   Canada;United States;
   Nemours Children's Clinic
      2012   Phase 1   NCT01721382   United States;
   University of British Columbia
      2010   Phase 2   NCT01257464   Canada;
   University of Pennsylvania
      2013   -   NCT01879228   United States;
SmartPill Motility System & PillCam Patency Capsule
   St. Louis University
      2019   Phase 4   NCT04210427   United States;
Snack beverage
   Institut de Recherches Cliniques de Montreal
      2019   -   NCT03710538   Canada;
Sodium (R)-8-methyl-2-(3-methylbenzofuran-2-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)ethoxy)quinoline-4-ca
   Proteostasis Therapeutics, Inc.
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-GB   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-DE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-003319-21-BE   Belgium;Canada;Denmark;France;Germany;United Kingdom;United States;
Sodium 4-Phenylbutyrate
   Children's Hospital of Philadelphia
      2003   Phase 1/Phase 2   NCT00590538   United States;
Sodium 4-Phenylbutyrate (4PBA)
   Children's Hospital of Philadelphia
      2001   Phase 1/Phase 2   NCT00016744   United States;
Sodium Pyruvate in Sodium Chloride Solution
   Emphycorp
      2006   Phase 1   NCT00308243   United States;
Sodium bicarbonate
   University of Pittsburgh
      2002   Phase 1   NCT00177645   United States;
Sodium chloride
   Joseph Pilewski
      2014   Phase 1   NCT03391414   United States;
Sodium chloride ()
   University of North Carolina, Chapel Hill
      2009   Phase 1   NCT01094704   United States;
Sodium chloride 0,
   University of Jena
      2010   -   NCT01086839   Germany;
Sodium nitrite
   Schmidhofer, Mark, MD
      2016   Phase 1/Phase 2   NCT02694393   United States;
Soluble fiber supplementation
   Institut de Recherches Cliniques de Montreal
      2016   -   NCT02810691   Canada;
Somalgen
   Genaera Corporation
      2005   Phase 2   EUCTR2004-004334-13-IE   Ireland;
Sperti Del Sol Lamp
   Atlanta VA Medical Center
      2006   -   NCT00450073   United States;
Spiriva Respimat 2.5 mcg
   Boehringer Ingelheim
      2010   Phase 3   EUCTR2010-019802-17-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2010-019802-17-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim España, S.A
      2010   -   EUCTR2010-019802-17-ES   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim France
      2010   -   EUCTR2010-019802-17-PT   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim Limited
      2010   -   EUCTR2010-019802-17-IE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
      2010   -   EUCTR2010-019802-17-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2010   -   EUCTR2010-019802-17-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co KG
      2010   -   EUCTR2010-019802-17-AT   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim RCV GmbH&Co KG
      2010   Phase 3   EUCTR2010-019802-17-SK   Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
   SCS Boehringer Ingelheim Comm.V
      2010   Phase 3   EUCTR2010-019802-17-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Spiriva Respimat 2.5 microgram, solution for inhalation
   BOEHRINGER ING.
      2010   -   EUCTR2010-019802-17-IT   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-001156-43-IT   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
   Boehringer Ingelheim
      2010   Phase 3   EUCTR2010-019802-17-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2010-019802-17-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim España, S.A
      2010   -   EUCTR2010-019802-17-ES   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim France
      2010   -   EUCTR2010-019802-17-PT   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
      2008   Phase 2   EUCTR2008-001156-43-FR   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
   Boehringer Ingelheim Limited
      2010   -   EUCTR2010-019802-17-IE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
      2010   -   EUCTR2010-019802-17-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
      2008   -   EUCTR2008-001156-43-GB   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2010   -   EUCTR2010-019802-17-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co.KG
      2008   -   EUCTR2008-001156-43-DE   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
   Boehringer Ingelheim Pharmaceuticals, Inc.
      2009   -   EUCTR2008-001156-43-PT   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
   Boehringer Ingelheim RCV GmbH & Co KG
      2010   -   EUCTR2010-019802-17-HU   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-019802-17-AT   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim RCV GmbH&Co KG
      2010   Phase 3   EUCTR2010-019802-17-SK   Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
   Boehringer Ingelheim bv
      2009   -   EUCTR2008-001156-43-NL   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
   SCS Boehringer Ingelheim Comm.V
      2010   Phase 3   EUCTR2010-019802-17-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
      2008   -   EUCTR2008-001156-43-BE   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Spirometry
   National Center for Research Resources (NCRR)
      2001   -   NCT00023465   United States;
Sporanox 10 mg/ml Oral Solution
   CHU de Rennes (Rennes University Hospital Centre)
      2012   -   EUCTR2011-005799-41-GB   United Kingdom;
Sputum
   University of Miami
      2010   -   NCT02198079   United States;
Sputum Collection
   The Hospital for Sick Children
      2010   -   NCT01155115   Canada;
Ss-Adrenergic cocktail
   Richard Barry Moss
      2015   -   NCT02310789   United States;
Standard Care
   Liverpool Heart and Chest Hospital NHS Foundation Trust
      2017   Phase 4   NCT02894684   United Kingdom;
Standard Dose YPT-01
   Yale University
      2021   Phase 1/Phase 2   NCT04684641   United States;
Standard Formula
   Laboratorios Ordesa
      2012   -   NCT02128984   Peru;Spain;
Standard Nutritional Supplement + PERT
   GlycosBio, Inc.
      2018   -   NCT04966897   United States;
Standard formula (Enfamil)
   University of Massachusetts, Worcester
      2003   -   NCT00530244   United States;
Standard of care IV antibiotic(s)
   Chris Goss
      2016   Phase 4   NCT02781610   Canada;United States;
Standard oxygen therapy/RA
   The Leeds Teaching Hospitals NHS Trust
      2019   -   NCT03965832   United Kingdom;
Standard sinus rinse
   Swansea University
      2019   -   NCT04589897   United Kingdom;
Standardized turmeric root extract
   Ramsey, Bonnie, MD
      2005   Phase 1   NCT00219882   United States;
Study medication, azithromycin
   Rigshospitalet, Denmark
      2008   Phase 4   NCT00411736   Denmark;Norway;Sweden;
Sulfato de amikacina
   Insmed Incorporated
      2011   Phase 3   EUCTR2011-000443-24-ES   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2011-000441-20-ES   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
Supplementation with vitamin D2/D3
   Karolinska Institutet
      2010   Phase 2   NCT01321905   Sweden;
Symbiotic Formula with DHA and antioxidants
   Laboratorios Ordesa
      2012   -   NCT02128984   Peru;Spain;
Symdeko
   University of Alabama at Birmingham
      2019   Early Phase 1   NCT03587961   United States;
   Vertex Pharmaceuticals Incorporated
      -   Phase 3   EUCTR2017-002968-40-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
Symdeko/Trikafta
   University of Alabama at Birmingham
      2018   Phase 4   NCT03624101   United States;
Symkevi
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-002968-40-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002968-40-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
Symkevi 100mg/150mg Film-coated tablets
   VERTEX PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2018-002835-76-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-002835-76-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001735-31-GB   Australia;Belgium;Germany;United Kingdom;
      2019   Phase 3   EUCTR2018-002835-76-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-PT   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-NL   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-GB   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-DE   Germany;Netherlands;Portugal;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001735-31-BE   Australia;Belgium;Germany;United Kingdom;
      -   Phase 3   EUCTR2018-002835-76-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-002835-76-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
Synrinse
   University of Washington
      2017   Phase 1/Phase 2   NCT03154541   United States;
T 100 PARI
   PARI GmbH
      -   Phase 1   EUCTR2005-004103-10-PL   Germany;Poland;
T100
   PARI Pharma GmbH
      -   Phase 1   EUCTR2010-023235-41-PL   Poland;
T100 PARI
   PARI GmbH
      2007   -   EUCTR2007-000959-33-DE   Germany;
   PARI Pharma GmbH
      2006   -   EUCTR2005-004103-10-DE   Germany;
TAD 600
   AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI
      2009   -   EUCTR2008-005080-33-IT   Italy;
   Mukoviszidose Institut gGmbH i. G.
      2006   -   EUCTR2005-003870-88-DE   Germany;
TAZOBACTAM SODIUM
   Ghent University
      2016   Phase 4   EUCTR2016-000398-19-BE   Belgium;
TBD
   AbbVie Deutschland
      2019   Phase 2   EUCTR2019-000750-63-NL   Belgium;Canada;Czech Republic;France;Hungary;Netherlands;Poland;Puerto Rico;Serbia;Slovakia;Spain;United Kingdom;United States;
TBM100
   NOVARTIS PHARMA SERVICES AG
      2016   Phase 2   EUCTR2015-003040-39-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Novartis Pharma GmbH
      2008   -   EUCTR2007-004507-36-DE   Germany;
   Novartis Pharma Services AG
      2017   Phase 2   EUCTR2015-003040-39-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-IE   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-GB   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2010   -   EUCTR2009-016590-15-DE   Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;
      2009   -   EUCTR2009-016590-15-HU   Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
      -   Phase 4   EUCTR2011-002000-32-FR   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
   Novartis Pharmaceuticals
      2013   Phase 4   NCT01775137   Argentina;Australia;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
      2012   Phase 4   NCT01519661   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TBM100C
   NOVARTIS FARMA
      2012   -   EUCTR2011-002000-32-IT   Argentina;Australia;Brazil;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
   Novartis Farmaceutica S. A
      2011   Phase 4   EUCTR2011-002000-32-ES   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
   Novartis Farmaceutica, S.A.
      2013   -   EUCTR2012-003532-23-ES   Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      2013   -   EUCTR2012-001565-33-ES   Germany;Ireland;Spain;Switzerland;United Kingdom;
   Novartis Pharma GmbH
      2014   Phase 4   EUCTR2014-001204-21-DE   Germany;
   Novartis Pharma Services AG
      2015   -   EUCTR2012-001565-33-IE   Germany;Ireland;Spain;Switzerland;United Kingdom;
      2013   Phase 4   EUCTR2012-001565-33-GB   Germany;Ireland;Spain;Switzerland;United Kingdom;
      2013   -   EUCTR2012-003532-23-DE   Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      2013   -   EUCTR2012-001565-33-DE   Germany;Ireland;Spain;Switzerland;United Kingdom;
      2012   -   EUCTR2012-003532-23-HU   Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      2011   Phase 3   EUCTR2005-003772-37-IE   Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
      2011   -   EUCTR2011-002000-32-HU   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      2011   -   EUCTR2011-002000-32-DE   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      2010   -   EUCTR2009-016734-26-LV   Bulgaria;Estonia;Latvia;Lithuania;
      2010   -   EUCTR2009-016734-26-LT   Bulgaria;Estonia;Latvia;Lithuania;
      2010   -   EUCTR2009-016734-26-EE   Bulgaria;Estonia;Latvia;Lithuania;
      2010   -   EUCTR2009-016734-26-BG   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-004764-39-LV   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-004764-39-LT   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-004764-39-EE   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-004764-39-BG   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-002318-22-LV   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-002318-22-LT   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-002318-22-EE   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-002318-22-BG   Bulgaria;Estonia;Latvia;Lithuania;
      2008   Phase 3   EUCTR2005-003772-37-GR   Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
      2007   -   EUCTR2005-003772-37-HU   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-003772-37-GB   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
TEZ
   Vertex Pharmaceuticals Incorporated
      2019   Phase 2   EUCTR2018-002496-18-PT   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-NL   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-GB   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-DE   Germany;Netherlands;Portugal;United Kingdom;United States;
      2018   Phase 3   NCT03691779   Australia;Ireland;United Kingdom;United States;
      2018   Phase 3   NCT03537651   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   NCT03525574   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   NCT03447262   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 2   NCT02951182   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;United Kingdom;United States;
      2016   Phase 1   NCT03486236   United Kingdom;
TEZ/150 mg IVA FDC
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2018-000184-89-NL   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-GB   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-BE   Belgium;Netherlands;United Kingdom;United States;
TEZ/IVA
   Vertex Pharmaceuticals Incorporated
      2019   Phase 2   NCT03912233   Germany;Netherlands;Portugal;United Kingdom;United States;
      2018   Phase 3   NCT03559062   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 1/Phase 2   NCT03768089   Netherlands;United Kingdom;
      2017   Phase 2   NCT03224351   Ireland;Israel;United Kingdom;United States;
      2017   Phase 1/Phase 2   NCT03227471   Australia;Belgium;Netherlands;United States;
      2016   Phase 3   NCT02953314   Canada;United States;
      2015   Phase 3   NCT02565914   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
THA
   Children's Hospital of Philadelphia
      2006   Phase 4   NCT00572975   United States;
TIOTROPIUM BROMIDE MONOHYDRATE
   Boehringer Ingelheim
      2010   Phase 3   EUCTR2010-019802-17-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2010-019802-17-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim España, S.A
      2010   -   EUCTR2010-019802-17-ES   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim France
      2010   -   EUCTR2010-019802-17-PT   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim Limited
      2010   -   EUCTR2010-019802-17-IE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
      2010   -   EUCTR2010-019802-17-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co KG
      2010   -   EUCTR2010-019802-17-HU   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-019802-17-AT   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim RCV GmbH&Co KG
      2010   Phase 3   EUCTR2010-019802-17-SK   Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
   SCS Boehringer Ingelheim Comm.V
      2010   Phase 3   EUCTR2010-019802-17-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
TIP
   Chiron Corporation Ltd
      2006   -   EUCTR2005-003772-37-ES   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
   Novartis Pharma Services AG
      2005   -   EUCTR2005-002035-28-LT   Lithuania;
      -   -   EUCTR2005-003772-37-DE   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
   Novartis Pharmaceuticals
      2017   Phase 2   NCT02712983   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
TIP (Tobramycin inhalation powder)
   Novartis Farmaceutica S. A
      2011   Phase 4   EUCTR2011-002000-32-ES   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
   Novartis Pharma Services AG
      2011   -   EUCTR2011-002000-32-HU   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      2010   -   EUCTR2009-016734-26-LV   Bulgaria;Estonia;Latvia;Lithuania;
      2010   -   EUCTR2009-016734-26-LT   Bulgaria;Estonia;Latvia;Lithuania;
      2010   -   EUCTR2009-016734-26-EE   Bulgaria;Estonia;Latvia;Lithuania;
      2010   -   EUCTR2009-016734-26-BG   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-004764-39-LV   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-004764-39-LT   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-004764-39-EE   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-004764-39-BG   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-002318-22-LV   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-002318-22-LT   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-002318-22-EE   Bulgaria;Estonia;Latvia;Lithuania;
      2009   -   EUCTR2008-002318-22-BG   Bulgaria;Estonia;Latvia;Lithuania;
      -   Phase 4   EUCTR2011-002000-32-FR   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TIS (Tobramycin Inhalation Solution)
   Horizon Pharma USA, Inc.
      2011   Phase 3   NCT01270347   France;Germany;Ireland;Israel;United Kingdom;United States;
TIS or TIP
   Novartis Pharmaceuticals
      2015   Phase 4   NCT02248922   Germany;
TNSE
   ECUPHARMA S.R.L.
      2007   -   EUCTR2007-003628-39-IT   Italy;
TOBI
   CHRU de Lille
      -   Phase 2   EUCTR2014-003882-10-FR   France;
   Gilead Sciences Inc
      2010   -   EUCTR2007-004277-26-AT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2007-004277-26-GB   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-FR   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-ES   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-BE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-PT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-NL   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-IE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-DK   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-DE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      -   -   EUCTR2007-004277-26-Outside-EU/EEA   United States;
   Mpex Pharmaceuticals, Inc.
      2011   -   EUCTR2010-019634-26-IE   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
   Novartis Pharma Services AG
      2011   Phase 3   EUCTR2005-003772-37-IE   Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2005-003772-37-GR   Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
      2007   -   EUCTR2005-003772-37-HU   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-003772-37-GB   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
      -   -   EUCTR2005-003772-37-DE   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
   Novartis Pharmaceuticals
      2010   Phase 3   NCT01082367   Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;United States;
   PARI GmbH
      -   Phase 1   EUCTR2005-004103-10-PL   Germany;Poland;
   St. Michael's Hospital, Toronto
      2014   Phase 1   NCT02212587   Canada;
   Universitaire Ziekenhuizen Leuven
      2001   Phase 4   NCT01400750   Belgium;
TOBI (tobramycin)
   Pari Pharma GmbH
      2013   Phase 1   NCT01953367   Germany;
TOBI 300 mg / 5 mL nebuliser solution
   Novartis Pharma Services AG
      2013   -   EUCTR2009-016590-15-PL   Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;United States;
      2009   -   EUCTR2009-016590-15-HU   Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
TOBI 300 mg/5 ml Lösung für einen
   Mpex Pharmaceuticals, Inc.
      2011   -   EUCTR2010-019634-26-DE   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
TOBI 300 mg/5 ml Lösung für einen Vernebler
   Novartis Pharma Services AG
      2010   -   EUCTR2009-016590-15-DE   Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;
TOBI 300 mg/5 ml Nebuliser Solution
   Forest Laboratories UK Ltd
      2005   -   EUCTR2004-003675-36-BE   Belgium;Denmark;
      2005   -   EUCTR2004-003675-36-AT   Austria;Belgium;Denmark;
TOBI 300 mg/5 ml solución para inhalación por nebulizador
   Novartis Farmaceutica, S.A.
      2013   -   EUCTR2012-001565-33-ES   Germany;Ireland;Spain;Switzerland;United Kingdom;
TOBI 300 mg/5 ml, solution pour inhalation par nébuliseur
   Mpex Pharmaceuticals, Inc.
      -   Phase 3   EUCTR2010-019634-26-FR   France;Germany;Ireland;United Kingdom;
TOBI 300mg/ 5ml solución para inhalación con nebulizador
   Insmed Incorporated
      2011   Phase 3   EUCTR2011-000441-20-ES   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
TOBI 300mg/5mL Nebuliser Solution
   Chiron Corporation Ltd
      2006   -   EUCTR2005-003772-37-ES   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
TOBI 300mg/5mL nebuliser solution
   Novartis Pharma Services AG
      2010   Phase 3   EUCTR2009-016590-15-FR   France;Germany;Greece;Hungary;Italy;Poland;
      2010   -   EUCTR2009-016590-15-GR   France;Germany;Greece;Hungary;Italy;Poland;
TOBI 300mg/5ml Nebuliser solution
   Insmed Incorporated
      2012   Phase 3   EUCTR2011-000441-20-BE   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-000441-20-NL   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-000441-20-IE   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-000441-20-DK   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2012   -   EUCTR2011-000441-20-BG   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-SK   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Serbia;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-HU   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-GR   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
      2011   -   EUCTR2011-000441-20-GB   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-DE   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
      2011   -   EUCTR2011-000441-20-AT   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;
TOBI PODHALER
   Novartis Farmaceutica S. A
      2011   Phase 4   EUCTR2011-002000-32-ES   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI PODHALER - 28 MG POLVERE PER INALAZIONE CAPSULA RIGIDA USO INALATORIO BLISTER(ALU/ALU) 56 CAPSULE + 1 INALATORE
   NOVARTIS PHARMA SERVICES AG
      2016   Phase 2   EUCTR2015-003040-39-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
TOBI PODHALER*448CPS 28MG+10IN
   NOVARTIS FARMA
      2013   -   EUCTR2012-003532-23-IT   Argentina;Australia;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI Podhaler
   Mylan Inc.
      2015   -   NCT02449031   United States;
   Novartis Farmaceutica, S.A.
      2013   -   EUCTR2012-003532-23-ES   Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      2013   -   EUCTR2012-001565-33-ES   Germany;Ireland;Spain;Switzerland;United Kingdom;
   Novartis Pharma GmbH
      2014   Phase 4   EUCTR2014-001204-21-DE   Germany;
   Novartis Pharma Services AG
      2017   Phase 2   EUCTR2015-003040-39-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-IE   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-GB   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2015   -   EUCTR2012-001565-33-IE   Germany;Ireland;Spain;Switzerland;United Kingdom;
      2013   Phase 4   EUCTR2012-001565-33-GB   Germany;Ireland;Spain;Switzerland;United Kingdom;
      2013   -   EUCTR2012-003532-23-DE   Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      2013   -   EUCTR2012-001565-33-DE   Germany;Ireland;Spain;Switzerland;United Kingdom;
      2012   -   EUCTR2012-003532-23-HU   Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      -   Phase 4   EUCTR2011-002000-32-FR   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
   Novartis Pharmaceuticals Corporation
      -   Phase 4   EUCTR2016-004318-82-Outside-EU/EEA   United States;
      -   Phase 4   EUCTR2016-001840-20-Outside-EU/EEA   United States;
TOBI Podhaler 28 mg Hartkapseln mit Pulver zur Inhalation
   Novartis Pharma Services AG
      2011   -   EUCTR2011-002000-32-DE   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI Podhaler 28 mg inhalációs por, kemény kapszula
   Novartis Pharma Services AG
      2011   -   EUCTR2011-002000-32-HU   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
TOBI*NEBUL 56F 1D 300MG/5ML
   AZIENDA OSPEDALIERA MEYER
      2008   -   EUCTR2008-006502-42-IT   Italy;
   Gilead Sciences Inc
      2008   -   EUCTR2007-004277-26-IT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   NOVARTIS FARMA
      2011   -   EUCTR2009-016590-15-IT   Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
TOBI®
   Forest Laboratories UK Ltd
      2005   -   EUCTR2004-003675-36-DK   Belgium;Denmark;
      2005   -   EUCTR2004-003675-36-BE   Belgium;Denmark;
      2005   -   EUCTR2004-003675-36-AT   Austria;Belgium;Denmark;
   Gilead Sciences, Inc.
      -   -   EUCTR2015-000398-11-Outside-EU/EEA   United States;
   PARI GmbH
      2007   -   EUCTR2007-000959-33-DE   Germany;
   PARI Pharma GmbH
      2006   -   EUCTR2005-004103-10-DE   Germany;
      -   Phase 1   EUCTR2010-023235-41-PL   Poland;
TOBI™ Podhaler™ 112 mg inhaled twice daily
   Dartmouth-Hitchcock Medical Center
      2014   -   NCT02113397   United States;
TOBRAMICINA SOLFATO
   UNIVERSITY OF LIVERPOOL
      -   Phase 4   EUCTR2009-012575-10-IT   Italy;Sweden;United Kingdom;
TOBRAMYCIN SULFATE
   Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III)
      2014   Phase 4   EUCTR2013-004295-35-AT   Austria;
   St. Vincent's University Hospital
      2016   Phase 4   EUCTR2016-001785-29-IE   Ireland;
TOTTIZIM - 1 G/10 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO ENDOVENOSO 1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 10 ML
   UNIVERSITY OF LIVERPOOL
      -   Phase 4   EUCTR2009-012575-10-IT   Italy;Sweden;United Kingdom;
TR02
   Transave, Inc
      2005   -   EUCTR2005-004389-17-HU   Hungary;
   Transave, Inc.
      2005   -   EUCTR2005-004899-21-BE   Belgium;
Ta1
   SciClone Pharmaceuticals Limited Ltd
      2019   Phase 2   EUCTR2019-001441-40-IT   Italy;
Tacrolimus and MMF
   University Hospital, Limoges
      2009   Phase 4   NCT00975663   Belgium;France;
Tacrolimus capsules
   Hopital Erasme - Chest service
      2009   -   EUCTR2009-014050-15-BE   Belgium;
Tacrolimus prolonged-release hard capsules
   Hopital Erasme - Chest service
      2009   -   EUCTR2009-014050-15-BE   Belgium;
Tad
   Aarhus University Hospital
      2014   Phase 2   EUCTR2013-005481-19-DK   Denmark;
Talniflumate
   Genaera Corporation
      2005   Phase 2   EUCTR2004-004334-13-IE   Ireland;
Tauroursodeoxycholic acid
   Children's Hospital Medical Center, Cincinnati
      1997   -   NCT00004441   Italy;United States;
Technetium Sulfur Colloid
   Tim Corcoran
      2017   Phase 1   NCT02947126   United States;
Tedizolid IV
   University of Southern California
      2015   Phase 4   NCT02444234   United States;
Tedizolid PO
   University of Southern California
      2015   Phase 4   NCT02444234   United States;
Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.
   Neupharma Srl
      2019   Phase 1   NCT04176328   Italy;
Telavancin Injection
   Joseph L. Kuti, PharmD
      2017   Phase 4   NCT03172793   United States;
Terlipressin acetate
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2021   Phase 3   EUCTR2020-005931-58-FR   France;
Tezacaftor
   VERTEX PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2020-003170-44-IT   Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
      2018   Phase 3   EUCTR2018-000185-11-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-005320-38-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      2021   Phase 3   EUCTR2021-001628-16-ES   Australia;Belgium;Canada;Spain;
      2021   Phase 3   EUCTR2020-004885-21-ES   Belgium;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-004885-21-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-002251-38-DE   Germany;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001404-42-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2021   Phase 3   EUCTR2020-001404-42-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2020-003170-44-CZ   Australia;Belgium;Czech Republic;Czechia;France;Italy;Netherlands;Spain;
      2020   Phase 3   EUCTR2020-001404-42-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2019   Phase 3   EUCTR2018-000185-11-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-NL   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-GB   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-BE   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-SE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2016   Phase 2   NCT02951195   United States;
      2016   Phase 1   NCT03029455   United Kingdom;
      -   Phase 3   EUCTR2021-005320-38-PT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-001628-16-BE   Australia;Belgium;Canada;Spain;
      -   Phase 3   EUCTR2020-004885-21-NL   Belgium;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-004885-21-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-003170-44-NL   Australia;Belgium;Czechia;France;Italy;Netherlands;Spain;
      -   Phase 3   EUCTR2020-003170-44-FR   Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
      -   Phase 3   EUCTR2020-003170-44-BE   Australia;Belgium;Czech Republic;France;Italy;Netherlands;Spain;
      -   Phase 3   EUCTR2020-002239-31-DE   Australia;Canada;Germany;United Kingdom;United States;
      -   Phase 3   EUCTR2020-001404-42-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2020-001404-42-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000185-11-SE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000183-28-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Tezacaftor (TEZ)
   VERTEX PHARMACEUTICALS INCORPORATED
      2017   Phase 2   EUCTR2016-000454-36-IT   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2017   Phase 2   EUCTR2017-000797-11-BE   Australia;Belgium;Netherlands;United States;
      2017   Phase 2   EUCTR2016-000454-36-NL   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-GB   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-ES   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-DE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-BE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-AT   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000454-36-DK   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Tezacaftor/Ivacaftor
   Vertex Pharmaceuticals Incorporated
      2017   Phase 3   NCT03150719   France;Germany;United States;
      2016   Phase 2   NCT02730208   Australia;
      2016   Phase 2   NCT02508207   United States;
      2015   Phase 3   NCT02412111   Australia;Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
Tezacaftor/Ivacaftor + Ivacaftor
   Nottingham University Hospitals NHS Trust
      2019   Phase 2   NCT04006873   United Kingdom;
Tezacaftor/Ivacaftor 100mg/
   Vertex Pharmaceuticals Incorporated
      2017   Phase 2   EUCTR2016-003585-11-GB   Ireland;Israel;United Kingdom;United States;
Tezacaftor/Ivacaftor/100mg/
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-004133-82-IE   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-GB   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-ES   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004133-82-DE   Australia;Germany;Ireland;Spain;United Kingdom;United States;
Tezacaftor/ivacaftor
   Vertex Pharmaceuticals Incorporated
      2017   -   NCT03278314   -
Tezacaftor/ivacaftor 100mg/
   VERTEX PHARMACEUTICALS INCORPORATED
      2017   Phase 2   EUCTR2016-000454-36-IT   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2019   Phase 2   EUCTR2018-002496-18-PT   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-NL   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-GB   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-DE   Germany;Netherlands;Portugal;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2018-000126-55-NL   Netherlands;
      2017   Phase 3   EUCTR2017-000540-18-DE   France;Germany;United States;
      2017   Phase 2   EUCTR2017-000797-11-NL   Australia;Belgium;Netherlands;United States;
      2017   Phase 2   EUCTR2017-000797-11-BE   Australia;Belgium;Netherlands;United States;
      2017   Phase 2   EUCTR2016-000454-36-NL   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-GB   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-ES   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-DE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-BE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-AT   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000454-36-DK   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000540-18-FR   France;Germany;United States;
Tham
   Lakshmi Durairaj
      2017   Phase 1   NCT03078088   United States;
The gut mycobiota and microbiota profile
   University Hospital, Bordeaux
      2018   -   NCT03565692   France;
The lung mycobiota and microbiota profile
   University Hospital, Bordeaux
      2018   -   NCT03565692   France;
Theophylline
   The First Affiliated Hospital of Guangzhou Medical University
      2012   Phase 4   NCT01684683   China;
   The first affiliated hospital of Guangzhou Medical University
      2012   -   ChiCTR-TRC-12002470   China;
Thymosin alpha 1
   SciClone Pharmaceuticals Limited Ltd
      2019   Phase 2   EUCTR2019-001441-40-IT   Italy;
Tigerase®
   AO GENERIUM
      2017   Phase 3   NCT04468100   Russian Federation;
Tiotropium Bromide (monohydrate)
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2010   -   EUCTR2010-019802-17-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Tiotropium Respimat
   Boehringer Ingelheim
      2010   Phase 3   EUCTR2010-019802-17-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
      2010   -   EUCTR2010-019802-17-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim España, S.A
      2010   -   EUCTR2010-019802-17-ES   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim France
      2010   -   EUCTR2010-019802-17-PT   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim Limited
      2010   -   EUCTR2010-019802-17-IE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
      2010   -   EUCTR2010-019802-17-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2010   -   EUCTR2010-019802-17-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
   Boehringer Ingelheim RCV GmbH & Co KG
      2010   -   EUCTR2010-019802-17-HU   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-019802-17-AT   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
   Boehringer Ingelheim RCV GmbH&Co KG
      2010   Phase 3   EUCTR2010-019802-17-SK   Austria;Belgium;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Slovakia;Spain;United Kingdom;
   SCS Boehringer Ingelheim Comm.V
      2010   Phase 3   EUCTR2010-019802-17-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Tiotropium Respimat 1.25 microgram solution for inhalation
   Boehringer Ingelheim France
      2008   Phase 2   EUCTR2008-001156-43-FR   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
   Boehringer Ingelheim Limited
      2008   -   EUCTR2008-001156-43-GB   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
   Boehringer Ingelheim Pharmaceuticals, Inc.
      2009   -   EUCTR2008-001156-43-PT   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
   Boehringer Ingelheim bv
      2009   -   EUCTR2008-001156-43-NL   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
   SCS Boehringer Ingelheim Comm.V
      2008   -   EUCTR2008-001156-43-BE   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium Respimat 1.25 microgram, solution for inhalation
   Boehringer Ingelheim Pharma GmbH & Co.KG
      2008   -   EUCTR2008-001156-43-DE   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium Respimat 1.25 micrograms solution for inhalation
   BOEHRINGER ING.
      2009   -   EUCTR2008-001156-43-IT   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium Respimat® inhaler
   Boehringer Ingelheim
      2010   Phase 3   NCT01179347   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Ireland;Israel;Italy;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States;
Tiotropium bromide
   BOEHRINGER ING.
      2010   -   EUCTR2010-019802-17-IT   Austria;Czech Republic;France;Germany;Hungary;Ireland;Italy;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2008-001156-43-IT   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium bromide 5 mcg
   Boehringer Ingelheim
      2008   Phase 2   NCT00737100   Australia;Belgium;France;Germany;Italy;Netherlands;New Zealand;Portugal;Russian Federation;United Kingdom;United States;
Tiotropium bromide high
   Boehringer Ingelheim
      2006   Phase 1   NCT02172534   -
Tiotropium bromide low
   Boehringer Ingelheim
      2006   Phase 1   NCT02172534   -
Tiotropium bromide medium
   Boehringer Ingelheim
      2006   Phase 1   NCT02172534   -
Tiotropium bromide monohydrate
   Boehringer Ingelheim Pharma GmbH & Co.KG
      2008   -   EUCTR2008-001156-43-DE   Belgium;France;Germany;Italy;Netherlands;Portugal;United Kingdom;
Tiotropium bromide-low dose-2.5mcg
   Boehringer Ingelheim
      2008   Phase 2   NCT00737100   Australia;Belgium;France;Germany;Italy;Netherlands;New Zealand;Portugal;Russian Federation;United Kingdom;United States;
Tobacco
   University Hospital, Toulouse
      2019   -   NCT04437641   France;
   University of Alabama at Birmingham
      2021   -   NCT04777344   United States;
Tobi
   EREMPHARMA SAS
      -   Phase 1   EUCTR2010-023533-34-FR   France;
   Erempharma SAS
      2009   -   EUCTR2009-013660-39-FR   France;
   INSMED INCORPORATED
      2011   -   EUCTR2011-000441-20-IT   Austria;Bulgaria;Canada;Denmark;Greece;Hungary;Ireland;Italy;Netherlands;Spain;United Kingdom;
   Novartis Pharma GmbH
      2008   -   EUCTR2007-004507-36-DE   Germany;
Tobi 300 mg/5 ml Nebuliser Solution
   Leeds Teaching Hospitals NHS Trust
      2007   -   EUCTR2007-005346-20-GB   United Kingdom;
   Mpex Pharmaceuticals, Inc.
      2011   Phase 3   EUCTR2010-019634-26-GB   Canada;France;Germany;Ireland;Israel;United Kingdom;United States;
Tobi 300mg/5ml Nebuliser solution.
   Chiesi Farmaceutici S.p.A
      2009   Phase 3   EUCTR2006-006215-68-FR   Czech Republic;France;Germany;Hungary;Spain;
      2008   Phase 3   EUCTR2006-006215-68-CZ   Czech Republic;France;Germany;Hungary;Spain;
      2008   -   EUCTR2006-006215-68-HU   Czech Republic;France;Germany;Hungary;Spain;
      2008   -   EUCTR2006-006215-68-DE   Czech Republic;France;Germany;Hungary;Spain;
Tobi 300mg/5ml Solución para inhalación por nebulizador.
   Chiesi Farmaceutici S.p.A
      2008   Phase 3   EUCTR2006-006215-68-ES   Czech Republic;France;Germany;Hungary;Spain;
Tobi Inhalant Product
   University Hospital, Lille
      2017   Phase 3   NCT03066453   France;
Tobi Nebcinal
   Erempharma
      2010   -   NCT01288170   France;
Tobi Podhaler
   Mylan Inc.
      2018   Phase 4   NCT03502070   United States;
   Novartis Pharmaceuticals
      2014   Phase 4   NCT02178540   United States;
Tobramcyin
   The Univeristy of Nottingham
      2010   Phase 4   EUCTR2010-023030-23-GB   United Kingdom;
Tobramicina
   Chiesi Farmaceutici S.p.A
      2008   Phase 3   EUCTR2006-006215-68-ES   Czech Republic;France;Germany;Hungary;Spain;
   Insmed Incorporated
      2011   Phase 3   EUCTR2011-000441-20-ES   Australia;Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom;United States;
Tobramicina polvere inalatoria
   NOVARTIS PHARMA SERVICES AG
      2016   Phase 2   EUCTR2015-003040-39-IT   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Tobramicyn
   UNIVERSITY OF LIVERPOOL
      -   Phase 4   EUCTR2009-012575-10-IT   Italy;Sweden;United Kingdom;
Tobramycin
   AZIENDA OSPEDALIERA MEYER
      2008   -   EUCTR2008-006502-42-IT   Italy;
   Chiesi Farmaceutici S.p.A
      2009   Phase 3   EUCTR2006-006215-68-FR   Czech Republic;France;Germany;Hungary;Spain;
      2008   Phase 3   EUCTR2006-006215-68-ES   Czech Republic;France;Germany;Hungary;Spain;
      2008   Phase 3   EUCTR2006-006215-68-CZ   Czech Republic;France;Germany;Hungary;Spain;
      2008   -   EUCTR2006-006215-68-HU   Czech Republic;France;Germany;Hungary;Spain;
      2008   -   EUCTR2006-006215-68-DE   Czech Republic;France;Germany;Hungary;Spain;
   Chiesi Farmaceutici S.p.A.
      2009   Phase 3   NCT01111383   France;Poland;Ukraine;
   Erempharma
      2011   Phase 1/Phase 2   NCT01337219   France;
   FDA Office of Orphan Products Development
      1995   Phase 3   NCT00004829   -
   Forest Laboratories UK Ltd
      2005   -   EUCTR2004-003675-36-DK   Belgium;Denmark;
      2005   -   EUCTR2004-003675-36-BE   Belgium;Denmark;
      2005   -   EUCTR2004-003675-36-AT   Austria;Belgium;Denmark;
   Gilead Sciences Inc
      2010   -   EUCTR2007-004277-26-AT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2009   -   EUCTR2007-004277-26-GB   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-FR   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-ES   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-004277-26-BE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-PT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-NL   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-IT   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-IE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-DK   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
      2008   -   EUCTR2007-004277-26-DE   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Imperial College London
      2010   Phase 4   NCT01044719   United Kingdom;
   Imperial College, London
      2009   -   EUCTR2009-014042-28-GB   United Kingdom;
   Leeds Teaching Hospitals NHS Trust
      2007   -   EUCTR2007-005346-20-GB   United Kingdom;
   NOVARTIS FARMA
      2013   -   EUCTR2012-003532-23-IT   Argentina;Australia;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
   National Jewish Health
      2016   Phase 4   NCT02918409   United States;
   Novartis
      2008   Phase 3   NCT00634192   Germany;
      2006   Phase 1   NCT00420836   -
      2006   Phase 1   NCT00399945   United Kingdom;
   Novartis Farmaceutica, S.A.
      2013   -   EUCTR2012-003532-23-ES   Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
   Novartis Pharma GmbH
      2008   -   EUCTR2007-004507-36-DE   Germany;
   Novartis Pharma Services AG
      2013   -   EUCTR2012-003532-23-DE   Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      2013   -   EUCTR2009-016590-15-PL   Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;United States;
      2012   -   EUCTR2012-003532-23-HU   Argentina;Australia;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      2011   -   EUCTR2011-002000-32-DE   Argentina;Australia;Brazil;Canada;France;Germany;Hungary;Italy;Mexico;Spain;United States;
      2010   Phase 3   EUCTR2009-016590-15-FR   France;Germany;Greece;Hungary;Italy;Poland;
      2010   -   EUCTR2009-016590-15-GR   France;Germany;Greece;Hungary;Italy;Poland;
      2010   -   EUCTR2009-016590-15-DE   Argentina;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Switzerland;
      2009   -   EUCTR2009-016590-15-HU   Canada;France;Germany;Greece;Hungary;Italy;Poland;Russian Federation;Switzerland;
   The Leeds Teaching Hospitals NHS Trust
      2015   -   NCT02489955   United Kingdom;
   University College Cork
      2015   -   NCT02526004   Ireland;
   University Hospitals Bristol NHS Foundation Trust
      2016   Phase 4   EUCTR2009-012575-10-SE   Sweden;United Kingdom;
      2009   Phase 4   EUCTR2009-012575-10-GB   Sweden;United Kingdom;
   University Medical Center Groningen
      2019   Phase 1/Phase 2   NCT03485456   Netherlands;
   University Medical Centre Groningen
      2013   Phase 1/Phase 2   NCT02035488   Netherlands;
   University of Jena
      2008   -   EUCTR2008-000164-17-DE   Germany;
   University of Milan
      2012   Phase 4   NCT01608555   Italy;
   University of Nottingham
      2011   Phase 4   NCT01207245   United Kingdom;
Tobramycin (Gernebcin®)
   University of Jena
      2008   Phase 2   NCT00774072   Germany;
Tobramycin / Bramitob
   Chiesi Farmaceutici S.p.A.
      2009   Phase 3   NCT00885365   Czech Republic;Czechia;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
Tobramycin / TOBI
   Chiesi Farmaceutici S.p.A.
      2009   Phase 3   NCT00885365   Czech Republic;Czechia;France;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;
Tobramycin 100 PARI
   PARI GmbH
      2007   -   EUCTR2007-000959-33-DE   Germany;
      -   Phase 1   EUCTR2005-004103-10-PL   Germany;Poland;
   PARI Pharma GmbH
      2006   -   EUCTR2005-004103-10-DE   Germany;
Tobramycin Inhalation Powder
   Chiron Corporation Ltd
      2006   -   EUCTR2005-003772-37-ES   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
   Novartis
      2005   Phase 3   NCT00125346   Argentina;Brazil;Bulgaria;Canada;Chile;Former Serbia and Montenegro;Lithuania;Mexico;United States;
   Novartis Pharma Services AG
      2005   -   EUCTR2005-002035-28-LT   Lithuania;
      -   -   EUCTR2005-003772-37-DE   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
   Novartis Pharmaceuticals
      2014   Phase 4   NCT02015663   United States;
      2013   Phase 4   NCT01844778   Germany;Ireland;Spain;Switzerland;United Kingdom;
      2009   Phase 3   NCT00918957   Bulgaria;Egypt;Estonia;India;Latvia;Lithuania;Romania;Russian Federation;South Africa;
      2006   Phase 3   NCT00388505   Australia;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Spain;United Kingdom;United States;
Tobramycin Inhalation Powder (TIP)
   Novartis Pharma Services AG
      2011   Phase 3   EUCTR2005-003772-37-IE   Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
      2008   Phase 3   EUCTR2005-003772-37-GR   Germany;Greece;Hungary;Ireland;Italy;Spain;United Kingdom;
      2007   -   EUCTR2005-003772-37-HU   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-003772-37-GB   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Tobramycin Inhalation Powder TIP delivered by the T-326 Inhaler
   CHIRON CORPORATION LIMITED
      2006   -   EUCTR2005-003772-37-IT   Germany;Greece;Hungary;Italy;Spain;United Kingdom;
Tobramycin Inhalation Solution (TIS)
   Gilead Sciences
      2008   Phase 3   NCT00757237   Austria;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Switzerland;United Kingdom;United States;
Tobramycin Powder
   University Hospital Tuebingen
      2014   Phase 3   NCT03341741   -
Tobramycin Solution for Inhalation
   Novartis Pharmaceuticals
      2006   Phase 3   NCT00388505   Australia;Canada;Chile;Colombia;France;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Spain;United Kingdom;United States;
Tobramycin Steri-Neb 300 mg/5 ml, inhalation solution
   Noordwest Ziekenhuisgroep
      2016   Phase 2;Phase 3   EUCTR2016-000166-35-NL   Netherlands;
Tobramycin dry powder
   University Medical Center Groningen
      2013   -   EUCTR2012-004437-16-NL   Netherlands;
Tobramycin for Inhalation
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 2   NCT00006280   United States;
Tobramycin inhalation powder
   NOVARTIS FARMA
      2012   -   EUCTR2011-002000-32-IT   Argentina;Australia;Brazil;Canada;Germany;Hungary;Italy;Mexico;Spain;United States;
   Novartis Pharma Services AG
      2017   Phase 2   EUCTR2015-003040-39-NL   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-IE   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-GB   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-FR   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-ES   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-DE   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2016   Phase 2   EUCTR2015-003040-39-BE   Belgium;France;Germany;Ireland;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Novartis Pharmaceuticals
      2010   Phase 3   NCT01069705   Bulgaria;Estonia;Latvia;Lithuania;Romania;Russian Federation;South Africa;
      2009   Phase 3   NCT00982930   Estonia;Russian Federation;
Tobramycin inhalation solution
   Gilead Sciences
      2012   Phase 3   NCT01641822   United States;
   Medical Center Alkmaar
      2016   Phase 2/Phase 3   NCT02657473   Netherlands;
   Novartis Pharmaceuticals
      2013   Phase 4   NCT01844778   Germany;Ireland;Spain;Switzerland;United Kingdom;
Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
   Insmed Incorporated
      2012   Phase 3   NCT01315678   Austria;Belgium;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;
Tobramycin injection 40mg/1ml
   The Univeristy of Nottingham
      2010   Phase 4   EUCTR2010-023030-23-GB   United Kingdom;
Tobramycin nebulized nasally
   Virginie ESCABASSE
      2017   Phase 3   NCT02888730   France;
Tobramycin solution for inhalation
   Bonnie Ramsey
      2014   Phase 3   NCT02054156   United States;
   Novartis
      2003   Phase 3   NCT00391976   -
   Novartis Pharmaceuticals
      2010   -   NCT01460836   -
Tobramycin solution for inhalation (TOBI)
   Seattle Children's Hospital
      2004   Phase 2   NCT00097773   United States;
Tobramycine
   Erempharma SAS
      2009   -   EUCTR2009-013660-39-FR   France;
   Novartis Pharma Services AG
      2005   -   EUCTR2005-002035-28-LT   Lithuania;
Tobramycinum
   PARI GmbH
      -   Phase 1   EUCTR2005-004103-10-PL   Germany;Poland;
   PARI Pharma GmbH
      -   Phase 1   EUCTR2010-023235-41-PL   Poland;
Tobrineb/Bramitob
   Chiesi Farmaceutici S.p.A
      2009   Phase 3   EUCTR2006-006215-68-FR   Czech Republic;France;Germany;Hungary;Spain;
      2008   Phase 3   EUCTR2006-006215-68-ES   Czech Republic;France;Germany;Hungary;Spain;
      2008   Phase 3   EUCTR2006-006215-68-CZ   Czech Republic;France;Germany;Hungary;Spain;
      2008   -   EUCTR2006-006215-68-HU   Czech Republic;France;Germany;Hungary;Spain;
      2008   -   EUCTR2006-006215-68-DE   Czech Republic;France;Germany;Hungary;Spain;
Tozinameran
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
Treatment
   Johns Hopkins All Children's Hospital
      2016   Phase 2   NCT02613884   United States;
Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor
   Charite University, Berlin, Germany
      2018   -   NCT04732910   Germany;
Treatment with polyethylene glycol (Macrogol 4000)
   University Hospital, Bordeaux
      2020   Phase 2   NCT04458129   -
Trifakta
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2018-000185-11-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Trikafta
   Emory University
      2019   Phase 2   NCT03506061   United States;
   VERTEX PHARMACEUTICALS INCORPORATED
      2018   Phase 3   EUCTR2018-000185-11-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-003455-11-DE   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-000833-37-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000185-11-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-SE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
Trimethoprim Sulfamethoxazole (TMP/SMX)
   University of North Carolina, Chapel Hill
      2018   Phase 2   NCT03489629   United States;
Trimethoprim and Sulfamethoxazole
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
Trimethoprim-sulfamethoxazole
   AOU Meyer
      2013   Phase 3   EUCTR2013-000219-25-IT   Italy;
Trimethoprim/Sulfamethoxazole
   University of North Carolina, Chapel Hill
      2011   Phase 2   NCT01349192   United States;
Trimethoprim/Sulfamethoxazole (TMP/SMX)
   Johns Hopkins University
      2012   Phase 2   NCT01594827   United States;
Trimetoprim
   Vãstre Gõtalandsregionen, Sweden
      2021   Phase 4   EUCTR2019-003501-10-NO   Denmark;Norway;Sweden;
   Västra Götalandsregionen
      2021   Phase 4   EUCTR2019-003501-10-DK   Denmark;Norway;Sweden;
      2020   Phase 4   EUCTR2019-003501-10-SE   Denmark;Norway;Sweden;
Triple combination therapy
   National Jewish Health
      2019   -   NCT04038710   United States;
ULTRESA
   AbbVie
      2012   -   NCT01652157   United States;
Ultrase® MT12
   Forest Laboratories
      2009   Phase 3   NCT00880100   United States;
Ultrase® MT20
   Forest Laboratories
      2007   Phase 3   NCT00513682   United States;
      2006   Phase 3   NCT00408317   United States;
Unconjugated Isoflavones 100 (PTI G-4660, Genistein)
   Children's Hospital of Philadelphia
      2001   Phase 1/Phase 2   NCT00016744   United States;
Uridine
   FDA Office of Orphan Products Development
      1996   -   NCT00004705   -
Urinary collect
   University Hospital, Strasbourg, France
      2008   -   NCT00476281   France;
Urinary levels of PIIINP as a marker of changes in renal function
   Nantes University Hospital
      2012   -   NCT01572194   France;
Ursodiol
   Children's Hospital Medical Center, Cincinnati
      1997   -   NCT00004441   Italy;United States;
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004315   United States;
V-Fend
   CHU de Rennes (Rennes University Hospital Centre)
      2012   -   EUCTR2011-005799-41-GB   United Kingdom;
VFEND 40 mg/ml powder for oral suspension
   CHU de Rennes (Rennes University Hospital Centre)
      2012   -   EUCTR2011-005799-41-GB   United Kingdom;
VITAMIN E - TGPS
   ORPHAN
      2007   -   EUCTR2007-001007-38-FR   France;
VR496
   VECTURA LIMITED
      2010   -   EUCTR2007-006276-11-IT   Ireland;Italy;
VRT-813077
   Vertex Pharmaceuticals Incorporated
      2010   Phase 3   EUCTR2009-012997-11-FR   Czech Republic;France;Germany;Ireland;United Kingdom;
      -   -   EUCTR2009-010261-23-Outside-EU/EEA   United States;
VRT-826809
   Vertex Pharmaceuticals Incorporated
      2009   -   EUCTR2008-006446-25-NL   Belgium;Germany;Netherlands;
      2009   -   EUCTR2008-006446-25-DE   Belgium;Germany;Netherlands;
      2009   -   EUCTR2008-006446-25-BE   Belgium;Germany;Netherlands;
VRT-893661
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-002968-40-PL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004479-35-PL   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-FR   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-DK   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-DE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-BE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2016   Phase 3   EUCTR2014-004827-29-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004827-29-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-004827-29-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002968-40-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002968-40-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2016-004479-35-IE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
VRT-893661 VRT-0893661
   Vertex Pharmaceuticals Incorporated
      2016   Phase 3   EUCTR2014-004838-25-DE   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004838-25-AT   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004788-18-BE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-IT   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-IE   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-BE   Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-SE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-NL   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-IT   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-IE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-GB   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-ES   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-DK   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-DE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-NL   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-IT   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-GB   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-DE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004787-37-ES   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   Phase 3   EUCTR2014-004787-37-DE   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   Phase 3   EUCTR2014-004787-37-AT   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
VX-121
   Vertex Pharmaceuticals Incorporated
      2019   Phase 2   NCT03912233   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-PT   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-NL   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-GB   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-DE   Germany;Netherlands;Portugal;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2018-000126-55-NL   Netherlands;
      2018   Phase 1/Phase 2   NCT03768089   Netherlands;United Kingdom;
VX-121/TEZ/D-IVA
   VERTEX PHARMACEUTICALS INCORPORATED
      2021   Phase 3   EUCTR2021-000694-85-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-000712-31-SE   Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000712-31-PT   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000712-31-DE   Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000694-85-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   NCT05076149   Australia;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
      2021   Phase 3   NCT05033080   Czechia;Germany;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NO   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-GR   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000712-31-IE   Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000712-31-CZ   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
VX-121/tezacaftor/deutivacaftor
   VERTEX PHARMACEUTICALS INCORPORATED
      2021   Phase 3   EUCTR2021-000694-85-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-000712-31-SE   Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000712-31-PT   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000712-31-DE   Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000694-85-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NO   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-GR   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000712-31-IE   Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000712-31-CZ   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
VX-152
   Vertex Pharmaceuticals Incorporated
      2016   Phase 2   NCT02951195   United States;
VX-371
   Parion Sciences
      2016   Phase 2   NCT02709109   France;Ireland;United Kingdom;United States;
VX-371 in hypertonic saline
   Vertex Pharmaceuticals Inc.
      2016   Phase 2   EUCTR2015-004841-13-IE   Czech Republic;France;Ireland;United Kingdom;United States;
      -   Phase 2   EUCTR2015-004841-13-FR   Czech Republic;France;Ireland;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2017   Phase 2   EUCTR2015-004841-13-CZ   Czech Republic;France;Ireland;United Kingdom;United States;
   Vertex Pharmaceuticals, Inc.
      2016   Phase 2   EUCTR2015-004841-13-GB   Czech Republic;France;Ireland;United Kingdom;United States;
VX-371 in saline
   Vertex Pharmaceuticals Inc.
      2016   Phase 2   EUCTR2015-004841-13-IE   Czech Republic;France;Ireland;United Kingdom;United States;
      -   Phase 2   EUCTR2015-004841-13-FR   Czech Republic;France;Ireland;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2017   Phase 2   EUCTR2015-004841-13-CZ   Czech Republic;France;Ireland;United Kingdom;United States;
   Vertex Pharmaceuticals, Inc.
      2016   Phase 2   EUCTR2015-004841-13-GB   Czech Republic;France;Ireland;United Kingdom;United States;
VX-440
   VERTEX PHARMACEUTICALS INCORPORATED
      2017   Phase 2   EUCTR2016-000454-36-IT   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2017   Phase 2   EUCTR2016-000454-36-NL   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-GB   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-ES   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-DE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-BE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-AT   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2016   Phase 2   NCT02951182   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000454-36-DK   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2016   Phase 1   NCT03486236   United Kingdom;
VX-445
   VERTEX PHARMACEUTICALS INCORPORATED
      2018   Phase 3   EUCTR2018-000185-11-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-003455-11-GB   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-DE   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-BE   Australia;Belgium;Germany;United Kingdom;
      2019   Phase 3   EUCTR2018-000185-11-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   NCT03691779   Australia;Ireland;United Kingdom;United States;
      2018   Phase 3   NCT03525574   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000797-11-NL   Australia;Belgium;Netherlands;United States;
      2017   Phase 2   EUCTR2017-000797-11-BE   Australia;Belgium;Netherlands;United States;
      2017   Phase 1/Phase 2   NCT03227471   Australia;Belgium;Netherlands;United States;
      -   Phase 3   EUCTR2018-000185-11-SE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-445 / TEZ / IVA
   Vertex Pharmaceuticals Incorporated
      2021   Phase 3   EUCTR2020-004885-21-ES   Belgium;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-004885-21-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-001404-42-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2021   Phase 3   EUCTR2020-001404-42-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2020-001404-42-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2020-004885-21-NL   Belgium;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-004885-21-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-001404-42-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2020-001404-42-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
VX-445 / TEZ / IVA FDC
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-001827-11-IE   Australia;Canada;Ireland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001695-38-GB   Australia;Canada;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001827-11-GB   Australia;Canada;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-001695-38-IE   Australia;Canada;Ireland;United Kingdom;United States;
VX-445 /50 mg TEZ/75 mg IVA FDC
   Vertex Pharmaceuticals Incorporated
      -   Phase 3   EUCTR2018-004652-38-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
VX-445 /TEZ/IVA
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-004652-38-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004652-38-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004652-38-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
VX-445/50 mg TEZ /75 mg IVA FDC
   Vertex Pharmaceuticals Incorporated
      -   Phase 3   EUCTR2018-000185-11-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-445/50mg TEZ /75mg IVA FDC
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2018-000184-89-NL   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-GB   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-BE   Belgium;Netherlands;United Kingdom;United States;
VX-445/TEZ/IVA
   VERTEX PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2019-000833-37-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-005320-38-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      2020   Phase 3   EUCTR2019-000833-37-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000833-37-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-002835-76-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001735-31-GB   Australia;Belgium;Germany;United Kingdom;
      2019   Phase 3   EUCTR2019-000833-37-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-ES   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001695-38-GB   Australia;Canada;Ireland;United Kingdom;United States;
      2018   Phase 3   NCT03525548   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   NCT03525444   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-NL   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-GB   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-BE   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-SE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-005320-38-PT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2019-001735-31-BE   Australia;Belgium;Germany;United Kingdom;
      -   Phase 3   EUCTR2019-000833-37-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-002835-76-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-002835-76-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-001695-38-IE   Australia;Canada;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000183-28-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-561
   Vertex Pharmaceuticals Incorporated
      2019   Phase 2   NCT03912233   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   NCT03911713   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-NL   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-GB   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-DE   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-BE   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-PT   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-NL   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-GB   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-DE   Germany;Netherlands;Portugal;United Kingdom;United States;
      2017   Phase 2   NCT03224351   Ireland;Israel;United Kingdom;United States;
      2017   Phase 1/Phase 2   NCT03227471   Australia;Belgium;Netherlands;United States;
      2016   Phase 2   NCT02971839   United States;
VX-561 (CTP-656)
   Vertex Pharmaceuticals Incorporated
      2017   Phase 2   EUCTR2017-000797-11-BE   Australia;Belgium;Netherlands;United States;
      2017   Phase 2   EUCTR2016-003585-11-GB   Ireland;Israel;United Kingdom;United States;
VX-659
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   NCT03447262   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 2   NCT03224351   Ireland;Israel;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-003585-11-GB   Ireland;Israel;United Kingdom;United States;
      2016   Phase 1   NCT03029455   United Kingdom;
VX-659/ TEZ/IVA
   Vertex Pharmaceuticals Incorporated
      2019   Phase 3   EUCTR2017-004134-29-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-ES   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
VX-659/TEZ/IVA
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   NCT03633526   United States;
      2018   Phase 3   NCT03460990   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   NCT03447249   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-IE   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-GB   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-ES   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-ES   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004133-82-DE   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004132-11-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
VX-659/Tezacaftor/Ivacaftor
   Vertex Pharmaceuticals Incorporated
      2019   Phase 3   EUCTR2017-004134-29-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-ES   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-IE   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-GB   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-ES   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-ES   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004133-82-DE   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004132-11-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
VX-661
   VERTEX PHARMACEUTICALS INCORPORATED
      2018   Phase 3   EUCTR2018-000185-11-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-004652-38-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004652-38-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004652-38-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000185-11-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-NL   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-GB   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000184-89-BE   Belgium;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-SE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2014   Phase 2   NCT02070744   United States;
      2014   Phase 1   NCT02015507   -
      2012   Phase 2   NCT01531673   Canada;Germany;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-SE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000183-28-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
VX-661 / VX-770
   VERTEX PHARMACEUTICALS INCORPORATED
      2019   Phase 3   EUCTR2018-002835-76-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2018-002835-76-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-001735-31-GB   Australia;Belgium;Germany;United Kingdom;
      2019   Phase 3   EUCTR2018-002835-76-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002835-76-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2019-001735-31-BE   Australia;Belgium;Germany;United Kingdom;
      -   Phase 3   EUCTR2018-002835-76-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-002835-76-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
VX-661 Plus Ivacaftor Combination
   Vertex Pharmaceuticals Incorporated
      2015   Phase 3   NCT02347657   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
VX-661 plus ivacaftor combination
   Vertex Pharmaceuticals Incorporated
      2015   Phase 3   NCT02516410   Australia;Austria;Canada;France;Israel;Spain;United States;
VX-661, VRT-893661
   Vertex Pharmaceuticals Incorporated
      2013   Phase 2   EUCTR2011-003821-93-DE   Canada;Germany;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-003821-93-GB   Canada;Germany;United Kingdom;United States;
VX-661/Ivacaftor
   Vertex Pharmaceuticals Incorporated
      2015   Phase 3   NCT02392234   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
VX-661/VX-770
   VERTEX PHARMACEUTICALS INCORPORATED
      2017   Phase 2   EUCTR2016-000454-36-IT   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2019   Phase 2   EUCTR2018-002496-18-PT   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-NL   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-GB   Germany;Netherlands;Portugal;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002496-18-DE   Germany;Netherlands;Portugal;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2018-000126-55-NL   Netherlands;
      2017   Phase 3   EUCTR2017-000540-18-DE   France;Germany;United States;
      2017   Phase 2   EUCTR2017-000797-11-NL   Australia;Belgium;Netherlands;United States;
      2017   Phase 2   EUCTR2017-000797-11-BE   Australia;Belgium;Netherlands;United States;
      2017   Phase 2   EUCTR2016-003585-11-GB   Ireland;Israel;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-NL   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-GB   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-ES   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-DE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-BE   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-000454-36-AT   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004838-25-DE   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004838-25-AT   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004827-29-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004827-29-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004788-18-BE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2016   Phase 2   EUCTR2016-000454-36-DK   Australia;Austria;Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-IT   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-IE   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-BE   Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-SE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-NL   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-IT   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-IE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-GB   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-ES   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-DK   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-DE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-NL   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-IT   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-GB   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-DE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004787-37-ES   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   Phase 3   EUCTR2014-004787-37-DE   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   Phase 3   EUCTR2014-004787-37-AT   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   -   EUCTR2014-004827-29-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-000540-18-FR   France;Germany;United States;
VX-661/VX-770 (TEZ/IVA)
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-004133-82-IE   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-GB   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004133-82-ES   Australia;Germany;Ireland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004133-82-DE   Australia;Germany;Ireland;Spain;United Kingdom;United States;
VX-661/ivacaftor (VX-770) 100mg/
   Vertex Pharmaceuticals Incorporated
      2016   Phase 3   EUCTR2014-004827-29-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004827-29-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-004827-29-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
VX-661/ivacaftor 100 mg/
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-002968-40-PL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004479-35-PL   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-FR   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-DK   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-DE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-BE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2017-002968-40-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002968-40-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2016-004479-35-IE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
VX-661/ivacaftor 100mg/
   Vertex Pharmaceuticals Incorporated
      2016   Phase 3   EUCTR2014-004838-25-DE   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004838-25-AT   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004788-18-BE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-IT   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-IE   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-BE   Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-SE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-NL   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-IT   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-IE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-GB   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-ES   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-DK   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-DE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-NL   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-IT   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-GB   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-DE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004787-37-ES   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   Phase 3   EUCTR2014-004787-37-DE   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   Phase 3   EUCTR2014-004787-37-AT   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
VX-661/ivacaftor 50 mg/
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-002968-40-PL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004479-35-PL   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-FR   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-DK   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-DE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-BE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2017-002968-40-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002968-40-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2016-004479-35-IE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
VX-77
   Vertex Pharmaceuticals Incorporated
      -   Phase 3   EUCTR2020-002239-31-DE   Australia;Canada;Germany;United Kingdom;United States;
VX-770
   VERTEX PHARMACEUTICALS INCORPORATED
      2021   Phase 3   EUCTR2021-000694-85-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-IT   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2022   Phase 3   EUCTR2021-005320-38-ES   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      2022   Phase 3   EUCTR2021-000712-31-SE   Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000712-31-PT   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000712-31-DE   Australia;Czech Republic;Czechia;Germany;Hungary;Ireland;Israel;New Zealand;Portugal;Spain;Sweden;United Kingdom;United States;
      2022   Phase 3   EUCTR2021-000694-85-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-001628-16-ES   Australia;Belgium;Canada;Spain;
      2021   Phase 3   EUCTR2021-000694-85-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NO   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-GR   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2021-000694-85-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004885-21-ES   Belgium;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-004885-21-CZ   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      2021   Phase 3   EUCTR2020-002251-38-DE   Germany;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-001404-42-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2021   Phase 3   EUCTR2020-001404-42-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2020-001404-42-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-NL   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-GB   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DK   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003554-86-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-GB   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-DE   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-003455-11-BE   Australia;Belgium;Germany;United Kingdom;
      2020   Phase 3   EUCTR2019-001827-11-IE   Australia;Canada;Ireland;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000833-37-NL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-000833-37-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004652-38-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-ES   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000833-37-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004652-38-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-004652-38-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001695-38-GB   Australia;Canada;Ireland;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000185-11-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004134-29-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-NL   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-GB   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-DE   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003970-28-BE   Australia;Belgium;Germany;Ireland;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-NL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000185-11-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-SE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-NL   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-GB   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-DE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-CZ   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-BE   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000183-28-AT   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-ES   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004134-29-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-IE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-GB   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-ES   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-DK   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004132-11-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-001379-21-GB   Canada;Germany;Ireland;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-001997-16-IE   Canada;Germany;Ireland;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001267-39-GB   Australia;Canada;France;United Kingdom;
      2015   Phase 3   NCT02514473   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-000386-20-GB   Canada;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-000204-15-GB   Canada;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000389-39-GB   Belgium;France;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000389-39-BE   Belgium;France;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000388-26-BE   Belgium;France;United States;
      2012   -   EUCTR2012-000387-19-GB   United Kingdom;United States;
      2011   -   NCT01381289   -
      2010   Phase 2   NCT01161537   United States;
      2010   Phase 1   NCT01216046   United States;
      2010   Phase 1   NCT01208285   Czech Republic;Slovakia;
      2010   Phase 1   NCT01153542   United States;
      2010   Phase 1   NCT01060566   United States;
      2009   Phase 1   NCT01018368   United States;
      -   Phase 3   EUCTR2021-005320-38-PT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-DE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-BE   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-005320-38-AT   Austria;Belgium;France;Germany;Italy;Netherlands;Portugal;Spain;Switzerland;
      -   Phase 3   EUCTR2021-001628-16-BE   Australia;Belgium;Canada;Spain;
      -   Phase 3   EUCTR2021-000712-31-IE   Australia;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000712-31-CZ   Australia;Czech Republic;Czechia;Germany;Ireland;Israel;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2021-000694-85-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004885-21-NL   Belgium;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-004885-21-BE   Australia;Belgium;Canada;Czech Republic;Czechia;Netherlands;Spain;
      -   Phase 3   EUCTR2020-002239-31-DE   Australia;Canada;Germany;United Kingdom;United States;
      -   Phase 3   EUCTR2020-001404-42-FR   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2020-001404-42-DE   Australia;Canada;Denmark;France;Germany;Israel;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2019-001827-11-GB   Australia;Canada;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2019-000833-37-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-004652-38-DE   Australia;Canada;Denmark;Germany;Ireland;Israel;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-001695-38-IE   Australia;Canada;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-SE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000185-11-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2018-000183-28-FR   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-004132-11-PL   Australia;Canada;Denmark;Germany;Ireland;Israel;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-001379-21-IE   Canada;Germany;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-001379-21-DE   Canada;Germany;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001997-16-GB   Canada;Germany;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001997-16-DE   Canada;Germany;Ireland;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001267-39-FR   Australia;Canada;France;United Kingdom;
      -   Phase 2   EUCTR2017-000673-37-Outside-EU/EEA   United States;
      -   Phase 2   EUCTR2017-000672-28-Outside-EU/EEA   United States;
      -   -   EUCTR2009-010261-23-Outside-EU/EEA   United States;
VX-770, VRT-8130077
   Vertex Pharmaceuticals Incorporated
      2010   Phase 3   EUCTR2009-012997-11-FR   Czech Republic;France;Germany;Ireland;United Kingdom;
VX-770, VRT-813077
   Vertex Pharmaceuticals Incorporated
      2018   Phase 3   EUCTR2017-002968-40-PL   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-IE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-GB   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-DK   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002968-40-BE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004479-35-PL   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-FR   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-DK   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-DE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-004479-35-BE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      2016   Phase 3   EUCTR2014-004838-25-DE   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004838-25-AT   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004827-29-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004827-29-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-004788-18-BE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-IT   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-IE   Austria;Belgium;Canada;France;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004838-25-BE   Austria;Belgium;Canada;Germany;Ireland;Italy;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-SE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-NL   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-IT   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-IE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-GB   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-ES   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-DK   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004837-13-DE   Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-SE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-IE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004827-29-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-NL   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-IT   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-GB   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004788-18-DE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-004787-37-ES   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   Phase 3   EUCTR2014-004787-37-DE   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   Phase 3   EUCTR2014-004787-37-AT   Australia;Austria;Canada;France;Germany;Israel;Spain;United States;
      2015   -   EUCTR2014-004827-29-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   Phase 2   EUCTR2010-020413-90-GB   Australia;Belgium;Germany;Ireland;United Kingdom;United States;
      2014   -   EUCTR2010-020413-90-IE   Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-003821-93-DE   Canada;Germany;United Kingdom;United States;
      2012   Phase 2   EUCTR2011-003821-93-GB   Canada;Germany;United Kingdom;United States;
      2011   -   EUCTR2010-020413-90-DE   Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
      2011   -   EUCTR2010-020413-90-BE   Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012997-11-GB   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2010   -   EUCTR2010-020546-96-GB   Canada;United Kingdom;United States;
      2010   -   EUCTR2009-012997-11-IE   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2010   -   EUCTR2009-012997-11-DE   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2010   -   EUCTR2009-012997-11-CZ   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-007479-26-GB   Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-007479-26-FR   France;Germany;Ireland;United Kingdom;
      2009   Phase 3   EUCTR2008-007416-15-GB   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-007416-15-FR   Czech Republic;France;Germany;Ireland;United Kingdom;
      2009   -   EUCTR2008-007479-26-IE   Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
      2009   -   EUCTR2008-007479-26-DE   Australia;Canada;France;Germany;Ireland;United Kingdom;United States;
      2009   -   EUCTR2008-007416-15-IE   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
      2009   -   EUCTR2008-007416-15-CZ   Czech Republic;France;Germany;Ireland;United Kingdom;
      2007   -   EUCTR2007-002657-23-DE   Germany;
      -   Phase 3   EUCTR2017-002968-40-FR   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002968-40-DE   Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2016-004479-35-IE   Australia;Belgium;Denmark;France;Germany;Ireland;Poland;Switzerland;United Kingdom;
      -   -   EUCTR2008-007416-15-DE   Australia;Canada;Czech Republic;France;Germany;Ireland;United Kingdom;United States;
VX-809
   Vertex Pharmaceuticals Incorporated
      2015   Phase 3   NCT02514473   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2010   Phase 1   NCT01216046   United States;
      2009   Phase 2   NCT00865904   Belgium;Canada;Germany;Netherlands;United States;
      2009   -   EUCTR2008-006446-25-NL   Belgium;Germany;Netherlands;
      2009   -   EUCTR2008-006446-25-DE   Belgium;Germany;Netherlands;
      2009   -   EUCTR2008-006446-25-BE   Belgium;Germany;Netherlands;
VX-809 & VX-770
   Vertex Pharmaceuticals Incorporated
      2009   Phase 1   NCT00966602   Netherlands;
VX-809 / VX-770
   Vertex Pharmaceuticals Incorporated
      2018   Phase 2   EUCTR2017-003761-99-DE   Germany;
      2016   Phase 3   EUCTR2015-001644-11-GB   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-FR   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-DK   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-DE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-001644-11-BE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000543-16-SE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000543-16-GB   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000543-16-DK   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000543-16-DE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000543-16-BE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-000604-41-NL   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-000604-41-IT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2014   -   EUCTR2013-000604-41-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-ES   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-000604-41-AT   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-DK   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003990-24-BE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-SE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-GB   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003989-40-CZ   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2013-000604-41-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003990-24-AT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-NL   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-IT   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-IE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-003989-40-DE   Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2015-001644-11-SE   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2015-000543-16-FR   Australia;Belgium;Canada;Denmark;France;Germany;Sweden;United Kingdom;United States;
VX-809, VRT-826809
   Vertex Pharmaceuticals Incorporated
      2014   Phase 2   EUCTR2010-020413-90-GB   Australia;Belgium;Germany;Ireland;United Kingdom;United States;
      2014   -   EUCTR2010-020413-90-IE   Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
      2011   -   EUCTR2010-020413-90-DE   Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
      2011   -   EUCTR2010-020413-90-BE   Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
VX-809/VX-770
   Vertex Pharmaceuticals Inc.
      2016   Phase 2   EUCTR2015-004841-13-IE   Czech Republic;France;Ireland;United Kingdom;United States;
      -   Phase 2   EUCTR2015-004841-13-FR   Czech Republic;France;Ireland;United Kingdom;United States;
   Vertex Pharmaceuticals Incorporated
      2017   Phase 2   EUCTR2015-004841-13-CZ   Czech Republic;France;Ireland;United Kingdom;United States;
      2016   Phase 4   EUCTR2016-000066-34-GB   Australia;United Kingdom;
      2014   Phase 2   EUCTR2010-020413-90-GB   Australia;Belgium;Germany;Ireland;United Kingdom;United States;
      2014   -   EUCTR2010-020413-90-IE   Australia;Belgium;France;Germany;Ireland;United Kingdom;United States;
      2011   -   EUCTR2010-020413-90-DE   Australia;Belgium;Germany;New Zealand;United Kingdom;United States;
      2011   -   EUCTR2010-020413-90-BE   Australia;Belgium;Germany;Ireland;New Zealand;United Kingdom;United States;
      -   Phase 3   EUCTR2017-001309-34-Outside-EU/EEA   United States;
      -   Phase 3   EUCTR2017-001078-41-Outside-EU/EEA   Canada;United States;
   Vertex Pharmaceuticals, Inc.
      2016   Phase 2   EUCTR2015-004841-13-GB   Czech Republic;France;Ireland;United Kingdom;United States;
Vaccin grippal pandémique H1N1
   Inserm
      2009   -   EUCTR2009-016662-90-FR   France;
Vaccination with vaccine against hepatitis A and B
   Karolinska University Hospital
      2015   -   NCT02605538   Sweden;
Valganciclovir [Valcyte]
   Hoffmann-La Roche
      2004   Phase 1   NCT00377741   United States;
Vancomycin
   Case Western Reserve University
      2012   Phase 1   NCT01509339   United States;
Vancomycin hydrochloride inhalation powder
   Savara Inc.
      2013   Phase 2   NCT01746095   United States;
Vancomycin inhalation powder
   Savara Inc.
      2017   Phase 3   NCT03181932   Canada;United States;
Vantobra (tobramycin)
   Pari Pharma GmbH
      2013   Phase 1   NCT01953367   Germany;
Vardenafil
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2011   Phase 2   NCT01002534   Belgium;
Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S
   Medical University of Innsbruck, University Clinic for Pediatrics III
      -   Phase 4   EUCTR2021-003277-55-AT   Austria;Canada;European Union;Ireland;United Kingdom;United States;
Ventolin® Evohaler
   ZAMBON SPA
      2017   Phase 3   EUCTR2015-002743-33-IT   Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Ventolin¿ Evohaler¿
   ZAMBON SPA
      2017   Phase 3   EUCTR2015-002743-33-IT   Australia;Belgium;France;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Portugal;Spain;Switzerland;United Kingdom;
Vfend
   Leeds Teaching Hospital NHS Trust
      2007   Phase 4   EUCTR2006-006362-41-GB   United Kingdom;
Vitamin D
   Hadassah Medical Organization
      2014   -   NCT02043717   Israel;
Vitamin D Oil
   Emory University
      2013   Phase 4   NCT01880346   United States;
Vitamin D Powder
   Emory University
      2013   Phase 4   NCT01880346   United States;
Vitamin D3
   Atlanta VA Medical Center
      2006   -   NCT00450073   United States;
   Emory University
      2020   Phase 4   NCT04118010   United States;
      2008   -   NCT00788138   United States;
   University of Southern California
      2019   -   NCT03734744   United States;
Vitamin K supplementation, dose #1
   Institut de Recherches Cliniques de Montreal
      2020   -   NCT04496921   Canada;
Vitamin K supplementation, dose #2
   Institut de Recherches Cliniques de Montreal
      2020   -   NCT04496921   Canada;
Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1
   University of British Columbia
      2007   -   NCT01070446   Canada;
Voriconazole
   CHU de Rennes (Rennes University Hospital Centre)
      2012   -   EUCTR2011-005799-41-GB   United Kingdom;
WATER FOR INJECTIONS, EP
   Fundació Parc Taulí
      2017   Phase 2   EUCTR2016-004033-25-ES   Spain;
Whole body Protein Turnover
   University of Texas Southwestern Medical Center
      2006   -   NCT00287456   United States;
Whole body Protein Turnover Study
   University of Texas Southwestern Medical Center
      2006   -   NCT00287430   -
Whole body protein turnover
   University of Texas Southwestern Medical Center
      2006   -   NCT00287443   United States;
Xenon
   Children's Hospital Medical Center, Cincinnati
      2021   -   NCT04793867   United States;
   Papworth Hospital NHS Foundation Trust
      2016   -   NCT02912637   United Kingdom;
Xenon-129
   The Hospital for Sick Children
      2015   Phase 2   NCT02740868   Canada;
Xolair
   Novartis Pharma Services AG
      2009   Phase 4   EUCTR2007-006648-23-IE   Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2007-006648-23-NL   Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
      2009   -   EUCTR2007-006648-23-GB   Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
      2008   -   EUCTR2007-006648-23-BE   Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Xolair 150 mg Pulver und Injektionslösung zur Herstellung einer Injektionslösung
   Novartis Pharma Services AG
      2008   -   EUCTR2007-006648-23-DE   Belgium;Germany;Ireland;Italy;Netherlands;United Kingdom;
Xylitol
   Joseph Zabner
      2013   Phase 1/Phase 2   NCT00928135   United States;
      2011   Phase 1/Phase 2   NCT01355796   United States;
ZENPEP
   AbbVie
      2012   -   NCT01652157   United States;
   EURAND SPA
      2010   -   EUCTR2009-012842-21-IT   Bulgaria;Germany;Hungary;Italy;United Kingdom;
ZITHOMAX 40 mg/ml ENFANTS
   ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
      -   Phase 3   EUCTR2014-003023-22-FR   France;
Zadaxin
   SciClone Pharmaceuticals Limited Ltd
      2019   Phase 2   EUCTR2019-001441-40-IT   Italy;
Zavesca
   Actelion Pharmaceuticals Ltd
      2008   -   EUCTR2008-002352-20-BE   Belgium;
      2007   -   EUCTR2006-002049-35-ES   Spain;
Zenpep
   Aptalis Pharma US Inc.
      2013   -   EUCTR2009-012842-21-HU   Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2012   Phase 3   EUCTR2009-012842-21-BE   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
      2011   -   EUCTR2009-012842-21-BG   Belgium;Bulgaria;France;Germany;Hungary;Ireland;Italy;Poland;Romania;Spain;United Kingdom;
      2010   Phase 3   EUCTR2009-012842-21-GB   Belgium;Bulgaria;Germany;Hungary;Italy;United Kingdom;
Zinc acetate (20mg/d)
   Cystic Fibrosis Foundation Therapeutics
      2004   -   NCT00104494   United States;
Zitromax
   Copenhagen CF-centre
      2009   Phase 4   EUCTR2006-003275-12-NO   Denmark;Norway;Sweden;
      2007   Phase 4   EUCTR2006-003275-12-DK   Denmark;
      -   Phase 4   EUCTR2006-003275-12-SE   Denmark;Norway;Sweden;
Zoledronic acid
   Papworth Hospital NHS Foundation Trust
      2013   Phase 4   NCT01702415   United Kingdom;
chlorhexidine gluconate liquid skin cleanser
   Johns Hopkins University
      2012   Phase 2   NCT01594827   United States;
normal saline (control)
   Mukoviszidose Institut gGmbH
      2007   Phase 2   NCT00506688   Germany;
saline
   Johns Hopkins University
      2007   Phase 2   NCT01293084   -
w/v sodium chloride solution
   Merck Sharp & Dohme Corp.
      2010   Phase 2   NCT01181622   United States;